Computational Study of Compounds with Biological Activity and their Interaction with Nano-Materials by Veclani, Daniele
  
Doctor of Philosophy degree in Environmental and Energy 
Engineering Science 
 
 
 
Cycle XXX 
 
 
 
 
Title 
 
“Computational Study of Compounds with 
Biological Activity and their Interaction with 
Nano-Materials” 
 
 
 
 
 
 
 
 
 
 
Ph. D. candidate     Supervisor 
Daniele Veclani     Prof. Andrea Melchior 
 
     Co-supervisor 
     Prof. Marilena Tolazzi 
 
 
2018 
 
 
 
 
 
  
 
 
 
 
Doctor of Philosophy degree in Environmental and Energy 
Engineering Science 
 
 
 
Cycle XXX 
 
 
 
 
Title 
 
“Computational Study of Compounds with 
Biological Activity and their Interaction with 
Nano-Materials” 
 
 
 
 
 
 
 
 
 
 
Ph. D. candidate     Supervisor 
Daniele Veclani     Prof. Andrea Melchior 
 
     Co-supervisor 
     Prof. Marilena Tolazzi 
 
 
2018 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
ͤͤJust reŵeŵďer ǁhat ol' Jack Burton does when the earth quakes,  
and the poison arrows fall from the sky, and the pillars of Heaven shake.  
Yeah, Jack Burton just looks that big ol' storm right square in the eye  
and he says, "Give ŵe your ďest shot, pal. I Đan take it."ͥͥ 
cit. Kurt Russell (Jack Burton) from Big Trouble in Little China 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I 
 
 Abstract  
 
In the last few decades, computer simulation became a potent tool to study experimental 
systems such as chemical reactions and adsorption mechanisms in more detail. Every day, 
developments in computers and computational software are made to increase the 
computational power and study more complex systems. Nowadays, computational 
chemistry is used in many different ways, and one of the important fields in which 
computational chemistry is used is drugs design. In this thesis, computational methods 
(the quantum mechanics method and molecular dynamics simulations in particular) were 
used to study the reactivity of two classes of pharmaceutical compounds and their 
interaction with carbon-based materials; the two classes are platinum-based antitumor 
drugs (chapter 3) and fluoroquinolones antimicrobials compounds (chapter 4).  
The first part of chapter 3 focuses on the hydrolysis reaction of cis-[Pt(PMe3)2(etga)], cis-
[Pt(PMe3)2(3-Hfl)]+ containing ethyl gallate (etga) and 3-Hydroxyflavone(3-Hfl), designed 
to try to limit the side effects of cisplatin, studied by means of density functional theory 
(DFT) calculations. The calculations showed that the rate determining step is the first step 
of the hydrolysis reaction and that the formation of the hydroxo species is observed in 
both complexes. Moreover, the activation energies are significantly lower than those 
calculated for cisplatin, with consequent high hydrolysis reaction rate that might make 
such complexes subject to fast degradation, causing potentially poor pharmacological 
activity; indeed, the complexes present lower cytotoxic activity compared to cisplatin. 
In the second part of chapter 3 the complete mechanism of action (hydrolysis reaction, 
reaction with DNA bases and reaction with cysteine) of phenanthriplatin, a 
monofunctional platinum complex, was studied by means of DFT calculations. Moreover, 
a comparison between phenanthriplatin and cisplatin was made with the aim of 
understanding why phenanthriplatin presents a higher cytotoxicity activity compared to 
cisplatin. The hydrolysis reaction showed that phenanthriplatin’s activation energy barrier 
is close to the energy barriers obtained for the first hydrolysis of cisplatin. Unlike cisplatin, 
phenanthriplatin reacts with both guanine and adenine bases; with the latter, the 
formation of two products, N7 and N1, occurs, and the reaction rate follows the order N7-
guanine > N7-adenine > N1-adenine; moreover, the reaction with guanine is kinetically 
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favoured in phenanthriplatin in respect to cisplatin. Finally, the reaction between 
phenanthriplatin and cysteine showed that such reaction is disadvantageous, both 
kinetically and thermodynamically, in phenanthriplatin in respect to cisplatin. This can 
explain why phenanthriplatin is more cytotoxic than cisplatin. 
In the last part of chapter 3 the non-covalent interaction between graphene prototypes, 
new candidates as drugs delivery systems, and cisplatin were investigated through MP2 
and DFT calculation. Different orientations of cisplatin in respect to the circumcoronene, 
one parallel and three perpendicular, were taken into account and different DFT 
functional were tested and compared with the interaction energy obtained from MP2 
calculations. The best DFT functional is M62X-D3, which was used to obtain the energy 
profiles. The parallel orientation presents the highest value of interaction energy in 
vacuum. The density of states (DOS) analysis showed that when cisplatin is adsorbed with 
perpendicular orientations a destabilization of the circumcoronene electronic structure is 
observed. Finally, the introduction of the solvent does not drastically change the 
interaction energy profiles between cisplatin and circumcoronene. Thus, a favourable 
adsorption of cisplatin on graphene can be predicted. 
As regards the fluoroquinolones (FQs) antimicrobials compounds, in the first part of 
chapter 4 the relative stability and photochemical behaviour of the different protonation 
states of ciprofloxacin (CFX) in gas phase and in water was studied by means of molecular 
dynamics simulations and DFT calculations. This work confirm the predominance of the 
zwitterionic form in water in respect to the neutral form, thanks to the introduction of a 
discrete-continuum approach (obtained by placing some water molecules around the 
protonated groups of the solute); the result was further confirmed through the calculated 
absorption UV-Vis spectra. Finally, the protonation sequence was confirmed through the 
comparison with the crystalline structures found in the literature, through the calculation 
of the relative stability for such species and the calculated absorption UV-Vis spectra. 
In the last part of chapter 4 the adsorption of both neutral and zwitterionic forms of CFX 
to the inner and outer surface of carbon nano-tubes (CNTs) in vacuum and in water was 
studied through molecular dynamics simulations. The simulation results showed that CFX 
remains adsorbed to the surface of CNT both in vacuum and in water thanks to - 
interactions. However, a change in CNT-CFX morphology was observed after the solvent 
was added; CFX molecules tend to form fewer hydrogen bonds between themselves and 
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more with water, leading to a dispersion of the molecules on the CNT surface. Finally, the 
adsorption Gibbs free energy were carried out for the adsorbed zCFX and nCFX using the 
umbrella sampling technique, finding out that adsorption is thermodynamically favoured 
and CFX molecules seem to interact more strongly with the inner surface than with the 
outer surface of CNT. Moreover, these values are in good agreement with the data 
reported in the literature. In conclusion, the use of computational chemistry can help to 
rationalize the experimental data and to investigate various mechanicistic hypothesis. 
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Computational Chemistry 
 
 
Anyone can do calculations nowadays. 
Anyone can also operate a scalpel. 
That doesn't mean all our medical problems are solved. 
Cit. ”Karl Irikura” 
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1.1 Introduction 
The use of computers in chemistry can be dated back to the beginning of the 50s, when 
the first software became available.[1] With the progressing development of theoretical 
methods and the improvement of computer codes, the interest in employing 
computational models for solving various chemical problems increased.[2] Recent years 
have witnessed an increase in the number of people using computational chemistry, 
facilitated by the development of a computer software that is increasingly easy to use. 
Indeed, computational chemistry is now very approachable, because calculations can be 
performed without knowing the underlying principles. As a result, many people do not 
understand even the most basic concepts involved in a calculation and their work results 
largely unfocused and remains often unknown.[3]  
The term theoretical chemistry could be defined as the mathematical description of 
chemistry; it is generally used when a mathematical method is sufficiently well developed 
to be automated for implementation on a computer. It is important to note that the words 
͞exact͟ and ͞perfect͟ do not appear in these definitions. Indeed, almost every aspect of 
chemistry has been described by qualitative or approximate computational schemes. 
Therefore, the biggest mistake a computational chemist can make is to assume that any 
computed number is exact. However, if the researcher understands what can or cannot 
be predicted, an approximate or qualitative calculation can give useful information.[3] 
 
1.2 Uses of Computational Chemistry 
Nowadays, computational chemistry is used in many different ways. For example, one 
way is to model a molecular system prior to synthesizing a molecule in the laboratory; in 
fact, computational models are good enough to eliminate most of the possible 
compounds not suitable for the intended purpose. The information provided is very 
useful, because synthesizing a single compound could require months of labour and a 
large quantity of raw materials and generate toxic waste. Computational chemistry is also 
used to understand a problem more completely. For example, there are some properties 
of a molecule, such as molecular bonding, absolute and relative (interaction) energies, 
electronic charge density distributions, dipoles and higher multipole moments, vibrational 
frequencies, reactivity and other spectroscopic quantities, which are easier to obtain 
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computationally than by experimental means.[3] Another important field in which 
computational chemistry is used is drugs design.[4–6] The design of a new drug is an 
incredibly difficult and frustrating task, because it does not entail a unique scientific 
technique, but a collaborative process in which all available techniques (experimental and 
computational) are used to achieve the desired results. The reality is that the use of 
computers and computational methods now permeates all aspects of drug discovery. In 
drug discovery campaign, such methods are usually used for three major purposes: 
 Filter a large compound into smaller sets of predicted active compounds that can 
be tested experimentally.  
 Guide the optimization of the compounds to increase its affinity or to optimize 
drug metabolism and pharmacokinetics properties, including absorption, 
distribution, metabolism, excretion, and the potential for toxicity. 
 Design novel compounds, either by "growing" starting molecules one functional 
group at a time or by piecing fragments together into novel chemotypes. 
 
Moreover, the use of these techniques allows researchers to save both money and time, 
because many compounds predicted to be inactive can be skipped, while those predicted 
to be active can be prioritized. This way, the cost and the workload are reduced without 
compromising lead discovery.[5] 
 
1.3 Outline 
The purpose of this thesis is to study, by computational chemistry techniques, the 
mechanism of action and adsorption of two classes of drugs on carbon-based materials; 
the two classes are the platinum-based chemotherapeutic compounds and the 
antimicrobials fluoroquinolones.  
Chapter 2 starts by presenting the basics of quantum mechanics simulation and molecular 
dynamics, the main methods used in this work. It describes the basic theory of both 
quantum and classical simulation, then goes on to discuss two different problem areas 
that have been addressed in this thesis. In chapter 3 the results of the investigation of the 
mechanisms of action and interaction of platinum-based chemotherapeutic compounds 
on graphene are presented. Chapter 4 discusses the acid-base properties and the 
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adsorption of fluoroquinolones on carbon nanotubes. Overall, the leading thread of this 
thesis is the interaction of the above-mentioned drugs with carbon-based surfaces; a brief 
introduction on carbon-based materials is provided in Chapters 3 and 4. 
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The mathematical framework of quantum theory  
has passed countless successful tests 
and is now universally accepted as a consistent  
and accurate description of all atomic phenomena. 
Cit ͞Erwin “chrödinger͟ 
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2.1 Modelling a Molecular System 
The systems that can be considered in molecular modelling[1–3] include a very wide range 
of molecules, from small isolated molecules to biological macromolecules (such as 
proteins and DNA) and solids. The nature as well as the dimension of the studied system 
guides the type of approach that will be used to study it. The two most common 
computational approaches are quantum mechanics (QM) and molecular mechanics (MM). 
The first one is based on an approximate solution of the Schrödinger equations, while the 
second one is based oŶ a classical descƌiptioŶ of the atoŵs (NeǁtoŶ’s laǁsͿ. Both 
computational approaches provide the total energy for a given atomic configuration. The 
QM and MM approaches have been used in this thesis with different levels of theory and 
different algorithms; a short discussion on the most common method will be discussed in 
this chapter, along with the computational procedure chosen to obtain the best 
geometrical arrangement (the one with the lowest energy), the reaction pathway, the 
behaviour of systems as a function of time and the value of various observables useful to 
rationalize or even predict, experimental data. A description of the computational 
procedures is also provided in the following chapter. 
 
2.2 Potential Energy Surfaces (PES) and Geometry Optimization 
A potential energy surface (PES) is a hypersurface definition of the potential energy (V) of 
a set of atoms, obtained by varying their relative position.[1,2,4] PES, in addition to the 
potential energy coordinate, has 3N-3 (N is the number of total atoms) Cartesian 
coordinates negligence to define the positions of all atoms. Such coordinates can be 
matched to the geometric parameters of the molecules, such as interatomic distances, 
angles and dihedral angles, called internal coordinates when the total number of the 
coordinates is 3N-6. The most important points of a PES are: 
 Local minima: correspond to optimal molecular geometries. 
 Saddle point: characterized by having a downward concavity along one 
coordinate, upward concavities for all the other coordinates and slope = 0 in all 
directions. 
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Saddle points are the lowest energy barriers in a path between two local minima and 
correspond to the chemical concept of transition state. An example of PES is reported in 
Figure 1. 
 
 
Figure 1 Diagram of potential energy surface (PES). 
 
The calculation of V for a coordinate set ⃗ݍ௞ (q is a vector consisting of all the cartesian or 
internal coordinates needed to define the positions of the atoms) is called single point 
calculation; in order to obtain a minimum energy as a function of ⃗ݍ௞ a geometry 
optimization will be performed. The aim of geometry optimization is to generate the 
optimal (lowest energy) structure of a molecule from an arbitrary starting state. There are 
several algorithms to find the minimum of PES[5], for example; Newton or Newton–
Raphson method, conjugate gradient method and geometry optimization direct inversion 
of the iterative subspace (GDIIS). 
 
2.3 Quantum Mechanics Calculations 
2.3.1 Introduction to quantum mechanics methods 
In 1926, Schrödinger provided a complete mathematical description of a generic 
molecular system through the known Schrödinger equation[6]: 
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Ĥ � = � �     
(eq1) 
In this equation  is the wave-function (eigen-function for a given Hamiltonian), which 
describes the system, Ĥ is the Hamiltonian operator and E is the energy of the system. 
Moreover,  takes as variables the positions of electrons and nuclei in the system: 
 Ĥ �� (⃗ݔଵ, … , ⃗ݔே , �⃗ଵ, … , �⃗�) = � �� (⃗ݔଵ, … , ⃗ݔே , �⃗ଵ, … , �⃗�)      
(eq2) 
where ⃗ݔே  describes the positions of the electrons, N is the number of the electron, �⃗� 
describes the positions of the nuclei and M is the number of the nuclei. The system's 
properties can be deduced from the knowledge of which must be chosen to be 
orthogonal and normalised (orthonormal) over the whole space:
 ⟨��|�௃⟩ =  ߜ�௝   
(eq3) 
ǁheƌe ɷij is the Kronecker symbol and takes ǀalue of 1 ǁheŶ i = j, ǁhile ǁheŶ i ≠ j it takes 
value of 0. Considering a generic molecule ̂ܪ is composed of 5 contributions: 
 ܪ =  �௘ +  �௡ +  �௡௘ +  �௘௘ + �௡௡   
(eq4) 
where Te and Tn are the kinetic energies for the electrons and the nuclei respectively; Vne 
represents the attractive potential between electrons and nuclei, Vee and Vnn the inter-
electronic and inter-nuclear repulsion potentials. Such term is represented with the 
following equation: 
 �௘̂ =  − ͳʹ ∑  ߘ�2ே�=ଵ  ;       �௡̂ =  − ͳʹ ∑ ͳܯ஺  ߘ஺2�஺=ଵ  
 �௡௘̂ =  − ∑ ∑ ஺ܼ��஺�஺=ଵே�=ଵ   
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�௘௘̂ = ∑ ∑ ͳ��௝ே௝>�ே�=ଵ  ;       �௡௡̂ = ∑ ∑ ஺ܼܼ஻�஺஻�஻>஺�஺=ଵ  
(eq5) 
where the index i and j denote the N electrons, A and B denote the M nuclei, MA is the 
mass of the nucleus, ZA and Zb are the atomic numbers of the nuclei, riA is the distance 
between the i electron and the A nucleus, rij is the distance between electrons and RAB is 
the distance between nuclei. Then Hamiltonian will be: ̂ܪ =  − ͳʹ ∑  ߘ�2ே�=ଵ  − ͳʹ ∑ ͳܯ஺  ߘ஺2�஺=ଵ   − ∑ ∑ ஺ܼ��஺�஺=ଵே�=ଵ  + ∑ ∑ ͳ��௝ே௝>�ே�=ଵ +  ∑ ∑ ஺ܼܼ௕�஺஻�஻>஺�஺=ଵ  
(eq6) 
 
2.3.2 Born-Oppenheimer approximation 
The Schrödinger equation described above is so complex that it can be unsolvable even 
for very simple systems such as the H2 molecule. In particular, all attractive and repulsive 
relationships between the particles represent an enormous obstacle, since the particles' 
motions are not independent. This non-independence is often referred to as correlation. 
A general approximation is given by the approximation of Born-Oppenheimer.[7] As 
previously reported, the wave-functions are functions of the positions of both the nuclei 
and the electrons of the system. The approximation is based on the fact that a nucleus is 
much heavier than an electron (approximately 1800 times more) and its movements, 
compared to the electrons’, are negligible. Therefore, the nuclei can be considered to be 
frozen, with their kinetic energy set to zero, but they still contribute to the potential 
energy of the system. Consequently,  depends only on Te, Vne and Vee, so the Hamiltonian 
becomes: 
 ̂ܪ =  − ͳʹ ∑  ߘ�2ே�=ଵ  − ∑ ∑ ஺ܼ��஺�஺=ଵே�=ଵ  + ∑ ∑ ͳ��௝ே௝>�ே�=ଵ +  �௡௡ 
(eq7) 
where Vnn represents the nucleus-nucleus repulsion and is a constant. Moreover, eq.7 is 
factorisable:  
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ܪ௘௟̂ =  ∑ ቌ− ͳʹ ߘ�2 −  ∑ ஺ܼ��஺஺ +  ∑ ͳ��௝௝>� ቍ�  
(eq8) 
We can observe that the wave-function now depends only on the electronic coordinates 
(el); this equation is called electronic Schrödinger equation and returns the electronic 
energy (Eel): 
 ܪ௘௟̂ �௘௟ (⃗ݔଵ, ⃗ݔ2 … , ⃗ݔ� , ⃗ݔ௝ , … , ⃗ݔே) = �௘௟ �௘௟ (⃗ݔଵ, ⃗ݔ2 … , ⃗ݔ�, ⃗ݔ௝ , … , ⃗ݔே) 
(eq9) 
Moreover, the electrons are also described by their spin quantum number, which can 
assume two ǀalues, −1/Ϯ oƌ 1/Ϯ, defined by the alignment of the spin with respect to an 
arbitrary axis. The tǁo tǇpes of spiŶ aƌe called α aŶd β and are orthonormalised: 
 ۦߙ|ߙۧ =  ۦߚ|ߚۧ = ͳ ۦߙ|ߚۧ =  ۦߚ|ߙۧ = Ͳ 
Both a spatial and a spin component describe the wave-function: 
 �ሺ⃗ݔሻ =  ߰ሺ�⃗ሻ�                 � =  ߙ ݋� ߚ 
(eq10) 
 
2.3.3 Slater determinant 
The antisymmetry principle:  itself is not observable, but the expression:  
 |�ሺ⃗ݔଵ, ⃗ݔ2 … , ⃗ݔேሻ|2 ݀⃗ݔଵ݀⃗ݔ2 … ݀⃗ݔே 
(eq11) ݀⃗ݔே denotes a small volume, which represents the probability of finding an electron at a 
given point in space. Since electrons are indistinguishable, the exchange of two electrons 
does not change the probability but leads to a change of sign of the wave-function;  is 
antisymmetric with respect to electron change. Such behaviour represents the quantum-
mechanical generalisation of the Pauli’s eǆclusioŶ pƌiŶciple (two or more fermions, 
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particles with spin = ½ such as electrons, cannot occupy the same state within a quantum 
system simultaneously).  
The exact wavefunction is unknown, therefore a trial wave-function that obeys the 
antisymmetry principle is necessary; in order to generate the trial wave-function, the N-
electron wave-function is expressed as an antisymmetric product of N one-electron wave-
functions χiሺ⃗ݔ�ሻ (χi = *σͿ. This product is indicated with φSD, called Slater determinant,[8] 
and presents this form: 
 
�ௌ� =  ͳ√ܰ! |߯ଵሺ⃗ݔଵሻ ߯2ሺ⃗ݔଵሻ … ߯ேሺ⃗ݔଵሻ߯ଵሺ⃗ݔ2ሻ ߯2ሺ⃗ݔ2ሻ … ߯ேሺ⃗ݔ2ሻ⋮ ⋮ ⋱ ⋮߯ଵሺ⃗ݔேሻ ߯2ሺ⃗ݔேሻ … ߯ேሺ⃗ݔேሻ| 
(eq12) 
The columns are single electron wave-functions (orbitals), while the rows are the electron 
indices. 
 
2.3.4 Variational method 
The equation eq9 is solved with the Rayleigh-Ritz variational method or, more simply, the 
variational method. The variational theorem states that the value calculated for the total 
energy of a trial wave-function can only be greater than or equal to the ground-state 
energy, E0: 
 � =  ۦ�|ܪ|�ۧ  ≥  �଴ 
(eq13) 
Such method provides a criterion for establishing the ͞ďest͟ wave-function, subject to a 
given set of constants. The two methods based on the variational method are the Hartree-
Fock method and Density functional theory; both will be described in this chapter. 
 
2.3.5 Hartree-Fock theory (HF) 
The approximation of Born-Oppenheimer[7] greatly simplifies the Schrödinger equation[6]. 
However, the equation still contains the term regarding inter-electronic repulsion, the 
calculation of which is difficult, being the motion of various electrons correlated to each 
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other. The Hartree-Fock (HF) method[1,2] is one of the most widely used computational 
approaches for the determination of the wave-function within the molecular orbital 
model. In the HF method, the Hamiltonian can be divided into two parts:  
 A core Hamiltonian Hc(i) describing the kinetic energy and the electron-nuclei 
attraction potential. 
 A part that describe the electron-electron repulsion. 
 
ܪ =  ∑ [ܪ௖ሺ�ሻ +  ∑ ͳ��௝௝>� ]�      ܪ௖ሺ�ሻ = − ͳʹ ߘ2 − ∑ ஺ܼ�஺�஺  
(eq14) 
The core Hamiltonian can be solved exactly, whereas the electron-electron repulsion part 
can only be treated in an average way, in which each electron is considered to be moving 
independently from the others in an average field created by the other electrons. The 
application of the variational method to a single Slater determinant allows the calculation 
of the lowest possible energy thƌough the optiŵisatioŶ of the oƌďitals χi. The resulting 
equations are called Hartree-Fock equations; their solution determines the best spin 
orbitals for which E will reach its lowest value. 
 ݂̂߯� =  ߝ�߯� 
(eq15) 
wheƌe χi is an eigen-function of the operator ݂̂, called Fock operator aŶd ɸi is the 
corresponding energy and represents the orbital energy. The negative of the eigen-value, 
−ɸi, coƌƌespoŶds to the ionisation potential according to Koopmans’ theoƌeŵ. The Fock 
operator has the following form: 
 ݂̂ =  − ͳʹ ߘ�2 −  ∑ ஺ܼ��௝஺ +  ���ሺ�ሻ 
(eq16) 
VHF is the Hartree-Fock potential and represents the average repulsive potential 
experienced by each electron due to the other N-1 electrons. VHF has replaced the 1/rij 
operator, which was too complex to be solved. Summing up the electronic repulsions of 
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different electrons in an average potential, the equation is now solvable. VHF consists of 
two terms: 
 ��� =  ∑ ቀܬఫ̂ሺݔଵ⃗⃗ ⃗⃗ ሻ − ܭఫ̂ሺݔଵ⃗⃗ ⃗⃗ ሻቁ௝  
(eq17) ܬఫ̂ሺݔଵ⃗⃗ ⃗⃗ ሻ = ∫|߯௝ሺݔ2⃗⃗⃗⃗⃗ሻ|2 ͳ�ଵ2  ݀ݔ2⃗⃗⃗⃗⃗ 
(eq18) ܭఫ̂ሺݔଵ⃗⃗ ⃗⃗ ሻ߯�ሺݔଵ⃗⃗ ⃗⃗ ሻ =  ∫ ߯௝∗ሺݔ2⃗⃗⃗⃗⃗ሻ ͳ�ଵ2 ߯�ሺݔ2⃗⃗⃗⃗⃗ሻ݀ݔ2⃗⃗⃗⃗⃗ ߯௝ሺݔଵ⃗⃗ ⃗⃗ ሻ 
(eq19) 
The operator ܬఫ̂ represents the potential experienced by an electron at position ݔప⃗⃗⃗⃗  due to 
the average charge distribution of another electƌoŶ iŶ the spiŶ oƌďital χi. The operator ܭఫ̂  
leads to an exchange of the variables in the two spin orbitals introducing the exchange 
potential. If two electrons have the same spin state, such energy reduces the electrostatic 
repulsion between them in different molecular orbitals (see Figure 2). The contribution 
due to the exchange energy is correctly calculated by the HF method.  
 
 
Figure 2 Exchange energy contribution. 
 
Finally, two methods can be used to solve the HF equation depending on the system. If 
the system contains an equal number of paired electrons it is solved using the RHF 
(Restricted Hartree-Fock) formalism. If the system contains an odd number of electrons 
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or an equal number, but with some unpaired electrons, the UHF (Unrestricted Hartree-
Fock) formalism can be used. In the RHF method, the equations of Roothan-Hall[9,10] are 
used to resolve the equation, whereas in the case of UHF the equation is resolved using 
the Berthier-Pople-Nesbert equations[11,12]. 
Moreover, the solution of the Hartree-Fock equations, even in RHF formulation, is not 
trivial, being the Fock operator a function of the molecular orbitals themselves, 
corresponding to the solutions of the eigenvalues equations. The algorithm used to solve 
the Roothaan-Hall equations[9,10] is an iterative approach (Figure 3) called Self Consistent 
Field (SCF) procedure[13]. According to this algorithm, an initial guess for the Fock matrix 
is built using the molecular orbitals obtained at a lower level of theory (for instance 
Extended Huckel or semiempirical methods, not discussed in this thesis). Then, the 
Roothaan-Hall equations[9,10] are solved to give atomic coefficients for each orbital and 
the relative energies and, consequently, the total energy. The procedure is repeated using 
the new coefficients to build a new Fock matrix and a new value of energy is obtained. 
The new total energy value is compared to the previous one. The procedure stops when 
this energy difference is smaller than a chosen value. 
 
 
Figure 3 Self Consistent Field (SCF) procedure. 
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2.3.6 Correlation energy 
The main problem of the HF method is that the total energy obtained is always higher 
than the real energy. Indeed, in the HF method the electrons are considered to move in 
an average electronic field, so the correlated motion of each electron with the others is 
omitted. The difference between the real energy and the HF energy is designated as the 
correlation energy: �௖௢௥௥௘௟௔��௢௡ =  ��௢� −  ��� 
(eq20) 
Correlation energy, in many cases, is approximately 1% of the total energy of the system. 
However, this small amount of the total energy could have a large influence on the 
properties of the calculated system. The usual method used to introduce the correlation 
takes into account the excitation of one or more electrons from one or more occupied 
orbitals to one or more virtual orbitals higher in energy (see Figure 4). 
 
Figure 4 Possible electronic configuration derived from HF. 
 
Each state is described by a Slater determinant, and the combination of them gives the 
new trial function, which should be closer to the real system than the original 
determinant. � =  ܿ� ��� +  ∑ ܿ����=ଵ  
(eq21) 
where the sum is over all the possible excited states and ci is the coefficient defining the 
contribution of each exited state to the wave-function. 
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2.3.7 Møller-Plesset perturbation theory (MP) 
Møller-Plesset perturbation theory[14] (MP) is one of the most popular quantum chemistry 
post-Hartree-Fock ab-initio method. Rayleigh-Schrödinger perturbation theory (RS-PT) is 
used to improve the HF energy. The acronyms MP2, MP3, MP4 and so on are used to 
denote a truncation of the perturbation series up to second, third, fourth order, 
respectively. The MP2 method, despite being more computationally expensive than HF, is 
often used to treat systems where electronic correlation effects play a key role. For 
instance, weak interactions like dispersion (London) forces or -stacking interactions 
between aromatic compounds can be properly described at MP2 level. 
 
2.3.8 Density Functional Theory (DFT)   
Unlike the HF theory, density functional theory (DFT) is based on electron density, , 
rather than on wave-functions. The electronic density can be expressed as a function of 
the molecular orbital by summing the molecular orbital squares. 
 ߩ = ∑|��|2�  
(eq22) 
The integration of  over all space gives the total number of electrons N: 
 ܰ =  ∫ ߩሺ�⃗ሻ݀�⃗ 
(eq23) 
The use of electron density associated with the correct Hamiltonian operator allows a 
complete description of the energy of the system. 
In 1964 Hohenberg and Kohn[15] postulated two fundamental theorems, which today 
represent the heart of the DFT method. The first theorem states that the external 
potential �௘��ሺ�⃗ሻ applied on the system is defined as a unique functional of the electronic 
deŶsitǇ, ρ(ƌͿ. Vext represents the attraction to the nuclei given by the usual expression. In 
turn, Vext fixes ܪ,̂ which is therefore a unique functional of ߩሺ�⃗ሻ. 
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ߩ଴  →  {ܰ, ܼ, �}  →  �௘��  →  ̂ܪ  →  �଴  →  �଴ 
(eq24) 
where N is the number of electrons, R is the electron-nucleus distance, Z is the nuclear 
charge; the ͞0͟ iŶdeǆ represents the system in its ground state and, consequently, the 
energy of the system in this state is written as: 
 �଴ = �[ߩ଴] +  �௘௘[ߩ଴] +  �ே௘[ߩ଴] 
(eq25) 
The T[ρ] aŶd Eee[ρ] paƌts of the equation are independent from the variables N, R and Z, 
while ENe depends on them. Equation 25 can be re-written as following: 
 �଴[ߩ଴] = �[ߩ଴] + �௘௘[ߩ଴] + ∫ ߩ଴ሺ�⃗ሻ �ே௘݀ሺ�⃗ሻ 
(eq26) 
The first part (T[0] + Eee[0]) is universally valid, while the second part (the part 
concerning the integral) depends on the system. This first part can be embedded in a new 
quantity, called Hohenberg-Kohn functional: 
 ܨ�௄[ߩ] =  �[ߩ଴] + �௘௘[ߩ଴] 
(eq27) 
The knowledge of the form of the FHK functional allows the calculation of E0. However, the 
explicit forms of the two terms that compose this functional are unknown. The Eee term 
can be divided in two terms: a Coulomb part, J[ρ] and a term containing all the non-
classical contributions to the electron-electron interaction, Encl[ρ]. 
The second Hohenberg-Kohn theorem simply consists in the variational theory applied to 
the electronic density. When an approximate electronic density ̃ߩሺ�⃗ሻ associated with an 
external potential Vext, is used, the resulting energy will always be greater than or equal 
to the exact ground state energy: �[̃ߩ] =  �[̃ߩ] +  �௘௘[̃ߩ] +  �ே௘[̃ߩ]  ≥  �௘�௔௖� 
(eq28) 
As reported above, the Hohenberg-Kohn theorems are the heart of the modern DFT. 
Despite being extremely powerful, the  Hohenberg-Kohn theorems do not offer a way of 
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computing the ground-state density of a system in practice. The success of modern DFT 
methods derives from the suggestion made by Kohn and Sham in 1965 that most of the 
problems are connected with the way the kinetic energy is described. The solution 
consisted in introducing the idea of a fictitious system built from a set of orbitals (one 
electron functions), where the electrons are non-interacting, so each electron is 
submitted to an average repulsion field coming from the other electrons. The total energy 
is divided as follows: 
 �[ߩ] =  �௦[ߩ] +  ∫[�௘��̂ ሺ�ሻ + ̂ܬሺ�ሻ]ߩሺ�ሻ݀� + �௑�[ߩ]  
(eq29) 
TS[ρ] coƌƌespoŶds to the electƌoŶ kiŶetic eŶeƌgǇ foƌ the hypothetical system; ρ is 
equivalent to the real system but refers to non-interacting electrons. ̂ܬሺ�ሻ represents the 
classical Coulomb interaction between electrons and �௘��̂ . This last operator presents this 
form: 
 ̂ܬሺ�ሻ =  ∫ ߩሺ�ሻ|� − �′| ݀�′ 
(eq30) �௘��̂ = ∑ ஺ܼ|�஺ − �|஺  
(eq31) 
wheƌe ƌ aŶd ƌ′ aƌe the coordinates of the two electrons. Kinetic energy can be expressed 
in terms of a one-electron function: 
 �௦[ߩ] =  − ͳʹ ∑ۦφ�|ߘ2|߮�ۧே�=ଵ  
(eq32) 
Finally, EXC is a term which encompasses all the contributions to the energy not accounted 
for in the previous terms, such as electron exchange, correlation energy and correction 
for the self-interaction included in the Coulomb term, as well as the portion of the kinetic 
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energy which corresponds to the differences between the non-interacting and the real 
system. 
At this point, a new Hamiltonian can be obtained by taking into account only the non-
interacting system: 
 ܪ௦̂ =  − ͳʹ ∑ ߘ�2ே� + ∑ �௦ሺ௥�⃗⃗⃗ ⃗ሻே�  
(eq33) 
One-electron functions are reintroduced in DFT in the form of Kohn-Sham orbitals ϕi, 
determined by: 
 ݂௄ௌ̂߮� =  ߝ�߮�     ݓℎ���    ݂௄ௌ̂ =  − ͳʹ ߘ2 +  �௦ሺ�⃗ሻ 
(eq34) ݂௄ௌ̂, known as the Kohn-Sham operator, is a one-electron operator, while ϕi is the Kohn-
Sham orbital. �௦ሺ�⃗ሻ describes the effective potential of the non-interacting reference 
system. The non-interacting system is related to the real system by choosing an effective 
potential VS so that: 
 ߩ௦ሺ�⃗ሻ =  ∑|߮�ሺ�⃗ሻ|2ே� =  ߩ଴ሺ�⃗ሻ 
(eq35) 
Returning to the original system: 
 ����[ߩ] =  �[ߩ] +  �ே௘[ߩ] + ܬ[ߩ] + �௑�[ߩ]   
(eq36) 
where the EXC has the following form: 
 �௑�[ߩ] = ሺ�[ߩ] − �௦[ߩ]ሻ + ሺ�௘௘[ߩ] − ܬ[ߩ]ሻ =  �௖[ߩ] +  �௡௖௟[ߩ] 
(eq37) 
Now the computation of the major part of the kinetic energy is possible. The Hohenberg-
Kohn functional then becomes: 
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 ܨ[ߩሺ�⃗ሻ] =  �௦[ߩሺ�⃗ሻ] + ܬ[ߩሺ�⃗ሻ] +  �௑�[ߩሺ�⃗ሻ] 
(eq38) 
The EXC term contains both the residual kinetic energy and the repulsion terms. As 
mentioned above, EXC is an unknown term of the equation that can be obtained only if 
approximated. In the Functionals session (2.2.10) the different approximation methods 
used to model the functional will be described. Finally, the resolution of eigenvalues 
equations based on Kohn-Sham operators, such as the equations underlying the HF 
method, require an interactive method of SCF type (see Figure 3).[16]  
 
2.3.9 Functionals 
Finding effective expressions for the functional Exc[ρ] is one of the crucial issues of DFT 
methods, and the development of new functionals is an ongoing and active area of 
research. As reported above, the EXC[ρ] fuŶctioŶal coŶtaiŶs the non-classical contributions 
to the potential energy due to the electron-electron interaction and the difference 
between the kinetic energy of the real system and the kinetic energy related to the non-
interacting system. The functionals described here represent different approximations to 
this exchange-correlation functional. 
 
2.3.9.1 Local Density Approximation (LDA) 
The local density approximation[17] (LDA) is one of the first methods used to calculate EXC; 
it is defined using the electronic density of a uniform electron gas. However, the constant 
value of the electronic density does not reflect the rapid variation of densities in a 
molecule. Although LDA is a rough approximation, it is the only system through which the 
density is defined, ďǇ ρ = N/V (N represents the number of electrons and V represents the 
volume of the gas); the form of the exchange and correlation energy functionals are 
known either exactly or with a very high accuracy. In systems including spin polarization 
(open-shell systems) the electƌoŶic deŶsitǇ ρ is ƌeplaced by the spin electronic densities 
ρα aŶd ρβ, so that ρ = ρα + ρβ; in this case, the approximation is called local spin-density 
approximation (LSDA). One of the most famous LDA functional is VWN, developed by 
Vosko, Wilk and Nusair[17], based on high-level quantum Monte Carlo calculations for 
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uniform electron gases. The use of LDA functionalities provides more accurate results than 
the HF method for determining molecular properties such as structures, vibration 
frequencies, charge moments, elastic modules. However, it shows some defects in the 
case of energy details such as bond energies and energy barriers in chemical reactions, 
which are poorly characterised by using this type of functional. 
 
2.3.9.2 Generalised Gradient Approximation (GGA) 
The LDA approximation describes the energies rather badly, so a new type of functional, 
the generalised gradient approximation (GGA)[17] has been introduced. These functionals 
include the gradient of the electron density, ∇ρ, which better describes the non-
homogeneity of electron density. 
The GGA is usually divided into two terms: one regarding exchange energy and the other 
one related to correlation energy. The two terms can be solved individually. 
 �௑�ீீ ஺ = �௑ீ ீ஺ + �௖ீ ீ஺ 
(eq39) 
A list of the most efficient GGA functionals commonly used in computational chemistry is 
provided below: 
 B is an exchange functional developed by Becke.[18] It is a gradient correction to 
the LSDA exchange energy. It includes a single parameter fitted on known atomic 
data from the rare gas atoms. 
 P86 is a correlation functional developed by Perdew.[19] It is a popular gradient 
correction to LSDA, which includes one empirical parameter fitted for the neon 
atom. 
 PW91 is a modification of the P86 functional developed by Perdew, Wang and 
Burke.[20,21]  
 PBE is an exchange-correlation functional developed by Perdew, Burke and 
Ernzerhof.[22] 
 LYP is a correlation functional developed by Lee, Yang and Parr.[24,25] It is the most 
extensively used GGA correlation functional. It contains four empirical parameters 
fitted to the helium atom. 
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Usually, a combination of exchange and correlation function is created to try to fully 
describe the systems. Some of the most common combinations are: BLYP, BP86 and 
BPW91. ∇2ρ, the laplacian of the electron density or the local kinetic energy density, could be used 
to achieve a better approximation of EC and Ex. The approach is called meta-GGA and is 
an expansion of the normal GGA. 
 
2.3.9.3 Hybrid functionals 
The problem with LDA and GGA approaches consist in the lack of a description of the 
exchange part, due to a problem of electronic self-interaction. However, the exchange 
part is defined exactly in HF. Therefore, an alternative approach would be to use a mix of 
DFT and HF to describe the exchange energy, although this type of approach gives poor 
results (worse than GGA). The final solution to this problem is the use of a combination of 
HF, GGA and LSDA functionals to describe the exact exchange and correlation terms; such 
approach is known as hybrid functional. The main element of these functionals come from 
GGA functionals, so they are often called GGA hybrid functionals. A list of the most used 
hybrid functionals is reported below: 
 B3 contains exact exchange and  by Becke.[26] It is a combination of LSDA and GGA 
functionals. 
 PBE0, also called PBE1PBE, was developed by Adamo and Barone.[27] It is a 
combination of 75% of PBE GGA exchange functional and 25% of HF exchange 
functional. 
 B97 and B98 were first developed by Becke (B97),[28] then modified by Becke and 
Schmider (B98).[29]  
A famous example of exchange and correlation combination is B3LYP, one of the more 
often used hybrid functionals.[29] The B3LYP functional is a mix between LDA and GGA 
functionals resulted from DFT and HF methods. In B3LYP scheme, Perdew-Wang gradient-
corrected correlation energy[21,23] is replaced by Lee-Yang-Parr correlation energy. B3LYP 
exchange-correlation energy functional is described with: 
 �௑� =  �௑௅ௌ�஺ሺͳ − ܽ଴ሻ + ܽ଴�௑௘�௔௖� +  ܽ௑∆�௑஻88 + ��௅ௌ�஺ + ܽ�∆��௅௒� 
(eq40) 
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in which the local spin-density functional of Vosko, Wilk, and Nusair[30] is used for �௑௅ௌ�஺ 
and ��௅ௌ�஺ . �௑௘�௔௖� is the exact nonlocal HF exchange energy. ∆�௑஻88 and ∆��௅௒� are 
Becke’s[26] and Lee-Yang-Paƌƌ’s gƌadieŶt coƌƌectioŶs[24,25] for local exchange and 
correlation energies respectively. The weight coefficients for gradient-corrected 
correlation energy, local exchange energy, and the exact HF exchange terms were 
determined by a linear least-square fitting of the thermochemical properties of some 
atoms and molecules to the experiments.  
Another important family of hybrid functionals is the Minnesota family (M), developed by 
Zhao and Truhlar, in particular the M06 family.[31,32] Specifically, M06 functional is based 
on LSDA components, GGA functional PBE and MGGA functional VSXC. The percentage of 
HF component for exchange energy is 27% in M06, 54% in M06-2X, 100% in M06-HF and 
0% in M06-L. Moreover, M06 is a functional with good accuƌacǇ ͞acƌoss-the-ďoaƌd͟ for 
transition metals, main group thermochemistry, medium-range correlation energy and 
barrier heights. M06-2X has an excellent performance for main group chemistry, predicts 
accurate valence and Rydberg electronic excitation energies and it is an excellent 
functional for aromatic-aromatic stacking interactions. M06-L is not as accurate as M06 
for barrier heights but it is the most accurate functional for transition metals and the only 
local functional with better across-the-board average performance than B3LYP. M06-HF 
has good performance for valence, Rydberg, and charge transfer excited states with 
minimal sacrifice of ground-state accuracy. 
 
2.3.10 Basis sets  
The simplest way to represent a molecular orbital (i) is by a linear combination of atomic 
orbitals (LCAO). The mathematical expression for atomic orbitals () and the dependence 
of  at the distance r from the nucleus is: 
 � ∝ �−௥ 
(eq41) 
The mathematical expression for the combination of atomic orbitals to obtain a molecular 
orbital is: 
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�� = ∑ ܽ௠�௠௠  
(eq42) 
The am coefficients have a decisive role in the calculation of the electronic structure of a 
system; in fact, during the SCF process; the am are varied at each cycle by generating a 
new molecular orbital. 
Basis functions are used to create atomic orbitals (AO) or molecular orbitals (MO). These 
basis functions can be classified into two main types: 
 Slater-type orbitals (STOs) have the exponential dependence of e−ζƌ and are very 
close in their mathematical expression to the real AO: 
 ߟௌ�ை = ܰ �௡−ଵ�఍௥ ௟ܻ௠ሺΘ, �ሻ 
(eq43) 
ǁheƌe N is a factoƌ of ŶoƌŵalisatioŶ, ζ is the eǆponent, r, Θ aŶd φ aƌe spheƌical 
coordinates and Ylm is the angular momentum part (function describing the 
͞shape͟Ϳ. Finally, n, l and m are the classical quantum numbers. 
 the Gaussian-type orbitals (GTOs) have the exponential dependence �−�௥2: 
 ߟீ�ை = ܰ ݔ௟ݕ௠ݖ௡�−�௥2 
(eq44) 
where x, y and z are Cartesian coordinates and other symbols have the same 
meaning as in STO. 
STOs appropriately describe the behaviour of atomic hydrogen orbital, because they 
exhibit a cusp at r = 0 and a good exponential decay. On the contrary, GTOs do not show 
a cusp at r = 0 and decrease too rapidly to obtain large values of r. However, STOs are 
computationally more expensive than GTOs, because the product of two GTOs centred on 
two different atoms is a third one situated between them, which cannot be obtained with 
STOs. A number of GTOs can be combined to approximate a STO, a procedure that often 
proves to be more efficient than using the STO itself. 
The precision of a basic set (and, therefore, its degree of complexity) is defined by the 
number of contracted functions (CGFs) used to represent each atomic orbital. For 
example, the STO-3G basis set (where G indicates a combination of contracted Gaussian 
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functions) is formed by a linear combination of three CGFs for each basis function, so as 
to resemble an STO. A better description of the system can be provided by using two or 
more functions to describe each type of orbital; triple-zeta and quadruple-zeta basis sets 
are usually characterized by a good precision. 
Valence electrons are more involved in the formation of chemical bonds, so a flexible 
description of such electrons is more useful than one of the core electrons. Basis sets 
where the core and valence orbitals are treated differently are called split valence basis 
sets. One of the most used split valence basis set is the 6-311G basis set. The 
nomenclature of this type of basis set (A-BCDG) is provided below: 
 A represents the number (six in this case) of primitives GTOs used to describe one 
single contracted Gaussian function of the core. 
 B, C and D represent the number of primitives GTOs describing the valence 
orbitals. In this case, the basis set is composed of three functions, one containing 
three primitives and the others containing only one. 
In addition, polarization and/or diffused functions can be added for greater accuracy of 
the basis set. Polarization is caused by to the deformation of the electronic cloud around 
each atom when atoms form a bond. The effect is achieved when functions with higher 
angular momentum are added to the basis set. Usually, a p polarisation function can be 
added to H atoms, a d function to a base set containing p valence orbital, and an f 
functions to d-valence orbitals. For example, a 6-311G basis set that implement p and d 
polarisation functions became 6-311G(d,p). Diffusion functions describe the part of 
atomic orbitals distant from the nuclei and can have a very important role when 
considering, for example, anions or diffuse electronic clouds in second or third row 
transition metals. The function is represented by a ͞+͟, thus a ďasis set implementing it 
became 6-311+G or 6-311++G. Moreover, the inner core of transition metals is very large, 
therefore the number of basic functions used to describe it would be very high. However, 
the problem can be solved by replacing the core basis function with an Effective Core 
Potential (ECP). ECPs are functions that represent electrostatic effects due to the 
electronic cloud of core orbits. Besides reducing the computational demand, the use of 
such functions, may also introduce some relativistic effects on the studied system, 
because the functions are generated from relativistic atomic calculations. 
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2.3.11 Molecular vibrations 
The vibrational states[4] of a molecule are experimentally observed by means of IR (Infra-
Red) and Raman spectroscopy and give precious information about the molecular 
structure and the environment. 
However, assigning any observed peak to a defined molecular motion is often difficult. 
The calculation of vibrational frequencies can be of great help in peak assignment and also 
in the calculation of some important thermodynamic parameters (molecular enthalpy, 
entropy, and free energy). The simplest description of a vibration is a harmonic oscillator: 
 �ℎ௔௥௠ = �ሺݔ − ݔ଴ሻ2 
(eq45) 
where Vharm is the potential energy, and x0 the equilibrium position. Better results can be 
achieved by using a more sophisticated potential, such as the Morse functional form. 
Vibrational frequencies and vibrational energy levels for a molecular system can be 
directly obtained from the Hessian matrix, which can be computed either analytically or 
numerically by means of a finite difference procedure applied to analytical first 
derivatives. As seen above, a geometric optimization calculation leads to a minimum 
energy value. However, the system can never reach such energy value because it always 
maintains a vibrational motion.  
 
 
Figure 5 Schematic representation of a harmonic potential energy function and first vibrational levels. The 
Zero Point Energy (ZPE) is indicated. 
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A more accurate value can be obtained through the evaluation of the energy associated 
with the lowest vibrational level (Zero-Point vibrational energy or ZPVE, see Figure 5), 
which is then summed to the potential energy to obtain. This is of particular importance 
when comparing the energy of different critical points of the surface (different 
conformers or in the investigation of a chemical reaction). 
 
2.3.12 Implicit solvation 
Most of the chemical processes take place in liquid media, so the properties of the solvent 
are often considered in computational studies in order to avoid unrealistic results. 
However, an explicit approach where a large number of solvent molecules is introduced 
around the solute makes the calculations computationally impossible. Therefore, some 
implicit, continuum treatment is typically used. A large number of implicit solvation 
models have been developed,[33]  and their common feature is solute placed in a cavity in 
an otherwise continuous and polarizable medium with a dielectric constant; the solvation 
energy is given by: 
 ∆ܩ௦௢௟ = ∆ܩ௖௔� + ∆ܩ��௦௣ + ∆ܩ௘௟ 
(eq46) 
where Gcav is the energetic penalty for creating the solvent cavity around the solute, the 
shape of which can be determined in several ways,[33] Gdisp is an energy contribution due 
to the dispersion interaction between solvent and solute and Gel is the variation of free 
energy associated with electrostatic interactions between solute and solvent. The two last 
terms in eq46 are typically stabilizing, due to simulated weak interactions and the 
solǀeŶt’s polaƌizatioŶ aligŶiŶg ǁith the solute’s dipole ŵoŵeŶt. Normally, the non-polar 
terms are separated from the electrostatic term, whose contribution to total energy is 
found through modified Hamiltonians: 
 ̂ܪ = ̂ܪ଴ + �ሺ�⃗ሻ 
(eq47) �ሺ�⃗ሻ is the electrostatic potential due to the polarization solvent and can be found by 
solving the Poisson equation:[2] 
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 ∇[ߝሺ�⃗ሻ∇�ሺ�⃗ሻ] = −4ߨߩሺ�⃗ሻ 
(eq48) 
where ߩሺ�⃗ሻ is the charge density. Eq 48 can be simplified in different ways, depending on 
the assumptions made for ߝሺ�⃗ሻ and ߩሺ�⃗ሻ. 
In the Poisson-Boltzmann (PB) methods, a ʽreaction field’ is geŶeƌated ďǇ coŵputiŶg � for 
vacuum and solvent dielectric constant and taking �௥௘௔௖ = �௦௢௟� − �ఌ=ଵ. �௥௘௔௖ is then 
used to obtain Gel by integration (or summation) over the charge density (or point 
charges). 
 ∆ܩ௘௟�஻ = ͳʹ ∫ ߩሺ�⃗ሻ �௥௘௔௖ሺ�⃗ሻ݀ሺ�⃗ሻ 
(eq49) 
The equation is further reduced in the Generalized Born (GB) model, where all atoms are 
treated as point charges qi interacting with each other and with the surrounding 
continuum. The two very different types of interactions are combined as in the following 
equation: 
 ∆ܩ௘௟ீ஻ = ͳʹ (ͳ − ͳ�௦௢௟�) ∑ ∑ ݍ�ݍ௝�݂௝௝=��  
(eq50) 
 where the Born radii fij depends oŶ the atoŵ paiƌs’ positioŶs aŶd their positions relative 
to the cavity. The polarization of the solvent affects the electronic structure of the solute. 
The modified wave function, in turn, changes �ሺ�⃗ሻ and so on, in a self-consistent way. 
Methods that carry out such iterations are called self-consistent reaction field (SCRF) 
models. Furthermore, more sophisticated implementations construct a molecular shape-
induced cavity and, therefore, have to divide them into segments, or tesserae, which have 
a partial charge density �௦ሺ�௦⃗⃗⃗ሻ. The potential for each tesserae is then given by: 
 �௦ሺ�⃗ሻ = ∫ �௦ሺ�௦⃗⃗⃗ሻ� − �௦ ݀�௦⃗⃗⃗ 
(eq51) 
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In the Polarizable Continuum Model (PCM),[34,35] the Conductor-like Screening Model 
(COSMO)[36,37] and the related C-PCM models[38] the cavity is determined by empirically 
scaled van der Walls radii, and the electrostatic effects are calculated as in eq48. They are 
all similar, but in the conductor-like models the continuum outside the cavity has a 
dielectric constant set to infinity. However, implicit solvation models cannot account for 
explicit solvation effects such as hydrogen bonding and electron pair coordination to 
cations. Such effects can have a great influence in predicting the properties of a solute in 
solution; an example is reported in Chapter 4, where the stability of the neutral and 
zwitterionic form of ciprofloxacin has been studied. 
 
2.4 Molecular Dynamics Simulation (MD) 
The molecular dynamics simulation method (MD) is based on NewtoŶ’s secoŶd laǁ. This 
method assumes that each particle constituting the system behaves like a Newtonian 
particle, and quantum behaviour is completely ignored. This means that electronic 
motions are not considered, electrons are assumed to remain in their ground state and 
adjust their dynamics instantly when atomic positions change (Born-Oppenheimer 
approximation) and the motion of the particles is described only through classical 
mechanics. The equation of motion: 
 ⃗ܨ = ݉ܽ⃗ 
(eq52) 
is applied on the particles where ⃗ܨ is the force, m is mass and ܽ⃗ is the acceleration of the 
particle. 
Once the speeds and position of each atom are known, the state of the system can be 
predicted and new positions and speeds can be calculated. The procedure can be 
repeated several times, thereby defining an atomic trajectory. Several algorithms can be 
used to solve NeǁtoŶ’s eƋuatioŶs of ŵotioŶ ďǇ integration; two common algorithms are 
the Verlet integrator and the leap-frog integrator, both implemented in GROMACS 
software.[39] 
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2.4.1 The Verlet and velocity Verlet algorithm 
The Verlet algorithm[40] uses positions and accelerations at time t and  positions from time 
(t-ΔtͿ to calculate Ŷeǁ positioŶs at tiŵe (t + ΔtͿ. The Verlet algorithm uses no explicit 
velocities and it is a two-step method, ďecause it estiŵates ǆ (t+ΔtͿǀ from the current 
position x(t) and the previous position x(t-ΔtͿ. Therefore, it is not self-starting: initial 
positions x(0) and velocities v(0) are not sufficient to begin a calculation, and a backward 
Euler method must be used at t = 0 to get x(-ΔtͿ. 
 ݔሺ� + ∆�ሻ = ͳʹ ܽ∆�2 + ݒሺ�ሻ∆� + ݔሺ�ሻ 
(eq53) ݔሺ� − ∆�ሻ = ͳʹ ܽ∆�2 − ݒሺ�ሻ∆� − ݔሺ�ሻ 
(eq54) ݔሺ� + ∆�ሻ = ܽ∆�2 − ݔሺ� − ∆�ሻ∆� + ʹݔሺ�ሻ 
(eq55) 
 
Velocity Verlet algorithm[41] is the complete form of Verlet algorithm. In this algorithm, 
both the atomic positions and velocities are calculated at the same time. Positions and 
velocities at time t are used to integrate the equations of motion. Therefore, positions, 
ǀelocities aŶd acceleƌatioŶs at tiŵe t + Δt aƌe oďtaiŶed fƌoŵ the saŵe ƋuaŶtities at tiŵe 
t. 
 ݔሺ� + ∆�ሻ = ∆�2ʹ݉ ܨሺ�ሻ +  ݒሺ�ሻ∆� + ݔሺ�ሻ 
(eq56) ݒሺ� + ∆�ሻ = ∆�ʹ݉ [ܨሺ�ሻ + ܨሺ� + ∆�ሻ] + ݒሺ�ሻ 
(eq57) 
 
2.4.2 Leap-frog algorithm 
The leap-frog algorithm[41] is similar to the Verlet algorithm, since it is made of two steps. 
First, the velocities are calculated at time ቀ� + ଵ2 ∆�ቁ; by using such velocity as an initial 
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velocity the position x can be calculated at time (x+ΔtͿ. IŶ this ǁaǇ, the velocities leap over 
the positions, then the positions leap over the velocities. 
 ݔሺ� + ∆�ሻ = ݒ (� + ͳʹ ∆�) + ݔሺ�ሻ 
(eq58) ݒ (� + ͳʹ ∆�) = ݒ (� − ͳʹ ∆�) + ܽሺ�ሻ∆� 
(eq59) ݒሺ�ሻ = ͳʹ [ݒ (� − ͳʹ ∆�) + ݒ (� + ͳʹ ∆�)] 
(eq60) 
 
2.4.3 Empirical force field 
The crucial step in MD simulations is describing the atomic interactions of a molecular 
system, called the force field (FF). The FF cover all relevant molecular interactions that will 
model the important degrees of freedom. So, first of all, the forces need to be evaluated. 
As described above, the force ܨప⃗⃗⃗ at time t is determined by the gradient of the potential 
energy E with respect to the position coordinates of the particle i according to: 
 ܨప⃗⃗⃗ = −∇�� 
(eq61) 
The potential energy can be calculated as bonded (intra-molecular) and non-bonded 
(intermolecular) interactions: 
 � =  ∑ ��௕௢௡�௘� + ∑ ��௡௢௡−௕௢௡�௘�  
(eq62) 
In Figure 6 the energy terms described in the force field are reported, while the bonded 
and non-bonded interaction will be explained below. 
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Figure 6 Graphic illustrations of the energy terms described in the force-field terms. 
 
2.4.4 Bonded interactions 
As reported in Figure 6, there are four types of interactions between bonded atoms: 
 Stretching along the bond (Vstr). 
 Bending between bonds (Vb). 
 Planar distortion or improper dihedrals (Vimp).   
 Torsion (Vtor). 
Vstr represents the energy required to stretch or compress a covalent bond. The bond is 
considered as a spring having its own equilibrium length, r0 (i.e., the bond distance where 
the molecule is at a minimum energy level), and the energy required to stretch or 
compress the bond can be approximated by Hooke’s laǁ (for an ideal spring): 
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�௦�௥ = ͳʹ �௦�௥,�௝(� �௝ − �଴)2 
(eq63) 
Vb is the energy required to bend a bond from its equilibrium aŶgle, θ0. Bending can also 
be modelled by a spring; the energy is given by Hooke's law with respect to angle: 
 �௕ = ͳʹ �௕,�௝௞(ߠ �௝௞ − ߠ଴)2 
(eq64) 
Vimp is the energy required to deform a planar group of atoms from its equilibrium angle 
(o), usually equal to zero. The system also can be modelled by a spring, and the energy 
is given by Hooke's law with respect to planar angle: 
 ��௠௣ = ͳʹ ��௠௣,�௝௞௟(߱ �௝௞௟ − ߱଴)2 
(eq65) 
Vtor is the energy needed to rotate around the bonds. Torsional interactions are modelled 
by the potential: 
 ��௢௥ = ∑ ܭ�ሺͳ − cosሺ݊� − ߜሻሻଵ−4 ௣௔�௥௦  
(eq66) 
ǁheƌe φ is the aŶgle, ɷ is the phase aŶd Ŷ is the Ŷuŵďeƌ of peaks iŶ a full rotation. In the 
equations, i, j, k, l are the various atoms or particles. 
 
2.4.5 Non-bonded interactions 
There are two potential functions to be concerned about between non-bonded atoms: 
 Columbic interactions between electrostatic charges. 
 Lennard-Jones interaction energy, which reflects the van der Waals interaction 
between atoms. 
In electrostatic interactions, atom charges are involved. Opposite atom charges attract 
and, like atom charges, repel each other.  
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In this potential, the force of the attraction is inversely proportional to the square of the 
distance: 
 ⃗ܨ = ݍଵݍ24ߨߝ଴�2 
(eq67) 
where q1 and q2 are the partial atomic charge of the atoms or particles, 0 is the dielectric 
constant of the medium, r is the distance between the two atoms. In van der Waals 
interactions, (VVdW) two atoms not having a moment of electrical multipole interact 
attractively among themselves thanks to an interaction known as induced dipole-dipole 
interaction. Such interaction gets stronger the more the atoms are polarizable and the 
closer they are to each other. However, the two atoms cannot approach the infinite, and 
for very short distances the repulsive force becomes dominant. The potential is defined, 
called Lennad Jones potential (LJ) as: 
 ��௝ = 4ߝ�௝ (ቆ��௝��௝ ቇଵ2 − ቆ��௝��௝ ቇ6) 
(eq68) 
ǁheƌe ɸ is the depth of the poteŶtial ǁell, σ is the fiŶite distaŶce at ǁhich the iŶteƌ-particle 
potential is zero and r is the distance between atom i and atom j.  
Most of the force field parameters are taken from experimental data on small molecules, 
while others are taken from theoretical calculations. In general, crystallographic data are 
useful to obtain reference bond lengths and angles. Indeed, spectroscopic data can 
provide force constants to bonds, angles and improper dihedral. Dihedral parameters and 
partial atomic charges are usually derived from quantum chemical calculations. The 
parameters for the Lennard-Jones function are usually derived from knowledge of 
diffusion, viscosity and heats of vaporization in the condensed phase and refined by 
molecular dynamics simulations.  
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Platinum-based Antitumor 
Drugs: Theoretical Study of 
the Mechanism of Action and 
Interaction with Graphene 
 
 
For years I’ve ďeen saying Đisplatin is the 
first platinum-based drug we discovered. 
It Đan’t possiďly ďe the ďest one! 
It’s disappointing that the sĐientifiĐ 
community has not been able to find 
better one 
Cit. ͞Barnett Rosenďerg” 
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3.1 Introduction 
3.1.1 A brief history of platinum-based antitumor drugs 
The history of platinum-based antitumor drugs started by accident over 50 years ago in 
the laboratory of the physicist Barnett Rosenberg at Michigan State University. Rosenberg 
was studying the effect of electromagnetic radiation on bacterial and mammalian cells in a 
growth chamber.  In the early experiments using Escherichia coli (E. coli), a set of platinum 
electrodes (considered to be inert) was included in the growth chamber, and after the 
electric field was activated the bacteria grew up to 300 times their normal length, 
becoming very long filaments.  Such effect has been shown to be due to electrolysis 
products derived from platinum electrodes rather than to the electric field. Detailed 
chemical analysis later identified the diamminedichloroplatinum(II) [Pt(NH3)2Cl2] complex 
as responsible for the phenomenon.  
 
 
Scheme 1 Schematic representation of cisplatin and transplatin. 
 
Rosenberg and his co-workers published the discovery in 1965[1] and, in order to further 
clarify it, they synthesised both cis and trans isomers of the [Pt(NH3)2Cl2] and tested their 
activity on E. coli, thereby finding out that the cis isomer caused an efficient inhibition of 
cell division, whereas the trans isomer was rather inefficient at inhibiting it. Hence, the cis 
isomer (the active complex) is now called cisplatin, while the trans isomer is now referred 
to as transplantin (see Scheme 1).[2–4]   
In 1968, following further tests against various bacteria, cisplatin was administered to 
mice possessing tumour sarcoma-180 at the non-lethal dose of 8 mg per kg, and was 
shown to cause marked tumour regression. In 1971, after a long series of tests, cisplatin 
was used to treat the first patients , and in 1978  it was finally approved by US Food and 
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Drug Administration (US FDA).[3] The  discovery  resulted in a revival of inorganic chemistry 
and  led to the synthesis and biological evaluation of many thousands of molecules similar 
to cisplatin; it also led to an in-depth investigation of other elements close in  the periodic 
table (eg. palladium and gold).[5–7] Currently, cisplatin is  primarily used  to treat testicular, 
ovarian, and bladder cancers, but it has also been used in the treatment of head and neck 
cancers, lung cancer, malignant pleural mesothelioma, neuroblastoma, tumors of the 
brain, and esophageal and cervical cancers.[8,9] 
 
3.1.2 Mechanism of action of cisplatin  
The generalized mechanism of action involves four key steps (Figure 1): (1) cellular uptake, 
(2) activation by the hydrolysis reactions, (3) DNA binding and (4) cellular processing of 
DNA lesions leading to cell death .[10,11]  
 
 
Figure 1 Extracellular and intracellular events that influence cisplatin activity. 
 
Cisplatin could enter the cell through two pathways by passive diffusion through the plasma 
membrane and by active transport mediated by membrane proteins.[12,13] The particular 
structure of cisplatin, characterized by a small size and a square-planar geometry, has long 
been cited as supportive of passive diffusion. Indeed, cisplatin uptake does not saturate 
with increasing concentration and is proportional to the administered concentration.[13] 
On the contrary, other studies suggest that the predominant mechanism of uptake is 
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active transport. Indeed, many works focus on the importance of copper transporters, 
such as CTR1, which can mediate the uptake of cisplatin.[14,15] A combination of both 
passive and active transport best explains the data accrued to date, but the relative 
importance of these pathways and the extent to which they influence each other remain 
to be determined. 
Besides affecting cisplatin uptake, the square-planar geometry of cisplatin facilitates the 
ligand substitution, which is indispensable for it to form the DNA lesions that characterize 
its activity. Upon entry into the cell, cisplatin ďecoŵes ͚actiǀated’ by the ligand 
substitution, in which chloride ligands are replaced by water molecules to form cis-
[PtCl(H2O)(NH3)2]+ and cis-[Pt(H2O)2(NH3)2]2+. A schematic representation of the hydrolysis 
reaction is reported in Scheme 2.  
 
 
Scheme 2 The hydrolysis reaction of cisplatin. The first hydrolysis reaction replaces a chloride ligand with a 
water molecule giving a net positive charge. The second stage hydrolysis reaction replaces the second 
chloride ligand with another water molecule which gives a 2+ net positive charge. 
 
Depending on the pH of the solution, the coordinated water molecules may deprotonate 
to give hydroxo complexes. Experimental evidence indicates that such aquation is 
suppressed in the bloodstream, where the chloride ion concentration is high (∼100 mM), 
but occurs more readily in the cytoplasm, where the chloride ion concentration falls below 
20 mM.[4,16,17] The positive charge on the aquated platinum complex can attract it to the 
negatively charged nuclear DNA. There is general agreement  that DNA is a key biological 
target of cisplatin[18,19], based on experiments in which DNA repair-deficient prokaryotic 
and eukaryotic cells were found to exhibit a hypersensitivity to cisplatin treatment.[20,21] 
Although decades of research have supported the hypothesis that nuclear DNA is the 
functional target of platinum drugs, interactions with proteins and RNA have also been 
suggested as possible targets.[22–24] Activated cisplatin can enter the nucleus, and the 
coordinated water molecule can be substituted by a heterocylic DNA base, being the Pt-
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OH2 bond much more reactive than Pt-Cl. The most nucleophilic sites of DNA are the N7 
atoms of the imidazole ring of DNA purine bases (guanine and adenine, see Scheme 3), 
which are preferentially platinated. 
 
 
Scheme 3 Schematic representation of the guanine and adenine purine bases. 
 
Spectroscopic experiments revealed that cisplatin first forms monofunctional adducts on 
DNA. Following this event, the remaining water ligand is substituted for a second guanine 
base, forming a cross-link on the DNA. The majority of DNA adducts result from the 
binding of cisplatin to adjacent purine bases on the same strand of the DNA helix; they 
are called intrastrand DNA adducts and they are the significant sites of cisplatin’s 
biological effectiveness and anti-tumour activity. However, a smaller proportion of its 
biological activity is attributed to DNA adducts formed at AG, GA and GC sequences.[25–27] 
An experiment was conducted on DNA fractions to assess the amount of cisplatin bound 
to DNA. 1,2 GG intrastrand adducts (formed between two adjacent guanine bases on the 
same DNA strand) are the most prevalent lesions, and account for approximately 65% of 
all DNA adducts. 1,2 AG intrastrand adducts (formed between adjacent adenine and 
guanine bases on the same DNA strand) account for about 25% of all adducts, and 1,3 GG 
intrastrand adducts (formed between two non-adjacent guanine bases on the same DNA 
strand) account for about 10 % of all adducts.[28,29] GG interstrand adducts (where 
platinum binds to guanine bases on opposite strands of the DNA) was also detected. Such 
adducts are considerably less common than intrastrand DNA adducts, accounting for only 
2% of all adducts formed by cisplatin .[29,30] The four different types of DNA adducts 
formed by cisplatin are shown in Figure 2. 
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Figure 2 Images showing the four different types of DNA adducts formed by cisplatin.  The 1,2 GG intrastrand 
adduct is formed by cisplatin binding to two adjacent guanine bases on the same DNA strand. The 1,2 GA 
intrastrand adduct is formed by cisplatin binding to adjacent guanines and adenines on the same DNA 
strand. The 1,3 GG intrastrand adduct is formed by cisplatin binding to two non-adjacent guanines on the 
same DNA strand. The GG interstrand adduct is formed upon cisplatin binding to two guanines on opposite 
strands of the DNA helix. 
 
These DNA adducts distort the structure of DNA in a substantial manner, resulting in the 
bending and unwinding of the double helix upon platination.[28] Atomic resolution 
structures of many adducts formed by different platinum anticancer agents are now 
available; some of them , relative to cisplatin, are reported in Figure 3.[31] Cells with DNA 
presenting these distortions arrest at the G2/M transition of the cell cycle and attempt to 
repair the platinated DNA. Lesions formed by cisplatin inhibit RNA polymerase II, the 
enzyme responsible for transcription of mRNA precursors that ultimately form proteins in 
humans.[32] If the polymerase becomes stalled at the platinum adduct, additional proteins 
are recruited to repair the damage. Cisplatin lesions are effectively removed by the 
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nucleotide excision repair (NER) machinery, and enhanced NER can produce cells that 
resist platinum treatment.[33,34] The repair machinery must be able to access the lesion, 
but there are some proteins, not involved in DNA repair, that bind to a platinum lesion 
and can effectively shield it from repair. 
 
 
Figure 3 Structures of double-stranded DNA adducts of cisplatin determined by X-ray crystallography or 
NMR spectroscopy. Cisplatin 1,2 GG intrastrand cross-link (PDB 1AIO). Cisplatin 1,3 GTG intrastrand cross-
link (PDB 1DA4).  Cisplatin interstrand cross-link (PDB 1A2E). 
 
One class of proteins includes the high-mobility group (HMG) box proteins, that recognize 
and bind distorted DNA. Indeed, cisplatin induces distortions in the DNA double helix 
resembling those recognized by some HMG proteins.[35] The HMGB proteins are among 
the most abundant proteins in the nucleus[36] and display a particular affinity to  
[Pt(NH3)2]2+ 1,2 GG intrastrand cross-links, the most abundant lesions.[37] The proteins’ 
ability to shield the platinum lesions could contribute to the cisplatin sensitivity of the 
cancer cells that overexpress them. However, the cellular redox environment can 
influence the interaction of HMGB with the platinated DNA and suggest that the redox 
state HMGB is a potential factor in regulating the role of the protein in modulating the 
activity of cisplatin as an anticancer drug.[38] If the cell is unable to repair the platinum-
DNA lesion, the expression of pro-apoptotic proteins increases, prompting the release of 
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cytochrome C and the activation of intracellular caspases, a family protease enzymes  
playing an essential role in programmed cell death. Such proteases effectively degrade 
the cell in a process of programmed cell death known as apoptosis.[39] 
However, there are many pathways in which platinum complexes can be deactivated to 
prevent the apoptosis.[40] The current platinum drugs are all administered intravenously 
and can interact with blood components, one of which is human serum albumin (HAS), 
the most abundant protein in the human bloodstream. This protein contains a cysteine 
residue that can interact with platinum complexes.[41] However, the main interaction of 
cisplatin with HAS seems to involve the thionester side chains of methionine residues 
rather than the cysteine thiol groups.[42] Moreover, once inside the cell and after 
hydrolysis reaction, platinum complexes can interact with biomolecules other than DNA. 
Cisplatin reacts with molecules containing sulfur atoms such as tripeptide glutathione 
(GSH) and metallothioneins (MT) (5), species rich in amino acids like cysteine and 
methionine, eventually causing the inactivation of cisplatin.[33]  Reactions with 
biomolecules other than DNA are among the possible causes of generation of drug 
resistance. As part of the cellular detoxification program, platinum-glutathione adducts 
are removed by dedicated export pumps from the cytoplasm. 
 
3.1.3 Other platinum(II) compounds with a mechanism of action similar to 
cisplatin’s 
Following the initial reports of the anticancer activity of cisplatin, inorganic chemists 
started preparing a variety of platinum complexes with different ligands and testing their 
anti-neoplastic effects. The results of these studies have revealed a set of rules governing 
the molecular structure, necessary for a platinum complex to have an activity.[43] The 
structures activity relationships (SARs) reveal that platinum complexes must have a 
square-planar geometry, be neutrally-charged, contain two cis amine ligands and have 
two cis anionic ligands. The anionic ligands cannot bind the platinum too tightly, otherwise 
its activity could be reduced. Moreover, the two amine ligands and the two anionic ligands 
can be replaced by a chelating diamine or chelating dicarboxylate respectively. Extensive 
drug discovery programs relying on systematic variation of ligands have been initiated 
according to such rules.[5–7,44,45] Many efforts have been made to find novel platinum 
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complexes that could be safer than cisplatin for patients. Indeed, although on the one 
hand cisplatin shows high antiproliferative activity, on the other hand it shows many side 
effects, including nephrotoxicity, ototoxicity, neurotoxicity, myelotoxicity, haematological 
toxicity and gastrointestinal reactions (see Figure 4).[8,33,46]  
 
 
Figure 4 Toxicities associated with treatment with platinating agents 
 
Unfortunately, most of the newly-found compounds were rejected in the preclinical stage; 
only carboplatin and oxaliplatin are now in world-wide clinical use (see scheme 4), while 
nedaplatin, heptaplatin and lobaplatin are marketed platinum antitumor drugs.[39] The 
toxicity of platinum-based drugs is directly related to the ease with which the leaving 
ligands are replaced by water molecules. Platinum complexes that present highly labile 
ligands, such as water or nitrate, are very toxic, whereas ligands such as bis-carboxylates, 
where the hydrolysis process is very slow, are significantly less toxic. Diammine [1,1-
cyclobutanedicarboxylato(2-)-O,O’] platinuŵ;IIͿ, noǁ known as carboplatin, was designed 
specifically to reduce the side effects associated with cisplatin treatment. In carboplatin, 
the chloride ligands were replaced with 1,1-cyclobutanedicarboxylate, leading to a 
reduced hydrolysis rate constant in respect to cisplatin (10-8 s-1 for carboplatin and 10-5 s-
1 for cisplatin).[47,48] Carboplatin is used primarily to treat ovarian cancer but has also found 
use in treating retinoblastomas, neuroblastomas, nephroblastomas and brain tumors, as 
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well as cancers of the head and neck and endometrium, cervix, testes, breast, lung and 
bladder cancers.[9] 
 
 
Scheme 4 Schematic representation of carboplatin and oxaliplatin and marketed platinum antitumor drugs. 
 
 [Oxalate(2-)-O,O’][1R,2R-cyclohexanediamine-N,N’] platinuŵ(II), now known as 
oxaliplatin, was the first drug capable of overcoming cisplatin resistance to be approved. 
In oxaliplatin the two ammine ligands have been replaced by a single bidentate ligand, 
(1R,2R)-cyclohexane-1,2-diamine(R,R-dach).[3] Oxaliplatin is thought to overcome 
cisplatin resistance through the different adducts it forms with DNA.[49] Oxaliplatin, like 
cisplatin, does form GG intrastrand adducts,  but the bulky hydrophobic ligand points into 
the DNA major groove and prevents the formation of the bond with proteins repairing 
DNA.[50] Moreover, the oxalate ligand greatly reduces the severity of the side effects of 
the drug compared with cisplatin.[49] Currently, Oxaliplatin  is widely approved for the 
treatment of adjuvant and metastatic colorectal cancers when used in combination with 
5-FU (5-fluorouracil) and folinic acid.[51] Diammine [hydroxyacetato(2-)-O,O’] platinum(II), 
nedaplatin, is a second-generation platinum analogue  ten times more water soluble than 
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cisplatin, and significantly less nephrotoxic than both cisplatin and carboplatin.[52,53] 
Preclinical and clinical studies demonstrated that nedaplatin’s anticancer activity is 
superior to carboplatin’s and equivalent to cisplatin’s.[53,54] Since its approval in 1995, 
nedaplatin has been used in the treatment of oesophageal cancer and head and neck 
cancers .[53,55] 
Heptaplatin was selected for clinical trials because its in vitro and in vivo cytotoxicity was 
equal or superior to cisplatin in various cell lines. Moreover, it also displayed high stability 
in solution, no remarkable toxicity and a potent anticancer activity towards cisplatin-
resistant cell.[56–58] 
Lobaplatin is a third-generation platinum anticancer drug delivered as a diastereomeric 
mixture of S,S and R,R configurations of the carrier ligand and presents less side effects 
than cisplatin and carboplatin.[59] Although our understanding of cisplatin and other novel 
anti-cancer drugs has advanced through an array of discoveries determined from past 
research investigations, further study and characterisation is much needed. The goal is to 
provide a greater understanding of DNA-drug interactions and potentially enable the 
design of enhanced anti-cancer drugs to overcome the cytotoxic effects and tumour 
resistance associated with cisplatin. 
 
3.2 Hydrolysis reaction in Triphenylphosphane Pt(II) Complexes 
Containing Biologically Active Natural Polyphenols: DFT Study. 
3.2.1 Introduction 
The antitumor activity of dietary flavonoids comprising a massive group of polyphenolic 
compounds[60,61] has recently been reviewed.[62] The pharmacological effects of flavonoids 
include induction of apoptosis, antiproliferation, antimetastatic and antiangiogenesis.[62] 
Because of structural differences, flavonoids are divided into eight different groups, 
flavonols being one of them. 3-Hydroxyflavone (3-Hlf, Scheme 5) is the backbone of all 
flavonols.[63] Due to their polyphenolic structure, flavonols are effective metal ion 
chelators, playing a key role in the initiation of free radical and antioxidant processes.[64] 
Moreover, flavonols can intercalate into DNA as well as covalently bind to DNA and 
proteins.[65,66] As a result of such characteristics, flavonols have complex biological 
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interactions and are combined in some therapies with cisplatin, increasing efficacy over 
individual treatments[67] and reducing side effects.[68] However, the combinations of 
flavonols with platinum are poorly.[69] Like flavonols, plant phenols such as ethyl gallate 
(etga, Scheme 5) also have an antitumor activity and can effectively bind metal ions.[70,71]  
 
 
Scheme 5 Schematic representation of 3-Hydroxyflavone and ethyl gallate. 
 
In some cases, phosphane ligands with a hydrophobic character have been shown to 
increase the cytotoxicity of their platinum complexes, due to a possible enhancement of 
the cellular membrane transfer process.[72] In previous works,[73,74] interesting results 
were obtained by synthetizing platinum compounds bearing two mutually cis-triphenyl-
phosphanes with bioactive ligands. The studies reported that Pt(II) complexes containing 
PPh3 have a remarkable cytotoxic activity on some cancer cell lines. However, a total 
replacement of the usually employed amine carrier ligands with air and water stable 
triaryl-phosphanes may exhibit some disadvantages, the major of which being tertiary 
phosphane’s inaďility to establish any hydrogen bond with the DNA backbone. However, 
triaryl-phosphane ligands may stabilize DNA-Pt adducts through - interactions 
occurring between the phosphane phenyl groups and the nucleobases.[75] 
In ϮϬϭ6 Dell’Anna[76] and co-workers synthetized and characterized three triphenyl-
phosphane Pt(II) complexes containing quercetin (Que) cis-[Pt(Que)(PPh3)2], etga cis-
[Pt(etga)(PPh3)2] and 3-Hfl cis-[Pt(3-Hfl)(PPh3)2]+ and they  have been biologically 
characterized 3-Hfl cis-[Pt(3-Hfl)(PPh3)2]+ and cis-[Pt(etga)(PPh3)2] (Table 1). 
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Table1 Cytotoxicity of hydroxyflavone, ethyl gallate, cis-[Pt(3-Hfl)(PPh3)2]+, cis-[Pt(etga)(PPh3)2], cis-
[PtCl2(PPh3)2] and cisplatin toward U87 and MCF-7 cancer cell lines.  
 IC50 (µM) 
Compound U87 MCF-7 
cis-[Pt(3-Hfl)(PPh3)2]+ 26.3 ± 2.1 55.2 ± 1.7 
3-Hydroxyflavone 27.5 ± 2.3 108.1 ±3.5 
cis-[Pt(etga)(PPh3)2] 123.7 ± 3.8 >200 
Ethyl gallate 97.7 ± 2.6 >200 
cis-[PtCl2(PPh3)2] >200 >200 
cisplatin 1.76 ± 0.22 14. ± 3 
 
As reported in Table 1, cell cycle studies (in the dark) of the complexes in two human cell 
cancers lines (U87, MCF-7) revealed that the cytotoxic activity of the complex bearing 3-
Hfl is higher than the one exhibited by 3-Hfl alone in MCF-7 cancer cell. cis-
[Pt(etga)(PPh3)2], instead, presents less cytotoxic activity than etga alone. However, both 
these complexes exhibit much lower cytotoxicity than cisplatin, while cis-[PtCl2(PPh3)2] 
results totally inert. 
The ligand released by hydrolysis, a key-step for DNA-adduct formation, attracted 
numerous experimental studies.[25] However, the results obtained through experimental 
studies do not always offer the same insight provided by computational studies. 
Therefore, the hydrolysis reaction of cisplatin and many other platinum-based drugs have 
been extensively studied using computational techniques, in particular the DFT 
approach.[53,77–88] 
Chval et al.[77] made one of the first computational works related to the study of the 
hydrolysis reaction in 2000. Their work investigated the hydrolysis reaction for cisplatin 
using MP2 and DFT calculations. The first and second step of the hydrolysis reactions 
belong to the class of second-order nucleophilic substitution (SN2) reactions. The reactions 
for square-planar complexes proceed via a collision between the reactant and two 
consecutive nucleophilic species, attacking the metal centre to release the ionic ligand. In 
such process, a transition state adopts a substantially trigonal bipyramid geometry, in 
which the entering molecule and the leaving group result weakly bound to the metal 
atom, suggesting an associative mechanism. The activation barrier attains 21.3 kcal mol-1 
in the first step and 26.1 kcal mol-1 in the second. 
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In 2005 Burda et al.[78] studied the thermodynamic and kinetic aspects of the hydrolysis 
reactions of cisplatin and transplatin. The hydration of Pt complexes was considered in 
two steps. In each of them concurrent reactions of dechlorination and deammination 
were expected. An associative mechanism was assumed for the reaction course, in which 
a trigonal bipyramidal structure of TS was determined. Results showed that the 
determined rate constants of the dechlorination process are by several (three to four) 
orders of magnitude larger than the constants of the deamination process, indicating that 
the deamination is highly disadvantaged. 
In 2009 Alberto et al.[53] studied the first and the second hydrolysis of Nedaplatin, using 
DFT calculation combined with CPCM approach, corresponding to the ring opening 
followed by the loss of the ligand, in neutral and acid conditions respectively. In addition 
to the reactive water molecule, their models featured an explicit water molecule, which 
could assist the degradation processes. They found out that the rate determining step in 
neutral conditions is the first hydrolysis process and, consequently, the double hydrated 
complex is suggested to be the species reacting with the DNA purine bases, while in acid 
conditions the trend is different, with the second hydrolysis process being the rate limiting 
step. 
In 2011 Melchior et al.[83] made a comparative study of the hydrolysis of cisplatin and the 
third-generation platinum anticancer compound picoplatin cis-[PtCl2(NH3)-(2-picoline)] 
using the DFT calculations. Solvent effects were taken into account either by applying the 
PCM approach or by introducing a cluster of water molecules solvating the complex. 
Results show that the steric hindrance of 2-picoline has a minimum impact on the 
activation barriers for picoplatin hydrolysis. Moreover, the authors demonstrated that the 
use of separated reactants as a reference for the energy barrier gives satisfactory results 
and produces correct relative magnitudes of the first and second hydrolysis rate constants 
for each compound. However, the approach is not able to predict the faster hydrolysis 
observed experimentally on cisplatin with respect to picoplatin, while the discrete 
solvation model is able to correctly predict a slightly slower hydrolysis of picoplatin. 
In 2017 Mitra el al.[87] studied the hydrolysis processes of cytotoxic Pt(II) and Pd(II) 
complexes bearing benzimidazole moieties combining DFT with CPCM approach. The 
results revealed that the rate-limiting step is the second aquation, suggesting that the 
monohydrated complex is most likely to react with the DNA bases. The results provided 
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detailed energy profiles for the hydrolysis mechanism, which help understanding the 
interaction of such anticancer agents with their ultimate cellular target. 
 
3.2.2 Aim of this work 
The aim of this work is to study the hydrolysis reaction in cis-[Pt(PMe3)2(etga)] and in cis-
[Pt(PMe3)2(3-Hfl)]+ by means of DFT calculations. A detailed computational study of the 
hydrolysis reaction could clarify the causes of the poor cytotoxicity of such complexes. In 
order to study the platinum complexes with two flavonols, two different hydrolysis 
pathways have been considered (Scheme 6), due to the asymmetry of the starting 
complex. Finally, the activation energy obtained for cis-[Pt(PMe3)2(etga)] and cis-
[Pt(PMe3)2(3-Hfl)]+ has been compared with the activation energies obtained for cisplatin 
and no-active cis-[Pt(Cl)2(PMe3)2]. 
 
 
Scheme 6 Hydrolysis reaction in (a) cis-[Pt(PMe3)2(etga)] and in (b) cis-Pt[(PMe3)2(3-Hfl)]+. 
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3.2.3 Computational details 
In this work we studied the hydrolysis reaction for cis-[Pt(PMe3)2(etga)], cis-[Pt(PMe3)2(3-
Hfl)]+, cispatin, and cis-[PtCl2(PMe3)2] by means of DFT calculations using mPW1PW91 
functional, which had been previously demonstrated to provide reliable structures and 
energies for cisplatin and its derivatives.[83] For computational convenience, Phenyls were 
replaced in PPh3 groups by methyl (Me) groups. Geometry optimizations were carried out 
in vacuum, with a 6-31+G(d) basis set for all atoms except the platinum atom, which was 
described by the quasi-relativistic Stuttgart– Dresden pseudopotential (SDD).[89] In order 
to confirm that stationary points were actually minima or transition state geometries, 
analytical calculations of second derivatives of the energy and vibrational frequency 
analysis were carried out. The frequencies are related to the eigenvalues of the Hessian 
matrix, which contains second derivatives. If the eigenvalues are all positive, then the 
frequencies are all real and the stationary point is a local minimum. If one eigenvalue is 
negative and one imaginary frequency is present, then the stationary point is a transition 
structure. The character of the transition states was confirmed by existence of a single 
negative eigenvalue of the hessian matrix corresponding to the appropriate 
antisymmetric stretching mode. Due to the key role of solvation in influencing 
thermodynamic and kinetic parameters in metal complex reactivity,[90–92] environmental 
effects were introduced by representing water surrounding the reagents, transition states 
and products as a polarizable continuum method (PCM).[93] Since the solvent is also the 
reagent, it has been represented as an explicit H2O molecule added to the initial reagent 
(R).[76,83] The initial position of the molecule is between the O atom of the leaving ligands 
and the P atom of the ancillary ligand, 3.0 Å to 3.5 Å from the Pt atom. Such adduct is 
called reactants adduct (RA). After the TS, the leaving Cl atom are in proximity of the 
acquo-complex (products adduct, PA); in the final product (P), the Cl atom have been 
separated. Potential energy profiles were estimated from total electronic energies adding 
zero ZPVE and thermal corrections at 298.15 K. Total electronic energies plus thermal 
corrections (instead of free energies) are reported in order to uniform our data to those 
obtained in previous works.[53,83] DFT calculations were performed with the Gaussian 09 
program.[94]  
 
 pag. 55 
 
Chapter 3 
3.2.4 Results and discussion 
The notion of hydrolysis of platinum(II) anticancer complexes as a bimolecular 
nucleophilic substitution SN2 has been widely accepted on the basis of a large number of 
experimental data. The initial square-planar complex is converted to a bipyramidal (5-
coordinated) transition state (TS), in which the incoming water molecule and the leaving 
chloride are weakly bound to the metal.[77] The structural features of this trigonal 
bipyramid are relevant for determining the hydrolysis activation barrier. 
The first hydrolysis (first step) leads to the ring-opening process, with the 3-Hfl and etga 
derivatives remaining mono-coordinated to the metal ion center. The second hydrolysis 
(second step) leads to the complete release of 3-Hfl and etga. The reaction profile of the 
hydrolysis reaction in cis-[Pt(PMe3)2(etga)] is discussed in paragraph 3.2.4.1, while the 
reaction profile for the hydrolysis reaction in cis-[Pt(PMe3)2(3-Hfl)]+ is discussed in 
paragraph 3.2.4.2. 
 
3.2.4.1 Hydrolysis reaction in cis-[Pt(PMe3)2(etga)] 
In Table 2 some selected bond lengths and angles along with the experimental data (with 
relative estimated standard deviations (esd)) for cis-[Pt(PMe3)2(etga)] are reported (Figure 
5).[76] The calculated bond lengths and angles are in good agreement with the 
experimental ones, confirming the reliability of the used computational protocol; the 
mean absolute error (MAE) and root-mean-square deviation (RMSD) index[95] calculated 
on bond lengths are 0.002 Å and 0.006 Å respectively. 
 
 
Figure 5 Crystal structures of cis-[Pt(PPh3)2(etga)]. 
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Table 2 Comparison selected bond lengths (Å) and angles (°) in cis-[Pt(PMe3)2(etga)] (optimized structures)  
and in cis-[Pt(PPh3)2(etga)] (experimental X-ray structures) with relative esd (in parentheses). 
Bond distances  Angles  
 
Exp. Calc. 
 
Exp. Calc. 
Pt1-P1 2.257(2) 2.255 P1-Pt1-P2 99.2(9) 103.16 
Pt1-P2 2.261(2) 2.256 P1-Pt1-O2 87.4(2) 83.24 
Pt1-O2 2.050(8) 2.033 P2-Pt1-O2 172.3(2) 173.55 
Pt1-O1 2.031(7) 2.041 P1-Pt1-O1 169.7(2) 166.75 
C7-O2 1.358(1) 1.351 P2-Pt1-O1 90.6(2) 90.07 
C1-O1 1.353(1) 1.348 Pt1-O1-C1 110.5(6) 101.43 
 
The investigated reaction paths for the hydrolysis of cis-[Pt(PMe3)2(etga)] shown in 
Scheme 6a are reported in Figure 6, while energy (E) profiles are reported in Figure 7. 
Energy (E) values are referred to separated reactants (R) rather than reactant adducts (RA) 
(Figure 6) since it is widely accepted that, at the beginning of the reaction, the water 
molecule in the second coordination shell of the metal is possible only in vacuum, but it 
seems an artifact in solution.[83] Relevant bond distances of all optimized complexes are 
reported in Table A1 and A2 in appendix A. The energy values corresponding to Figure 7 
are reported in Table A3 in appendix A.  The detachment of the etga ligand in the first 
hydrolysis can occur in two different ways (Scheme 6a): by breaking the bond connecting 
the oǆygen in α position to the OH group (O1 path) or by breaking the other P-O bond (O2 
path). Both O1 and O2 paths (Figure 6a) showed a proton transfer from the incoming 
water molecule to the closer oxygen of the ligand (OL). The result obtained through DFT 
calculations had been previously reported for the hydrolysis of other platinum drugs in 
neutral conditions.[82,96] The products obtained in the second step of the hydrolysis 
reaction (Figure 6b) are the di-hydroxo complex and the formation of free etga. Mono- 
and di-hydroxo complexes should form under physiological conditions, but it has been 
reported that the local pH in the vicinity of macromolecules could be different from the 
physiological one.[97,98] The energy profiles for the first step (Figure 7a) show that the 
formation of the reactant adducts (RA1-O1 and RA1-O2) is energetically favored, although 
the RA1 obtained for the O2 path is slightly more stable (Figure 6a and Table A3 in 
appendix A). 
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Figure 6 a) Optimized structures for the first step of the hydrolysis of cis-[Pt(PMe3)2(etga)]; b) optimized 
structures for the second step of the hydrolysis of cis-[Pt(PMe3)2(etga)]. 
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Figure 7 Activation energy profiles for the hydrolysis of cis-[Pt(PMe3)2(etga)] in PCM water. The Ea of 
Cisplatin and cis-[PtCl2(PMe3)2] are reported for comparison. 
 
Both transition states, TS1-O1 and TS1-O2, show a penta-coordinated structure according 
with an associative SN2 reaction. The imaginary frequencies observed in the transition 
states are about 99.7 cm-1 for TS1-O1 and 157.8 cm-1 for TS1-O2. The analysis of such 
vibrational modes clearly indicates the rupture of the bond between platinum and the 
etga ligand (Pt-OL) and the formation of the metal-water bond. The activation energies 
(Ea = Etransition state – Ereactants) for the two paths are rather different: Ea = 22.8 kcal mol-1 for 
the O1 path and a Ea = 18.7 kcal mol-1 for the O2 path (Table A3 in appendix A). According 
to the results, the release of etga upon opening of the Pt-O2 bond is kinetically preferred. 
Furthermore, such pathway leads to the most stable product (E = EPA1-O1 - EPA1-O2 = 3.6 
kcal mol-1). The difference could be due to the formation of a hydrogen bond (H-bond) 
between OH and the oxygen in  to OH (Figure 8) in TS and in products. 
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Figure 8 Optimized structures of a) TS1-O1, b) TS1-O2, c) PA1-O1 and d) PA1-O2, the most important 
hydrogen bonds are highlighted in blue. 
 
The transition states in the second hydrolysis have a penta-coordinated structure with 
imaginary frequencies of 103.9 cm-1 for TS2-O1 and 101.7 cm-1 for TS2-O2 (Figure 6b). The 
analysis of the two vibrational modes clearly indicates the rupture of the bond between 
platinum and the etga ligand (Pt-OL) and the formation of the metal-water bond. 
The calculated profiles (Figure 7b) show that the two reaction paths have comparable 
activation energy (Ea = EaTS2-O1 - EaTS2-O2 = 0.4 kcal mol-1, Table A3 in appendix A). In 
addition, the final products (P2) do not show a significant energy difference (Table A3 in 
appendix A).  
As shown in Figure 7 (Table A3 in appendix A), the first hydrolysis step has a higher Ea 
compared to the second step, irrespective of the ring opening order; thus, the first 
hydrolysis process is the rate determining step (RDS) of the whole reaction leading to the 
release of etga in the solution.  
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When comparing the energy profiles of cis-[Pt(PMe3)2(etga)] with those of the highly 
cytotoxic cisplatin in the first hydrolysis (Figure 7a), the Ea in the O2 path appears to be 
lower than the Ea of cisplatin ;ΔEa=Ea-TS1-O2 – Ea-cisplatin =−2.7 kcalmol−1). On the contrary, 
the Ea in the O1 path is higher than the one calculated for cisplatin ;ΔEa = +1.4 kcal mol−1) 
(Figure 7a, Figure A1, Table A3 and Table A4 in appendix A). In the second hydrolysis step, 
Ea values for both O1 and O2 paths are much lower than cisplatin Ea value ;ΔEa = −6 kcal 
mol−1 for Oϭ path and ΔEa = −6.4 kcal ŵol−1 for O2 path) (Figure 7b, Figure A2, Table A3 
and Table A5 in appendix A). The results obtained suggest that cis-[Pt(PMe3)2(etga)] leads 
to a mono-hydroxo complex with etga mono-coordinated to the metal, which promptly 
reacts with another water molecule, giving the di-hydroxo species. The mono-hydroxo 
and di-hydroxo species are considered poorly reactive for DNA coordination, therefore 
their formation can limit the efficacy of a platinum metallodrug.[4] Furthermore, the low 
activation energy barriers of the second step and the consequent high hydrolysis reaction 
rate might make this complex subject to fast degradation, causing potentially poor 
pharmacological activity.[99] The obtained Ea value (11.3 kcal mol−1) calculated for the first 
hydrolysis of cis-[PtCl2(PMe3)2], analogue of the cisplatin but biologically inactive, is much 
lower than the Ea calculated for cis-[Pt(PMe3)2(etga)] and cisplatin (Figure 7 and Table A3 
in appendix A). Finally, the Ea calculated for the second hydrolysis of cis-[Pt(PMe3)2(etga)] 
is close to the Ea of cis-[PtCl2(PMe3)2] (Figure 7) and much lower than cisplatin. On the 
basis of the DFT calculations, the complex cis-[Pt(PMe3)2(etga)] should not be expected to 
be highly cytotoxic. 
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3.2.4.2 Hydrolysis reaction in cis-[Pt(PMe3)2(3-Hfl)]+ 
The investigated reaction paths for the hydrolysis of cis-[Pt(PMe3)2(3-Hfl)]+ (Scheme 6b) 
are reported in Figure 9, while the energy profiles are reported in Figure 10. The energy 
values corresponding to Figure 10 profiles and the relevant bond distances of all optimized 
complexes are reported in Table A3-A6 and in Table A7 in appendix A.  
 
 
Figure 9 a) Optimized structures for the first step the hydrolysis of cis-[Pt(PMe3)2(3-Hfl)]+; b) optimized 
structures for the second step the hydrolysis of cis-[Pt(PMe3)2(3-Hfl)]+. 
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Figure 10 Activation energy profiles for the hydrolysis of cis-[Pt(PMe3)2(3-Hfl)]+ in PCM water. The Ea of 
Cisplatin and cis-[PtCl2(PMe3)2] are reported for comparison. 
 
The formation of the intermediate RA1-O2 is slightly energetically favored, while RA1-O1 
formation energy is slightly positive. The difference is probably due to the stronger 
interaction between the O atom of the 3-Hfl ligand and the H atom of the incoming water 
present in RA1-O2. Indeed, an H-bond between such atoms is observed in RA1-O2, but 
not in RA1-O1 (see Figure 9a); the distance between O and H is 1.883 Å in RA1-O2 and 
2.116 Å in RA1-O1. 
As in the previous case, the transition states of both O1 and O2 paths have a penta-
coordinated structure with imaginary frequencies of 87 cm-1 for TS-O1 and 78 cm-1 for TS-
O2. The calculated Ea value is 15.7 kcal mol-1 for the O2 path and Ea = 14.4 kcal mol-1 for 
the O1 path. The O1 opening produces a mono-aquo derivative, while in the O2 path a 
proton transfer leading to the mono-hydroxo complex occurs.  The PA1-O1 is also more 
stable than PA1-O2 (E = EPA1-O1 – EPA1O2 = -1.7 kcal mol-1, Table A3 in appendix A). Here 
again, the difference could be related to the formation of an H-bond between the O atom 
of the 3Hfl ligand and the coordinated water; the distance between the atoms is 1.443 Å 
in PA1-O1 and 1.542 Å in PA1-O2. In conclusion, in the first hydrolysis step the O1 path, 
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leading to a mono-aqua Pt complex, should be more favored than the O2 path (which 
leads to a mono-hydroxo Pt complex). 
In the second hydrolysis (Figure 10b), transition states with a penta-coordinated Pt 
geometry are characterized by a single imaginary frequency (imaginary frequencies: 89 
cm-1 for TS2-O1 and 83 cm-1 for TS2-O2). The calculated Ea values are 11.9 kcal mol-1 and 
9.5 kcal mol-1 for the O1 and O2 path respectively (Table A3 in appendix A). Therefore, 
first hydrolysis is the rate determining step of the process leading to the complete release 
of the 3-Hfl for cis-[Pt(PMe3)2(3-Hfl)]+ too. Furthermore, a comparison between the 
obtained Ea (Figures 7 and 10, Table A3 in appendix A) shows that in both the first and the 
second step the hydrolysis reactions for cis-[Pt(PMe3)2(3-Hfl)]+ proceed faster than the 
reactions for cisplatin (Figure 7 and Table A3 in appendix A). On the contrary, the 
hydrolysis of cis-[Pt(PMe3)2(3-Hfl)]+ is slower than the hydrolysis of cis-[PtCl2(PMe3)2] in 
the first step and faster in the second one. In the O1 path, the final product shows a proton 
transfer from the water molecule bonded to platinum to the closest oxygen of the ligand, 
while in the O2 path such transfer does not occur. The final product of cis-[Pt(PMe3)2(3-
Hfl)]+ hydrolysis is the mono-aquo-mono-hydroxo complex cis-[Pt(PMe3)2(H2O)(OH)]+ (see 
Figure 9b). On the one hand, on the basis of the DFT calculations, some synergic cytotoxic 
effect between the platinum center and the 3-Hfl leaving group effect might be expected 
for cis-Pt[(PMe3)2(3-Hfl)]+, because the mono-aquo platinum species formed in both the 
first and second hydrolysis steps could coordinate DNA.[25] On the other hand, the 
theoretical hydrolysis activation energy, mainly affected by the trans influence of the 
carrier ligand, is significantly lower with respect to cisplatin (Figure 10) and could lead to 
a fast deactivation of the platinum compound and, thus, to a poorer biological activity.[99] 
 
3.2.5 Conclusions 
In the case of cis-[Pt(PMe3)2(etga)], the formation of the hydroxo species has been 
observed in both steps and both reactive pathways (Figure 6). In the case of cis-
Pt[(PMe3)2(3-Hfl)]+, the formation of a mono-acquo species can be observed in the O1 
path, while in the O2 path the formation of mono-hydroxo occurs (Figure 9a). The 
opposite behavior takes place in the second step, with the formation of cis-
[Pt(PMe3)2(H2O)(OH)]+ as the final product. In both complexes, the rate determining step 
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is the first step of the hydrolysis reaction, the one controlling the release of the 
polyphenols. The activation energies (except for the O1 opening in the cis-
[Pt(PMe3)2(etga)] first hydrolysis) are significantly lower than those calculated for cisplatin 
and closer to the cis-[PtCl2(PMe3)2] complex. The results suggest that tuning the hydrolysis 
rate is fundamental to design an effective combined platinum-polyphenol drug.  
 
3.3 Phenanthriplatin, a Unconventional Platinum Drug: 
Disentangling the Hydrolysis and DNA-binding Mechanisms by 
Theoretical Calculations 
3.3.1 Introduction 
Despite the clinical success enjoyed by cisplatin, carboplatin, and oxaliplatin, the 
treatment with such compounds causes a number of deleterious side effects that have 
already been discussed.[8,33,46] Moreover, another serious limitation of the current 
platinum-based drugs lies in the fact that some types of cancer are inherently resistant to 
treatment and many others develop resistance with time.[100] In an effort to circumvent 
the mechanisms that give rise to such inherent or acquired resistance and to mitigate 
other side-effects, platinum compounds deviating in structure from the prescripts of the 
traditional SARs have been investigated. The hypothesis is that a difference in structure 
will result in an altered mechanism of action and, consequently, in a different spectrum 
of anticancer activity. 
Several different strategies have been used to design drugs that could be more selective 
and less toxic than traditional metallodrugs, e.g., complexes with trans-stereochemistry, 
polyplatinum molecules, platinum-tethered intercalators, and monofunctional 
complexes.[7] Moreover, Pt(IV) complexes have also been studied and are believed to act 
primarily as prodrugs that release active Pt(II) species following their intracellular 
reduction.[101] Among them, the monofunctional platinum complexes have emerged as 
promising non-classical platinum drug candidates.[102] The cis-[Pt(NH3)2(pyridine)Cl]+ 
cation, called pyriplatin, was the first monofunctional platinum compound to be studied. 
Pyriplatin contains only a single leaving chloride ligand so, unlike cisplatin, can only form 
a monofunctional adduct on DNA after the activation by the hydrolysis reaction. The 
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nature of such adduct was revealed by an X-ray crystallographic analysis and is reported 
in Figure 11 together with the schematic structure of pyriplatin.[103] Compared with 
cisplatin-DNA adducts (see Figure 3), pyriplatin only causes a little distortion of the DNA 
structure. However, the pyriplatin lesion can inhibit the RNA polymerase II enzyme and, 
consequently, the transcription in cells as readily as the site-specific bifunctional cisplatin 
lesion.[104] The polymerase was unable to extend the RNA transcript past the pyriplatin 
lesion. In order to better understand the interaction of the pyriplatin lesion with RNA 
polymerase II, the crystal structure of the enzyme stalled at the lesion was solved.[105] The 
X-ray analysis shows that the growing RNA strand terminated at the post-translocation 
step of transcription. Such result stands in contrast to similar stalling induced by cisplatin, 
which block RNA polymerase II procession at the translocation step.[106] Detailed analysis 
of the crystal structure indicated the steric bulk of the pyridine ligand to be instrumental 
in blocking subsequent translocation. Moreover, the monofunctional lesions formed by 
pyriplatin are repaired by NER, but not with the same fidelity as bifunctional lesions.[104] 
 
 
Figure 11 a) Schematic structure of pyriplatin, b) X-ray pyriplatin-DNA adduct[103]. 
 
However, the cytotoxicity of pyriplatin was found to be much lower than the cytoxicity of 
cisplatin.[107] The structural studies with RNA polymerase II highlighted the importance of 
steric hindrance on enzyme action by the pyridine ligand. In order to improve its efficacy, 
different N-heterocyclic Am of cis-[Pt(NH3)2(Am)Cl]+ was systematically varied with an 
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emphasis on increasing steric bulk.[108] The results of these studies indicated that the most 
potent compound was the one in which Am was phenanthridine (see Scheme 7).  
Such complex, called phenanthriplatin, exhorts a significantly greater cytotoxicity than 
cisplatin in the NCI60 panel of cancer cells.[7,40,102,103,108] The panel is made of the 60 
human cancer cell lines used by the National Cancer Institute (NCI) to screen compounds 
for anticancer activity.[109] The mechanism of action of phenanthriplatin is analogous to 
those described above for pyriplatin, even though the large, planar structure of the 
aromatic phenanthridine ligand may indicate a possible interaction with DNA by an 
intercalative mechanism. However, experimental evidence reports that phenanthriplatin 
binds to DNA in a purely covalent manner, like cisplatin.[7,40] 
It is worth noting that the latest experimental evidences hint that phenanthriplatin not 
only reacts with guanosine residues (similar to cisplatin), but also forms adducts with 
adenine residues (the most nucleophilic site after guanosine), a behaviour which has 
never been observed for cisplatin.[110] More specifically, the experimental measures 
reveal that phenanthriplatin binds to the N1 or N7 position of 9-methyladenine (see 
Scheme 3), while the reaction with 9-methylguanine mainly leads to the formation of the 
N7 adduct. Furthermore, due to the rotation of the aromatic ligands, the N1 and N7 
adducts of 9-methyladenine exist as two diastereomeric species, and their activation 
energies for ligand rotation are comparable. In the end, kinetic analysis show that 
phenanthriplatin reacts more rapidly with 9-methylguanine than with 9-methyladenine, 
indicating that the distribution of lesions formed on DNA is kinetically controlled. 
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3.3.2 Aim of this work 
As reported above, many theoretical studies have been done to define the reaction 
energy profiles of hydrolysis reaction.[53,77–88] Moreover, the reaction between Pt 
complexes and DNA bases like guanine and adenine has been extensity studied,[111–117] as 
well as the reaction with sulfur molecule.[118,119] 
In 2003 Baik and his co-workers studied the reaction between mono-aqua cisplatin and 
guanine or adenine bases using DFT calculation. The results show that guanine is 3-4 
orders of magnitude more reactive toward cisplatin than adenine. Such difference is due 
to two effects: firstly, the transition state is characterized by a strong hydrogen bond 
between the ammine-hydrogen of cisplatin and the O=C moiety of guanine while when 
adenine is  binds, only a weak hydrogen bond is formed between the chloride ligand of 
cisplatin and the H2N-C group of adenine. Secondly, a significantly stronger molecular 
orbital interaction is identified for guanine compared to adenine. 
To the best of our knowledge, however, no theoretical comparison work between 
phenanthriplatin and cisplatin, which could help to design a new generation of 
monofunctional drugs, is reported in the literature, where only a few theoretical works 
studying the diastereoselectivity of phenanthriplatin can be found. In 2014 Johnstone ad 
co-workers[120] performed a set of molecular mechanics and DFT calculation to study such 
topic. They found out that the energetic difference between the two diastereomeric 
forms is small. The origin of the diastereoselectivity seems to result from the rotation of 
the phenanthridine ligand, which relieves steric congestion over one face of the platinum 
complex. Herein, we present a computational study of the chloride hydrolysis of 
phenanthriplatin, and the reaction between such complex and 9-methyladenine, 9-
methylguanine, cysteine in comparison with cisplatin (see scheme 7). Given the great 
potential of the complex, the purpose of my work is to clarify the reaction mechanisms of 
phenanthriplatin and to confront them with those obtained for cisplatin by means of DFT 
calculations. 
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Scheme 7 Schematic representation of phenanthriplatin and the reaction studied in this thesis. 
 
3.3.3 Computational details  
All DFT calculations were performed at the M06 level of theory[121,122] using Gaussian 09 
program.[94] Previous works have shown that M06 hybrid density functional provides 
reliable results for thermochemistry and kinetics of organometallic compounds.[123–128] 
However, the reaction between phenanthriplatin and the bases was also investigated 
using M06 and B3LYP[129] functionals with the inclusion of the latest dispersion 
contribution correction (D3) of Grimme.[130] 
Geometry optimizations were carried out in vacuum with a 6-311+G(d,p) basis set for all 
atoms except the platinum atom, which was described by the quasi-relativistic Stuttgart-
 pag. 69 
 
Chapter 3 
Dresden pseudopotential (SDD).[89] In order to confirm that stationary points were 
actually minima or transition state (TS) geometries, analytical calculations of second 
derivatives of the energy and vibrational frequency analysis were carried out. The 
character of the transition states was confirmed by existence of a single negative 
eigenvalue of the hessian matrix corresponding to the appropriate antisymmetric 
stretching mode. Due to the key role of solvation in influencing thermodynamic and 
kinetic parameters in metal complex reactivity, environmental effects were introduced by 
representing water surrounding the reagents, transition states and products as a 
polarizable continuum method (PCM).[93] Single point calculations on the gas phase 
optimized geometries were performed using PCM on the M06, M06-D3 and B3LYP-D3/6-
311+G(d,p)/SDD level of theory. All solvation calculations were carried out in water. Since 
the solvent is also the reagent, it has been represented as an explicit H2O molecule added 
to the initial reagent (R).[76,83] The initial position of the molecule is between the N atom 
and the Cl atom at about 3.5 Å from the Pt atom (RA). After the TS, the leaving Cl atom 
are in proximity of the aqua-complex (products adduct, PA); in the final product (P) the Cl 
atom has been separated.  
 
3.3.4 Results and discussion 
Phenanthriplatin could exist as two isomers (P and M) arising from the rotation of the 
phenanthridine ligand along the Pt--N bond (see Scheme 8a). Aiming to provide a 
complete picture of the phenanthriplatin reactivity, we included both structures in our 
computational approach and calculated the reaction involving isomer P and insomer M of 
phenanthriplatin to understand how a different stereochemistry can influence the 
activation energy barriers. 
 
Scheme 8 a) The two possible phenanthriplatin isomers, labelled as P and M depending on the orientation 
of the phenanthridine ring b) X-ray structures of structures of phenanthriplatin.  
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3.3.4.1 Hydrolysis reaction 
The work started by analysing the similarities and differences between the hydrolysis of 
phenanthriplatin and cisplatin, which is the rate-determining step of the process during 
the attack to DNA.[25] Since the structural features of the pentacoordinated structure have 
been shown to govern the hydrolysis activation barrier,[131,132] the accuracy of the selected 
computational protocol were initially assessed by comparing the optimized DFT structure 
with the available X-ray data (see scheme 8b and Table 3).[120] The calculated bond lengths 
and angles are in good agreement with the experimental ones, confirming the reliability 
of the used computational protocol, as can be seen from the MAE and RMSD indexes[95] 
calculated on bond lengths (0.027 Å and 0.044 Å respectively). 
 
Table 3 Comparison selected bond lengths (Å) and angles (°) in phenanthriplatin, with relative esd (in 
parentheses) for experimental measurements. 
Bond distance  Exp. Calc. Angles Exp. Calc. 
Pt1-Cl 2.296(7) 2.308 Cl1-Pt1-N1 90.25(6) 85.44 
Pt1-N1 2.039(2) 2.105 Cl1-Pt1-N2 87.71(6) 89.82 
Pt1-N2 2.025(2) 2.062 N1-Pt1-N3 89.08(8) 95.70 
Pt1-N3 2.047(2) 2.145 N2-Pt1-N3 92.95(8) 89.02 
 
The optimized structures of R, RA, PA, P and TS are shown in Figure 12 while the structure 
of cisplatin is reported in Figure A3. Relevant bond distances and angles of the optimized 
complexes are reported in Table A8-A10 in appendix A (see also Figure A4 in appendix A). 
The Gibbs reaction free energy (G) profiles are shown in Figure 13 (see also Table A11 in 
appendix A). This activation energy will then be compared to the one obtained for the first 
hydrolysis of cisplatin.  
 
 
Figure 12 Optimized structures for the hydrolysis reaction of isomers P (a) and isomers M (b). 
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Figure 13 Activation Gibbs free energy profiles of isomers P (blue line) and isomers M (green line) and first 
step (red dot line) of the hydrolysis of cisplatin in PCM water. 
 
The G energy profiles (Figure 13) for the hydrolysis reaction show that the RAs of isomers 
P and M of phenanthriplatin lie above the reactant molecules and present similar values 
(5.3 and 5.1 kcal mol-1 respectively see also Table A11 in appendix A). In both cases, the 
formation of a hydrogen bond (H-bond) between the O atom of the water and the H atom 
of the ammonia group (Figure 12) is observed.  
As expected, the initial square-planar complexes become a bipyramidal TS. The analysis 
of the single-imaginary vibrational mode (144.77i cm-1 for isomer P and 151.09i cm-1 for 
isomer M) confirms the rupture of the bond between platinum and the chloride ligand 
and the simultaneous formation of the metal-water bond. As shown in Figure 13, the 
activation Gibbs free energy barrier for isomers P and M are slightly different: isomer P 
has Ga = GTS - GRA = 22.4 kcal mol-1, while isomer M shows Ga = 23.9 kcal mol-1 (see Table 
S5).  
The rate constants (k) for the hydrolysis reaction have been calculated by means of the 
Eyring equation at 298.15 K: 
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(eq1) 
 
kB is Boltzmann's constant, and h is Planck's constant. These values are k = 2.37*10-4 s-1 
for isomer P and k = 1.89*10-5 s-1 for isomer M. According to the results, the release of Cl- 
ligands is slightly kinetically favoured in complex P moreover the G profiles confirm that 
the relative position of the phenanthridine ring does not impact on the activation step of 
the monovalent platinum drug. Isomer M conduces to the most stable PA, where the G 
energy difference (GPA = GPA-isomer P - GPA-isomer M) is 2.7 kcal mol-1 (see Table A11 in 
appendix A), probably due to the stronger interaction present in isomer M between the H 
atom of the coordinated water and the Cl- ion. Indeed, an H-bond between such atoms is 
observed in both complexes (Figure 12), but in isomer M the distance between H and Cl- 
is 1.796 Å, whereas in isomer P it is 1.873 Å. The final P is less stable in isomer P than in 
isomer M (GP = GP-isomer P – GP-isomer M is +0.7 kcal mol-1). 
The comparison between the energy profiles for the first hydrolysis reaction of cisplatin 
(Figure 13 and Table A11 in appendix A) and the hydrolysis of isomer P and isomer M 
shows that the RA for cisplatin lies above the reactant molecules and seems more stable; 
the GRA = GRA-isomer P or M - GRA-cisplatin is 1.1 kcal mol-1 for isomer P and 0.9 kcal mol-1 for 
isomer M (see table A11 in appendix A). Moreover, the Ga in isomer P is slightly lower than 
the one in cisplatin (Ga = Ga-TS-isomer P - Ga-TS-cisplatin = -1.0 kcal mol-1); on the contrary, the 
Ga in isomer M is slightly higher than the one calculated for cisplatin (Ga = +0.5 kcal mol-
1) (Figure 13 and Table A11 in appendix A). For this reaction, cisplatin presents k = 4.39*10-
5 s-1, which is in excellent agreement with the experimental one (5.18*10-5 s-1[4]) and is 
intermediate to the values calculated for isomer P and M. However, both PA and P for 
isomer P and M are less stable than PA and P obtained for cisplatin (Figure 13 and table 
A11 in appendix A). 
In conclusion, phenanthriplatin shows activation barriers which are very similar to those 
obtained for the first hydrolysis reaction of cisplatin. The similarity could be related to its 
high cytotoxicity. In fact, low activation energy barriers and the consequent high 
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hydrolysis reaction rate seem to submit such complexes to fast degradation, causing 
potentially poor pharmacological activity.[76,99] 
 
3.3.4.2 Reaction with bases 
The interaction of the resulting aqua-activated phenanthriplatin with 9-methylguanine 
and 9-methyladenine is explored according to the general scheme depicted in Scheme 7. 
The latest experimental evidence[110] shows that phenanthriplatin forms bonds with N7 
atom of 9-methylguanine (N7-Me-Gua), a behaviour observed also for cisplatin. However, 
phenanthriplatin forms bonds with N7 and N1 atoms of 9-methyladenine (N7-Me-Ade, 
N1-Me-Ade) too, and such a behaviour not observed for cisplatin. Unlike 
phenanthriplatin, cisplatin reacts with two guanine molecules, leading to the formation 
of intra and inter-molecular bonds with DNA.[10] The activation energy barrier for 
phenanthriplatin will then be compared to the one obtained for the first step (addition of 
one guanine molecule) of cisplatin. 
In Figure 14 the optimized structures of R, RA, PA, P and TS at M06 level of theory are 
shown for both complexes of phenanthriplatin, while the structure of cisplatin is reported 
in Figure A5. Relevant bond distances and angles of optimized complexes are reported in 
Table A12-A18 in appendix A.  The reaction G energy profiles are shown in Figure 15 (see 
also Table A19 in appendix A). The G energy profiles (Figure 15) for the reaction between 
N7-Me-Gua and phenanthriplatin show that the RA of isomer P and M lie under the 
reactant molecules, and that the RA of isomer P (-4.3 kcal mol-1) seem to be more stable 
than those of isomer M (-3.0 kcal mol-1, see Table A19 in appendix A). The formation of 
multiple H-bonds is observed in both isomers (Figure 14); the first H-bond is reported 
between the H atom of the coordinated water and the N7 atom of the guanine; the second 
one is observed between the other H atom of the coordinated water and the O atom of 
the guanine, and forms an additional H-bond with the H atom of the amino group of the 
Pt fragment.  
The reaction with N7-Me-Ade and N1-Me-Ade, instead, shows a proton transfer from the 
coordinated water molecule to the N atom of adenine (see Figure 14). This behaviour was 
not observed for the reaction with guanine. However, similar proton transfer were 
reported in previous theoretical studies of platinum antitumor drugs interacting with 
adenine bases.[115]  
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Figure 14 Optimized structures for the reaction between bases and isomer P (a) and isomer M (b) at M06 
level of theory. 
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Figure 15 Activation Gibbs free energy profiles of isomer P (grey line) with N7-9-methylguanine, isomer M 
(black line) with N7-9-methylguanine, isomer P (blu line) with N7-9-methyladenine, isomer M (light blue 
line) with N7-9-methyladenine, isomer P (green line) with N1-9-methyladenine, isomer M (light green line) 
with N1-9-methyladenine, and first step (red dash line) of the reaction between N7-9-methylguanine and 
cisplatin in PCM water. At M06 level of theory. 
 
Furthermore, the RAs for the reaction with N1-Me-Ade are more stable than those 
obtained for N7-Me-Ade, due to the different formation of H-bonds. As for N1-Me-Ade, 
the formation of three H-bonds is observed in isomer P and M. The O atom of the 
coordinated water molecule forms two H-bonds; the first with the H atom bond to N1 of 
the adenine and the second with the H atom of the N1-Me-Ade amino group (see Figure 
14). The last H-bond is formed between the N atom of the amino group in N1-Me-Ade and 
the H atom of the amino group of the Pt fragment (see Figure 14). As for N7-Me-Ade, the 
RA of isomer P and M presents only two H-bonds; one between the H atom bond to N7 of 
adenine and the O atom of the coordinated water molecule and the second one between 
the N atom of the amino group of the adenine and the H atom of the amino group of the 
Pt fragment. In conclusion, the most stable RA was observed for N7-Me-Gua (see Figure 
15 and Table A19 in appendix A), due to a greater interaction involve involving the O--H 
H-bond in respect to the N--H H-bond. 
All transition states show a penta-coordinated structure; the imaginary frequencies, the 
Ga values and the relative calculated and experimental k are reported in Table 4. The 
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analysis of the vibrational modes clearly indicates the rupture of the bond between 
platinum and the water ligand (Pt-Ow) and the simultaneous formation of the metal-N 
bond of the N7-Me-Gua, N7-Me-Ade and N1-Me-Ade. 
 
Table 4 Imaginary frequencies (i Freq, cm-1), activation Gibbs free energy (Ga, kcal mol-1), calculated (by eq1 
at 298.15  K) and experimental rate constants k (s-1) for the reaction between phenanthriplatin and N7-Me-
Gua, N7 and N1-Me-Ade. At M06 level of theory. 
 i Freq Ga kcalc kexp 
Isomer-P + N7-Me-Gua 144.39 13.9 4.03*102 3.6*10-5[110] 
Isomer-M + N7-Me-Gua 144.64 13.6 6.69*102 3.6*10-5[110] 
Isomer-P + N7-Me-Ade 141.28 15.2 4.49*101 4.2*10-6[110] 
Isomer-M + N7-Me-Ade 149.96 14.4 1.73*102 4.2*10-6[110] 
Isomer-P + N1-Me-Ade 137.11 16.9 2.55 - 
Isomer-M + N1-Me-Ade 129.47 16.9 2.55 - 
Cisplatin + N7-Me-Gua 143.90 14.8 8.82*101 3.20*101[133] 
 
Examining the data shown in Table 4, aqua-activated phenanthriplatin seems to react 
faster with N7-Me-Gua than N7-Me-Ade and N1-Me-Ade, while isomer M reacts slightly 
faster than isomer P. N7-Me-Ade, instead, seems to react faster than N1-Me-Ade; even in 
this case the M isomer seems to react slightly faster than the P isomer. As for N1-Me-Ade, 
isomers P and M show equal Ga values. The difference in reaction rates can be explained 
by observing the structures of the transition states (only for isomer M, where the reaction 
proceeds faster). All transition states have an H-bond between the H atom of the amino 
group of the Pt fragment and the O atom of guanine or N atom of the amino group adenine 
(see Figure 14). The distance between O and H is 1.756 Å for isomer M of N7-Me-Gua, 
1.970 Å for isomer M of N7-Me-Ade and 2.030 Å for isomer M of N1-Me-Ade.  
The reaction between aqua-activated phenanthriplatin and N7-Me-Gua leads to PA, 
which is more stable than RA (at M06 level of theory, see Figure 15), so the reaction is 
thermodynamically favoured in both complexes. Moreover, isomer P conduces to the 
most stable PA (GPA = GPA-isomer P - GPA-isomer M = -0.6 kcal mol-1, see Figure 15). 
Such behaviour is also observed in the final products (GP = GP-isomer P - GP-isomer M = -0.4 kcal 
mol-1, see Figure 15, Table A19 in appendix A). The formation of H-bonds between the O 
atom of the guanine and H atom of the amine group is observed in both PA and P of both 
isomers, which are also more stable than those obtained for the reaction between 
phenanthriplatin and adenine. 
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Here too, the formation of H-bonds between the N atom of the adenine and the H atom 
of the amine group in Pt fragment is observed in PA and P. As for N7-Me-Ade, isomer M 
seems to conduce to the most stable PA (GPA = 0.5 kcal mol-1), and the same behaviour 
was observed for N1-Me-Ade (GPA = 1.2 kcal mol-1, see Table A19 in appendix A). In 
conclusion, the reaction between phenanthriplatin and N7-Me-Gua seems to be favoured 
from both a kinetic and thermodynamic point of view in respect to N7 and N1-Me-Ade, 
while the reaction with N1-Me-Ade seems to be thermodynamically favoured but 
kinetically least-favoured with respect to the reaction with N7-Me-Ade (see Table 4 and 
Table A19 in appendix A). According to these results, the release of water ligands and the 
consequent addition bases follow the order N7-Me-Gua > N7-Me-Ade > N1-Me-Ade. Such 
sequence is observed also experimentally[110], but the calculated reaction rates differ 
considerably (5-6 orders of magnitude) compared to the experimental ones (see Table 4).  
The inconsistency may depend on the different positions in which the bases can be found 
in RAs. In fact, a potential interaction between the bases and the phenanthridine rings via 
- has been observed. This type of structures were studied using M06, M06-D3 and 
B3LYP-D3 functionals (used for comparison). The M06-D3 and B3LYP-D3 functionals 
include the latest dispersion contribution correction (D3) of Grimme[130]. This contribution 
in simulations of weakly bonded (van der Waals, vdW) systems is indispensable to reach 
chemical accuracy and can influence the accuracy of thermodynamics. Such optimized 
structures, at M06 level of theory, are shown in Figure 16 for isomer M only, because the 
reaction takes place faster. Relevant bond distances and angles for optimized RA and TS 
are reported in Table A20 and A21 in appendix A. 
 
 
Figure 16 Optimized structures for the reagent adduct, - interaction between DNA bases and aromatic 
ligand of phenanthriplatin at M06 level of theory. 
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Here again, the results obtained at M06 level of theory show that  the RA for the reaction 
with adenine has a proton transfer (see Figure 16), while no such behaviour was observed 
for guanine. Moreover, the formation of H-bonds is observed. The O atom of the 
coordinated water molecule forms two H-bonds; one with the entering N atom and one 
with the H atom of the amino group for N7 of adenine or the O atom of guanine (see 
Figure 16). Using these RAs and re-optimizing the transition states, Ga values are higher 
than in the previous case. The values are reported in Table 5 together with the energy 
difference between the RA in - (RA-) configuration and RA (GRA = GRA-- GRA) and  
relative k and imaginary frequencies. 
 
Table 5 Energy difference between RA in - (RA-) configuration and RA (GRA = GRA-- GRA, kcal mol-1), 
imaginary frequencies (i Freq, cm-1), activation Gibbs free energy (Ga, kcal mol-1) of theory and calculated 
(by eq1 at 298.15 K) and experimental rate constants k (s-1). Calculation at M06, M06-D3 and B3LYP-D3 level 
of theory. 
M06 
 GRA i Freq Ga kcalc kexp 
Isomer-M + N7-Me-Gua -3.6 144.65 17.2 1.53 3.6*10-5[110] 
Isomer-M + N7-Me-Ade -5.1 150.50 19.0 7.36*10-2 4.2*10-6[110] 
Isomer-M + N1-Me-Ade -4.4 128.20 22.1 3.75*10-4 - 
M06-D3 
 GRA i Freq Ga kcalc kexp 
Isomer-M + N7-Me-Gua -7.2 -119.18 21.7 7.36*10-4 3.6*10-5[110] 
Isomer-M + N7-Me-Ade -8.5 -149.77 22.0 4.29*10-4 4.2*10-6[110] 
Isomer-M + N1-Me-Ade -8.1 -141.66 23.9 1.88*10-5 - 
Cisplatin + N7-Me-Gua - 144.91 14.6 1.32*102 3.20*101[133] 
B3LYP-D3 
 GRA i Freq Ga kcalc kexp 
Isomer-M + N7-Me-Gua -1.6 161.81 19.3 4.02*10-2 3.6*10-5[110] 
Isomer-M + N7-Me-Ade -5.0 145.29 23.8 2.39*10-5 4.2*10-6[110] 
Isomer-M + N1-Me-Ade -6.4 135.40 25.8 7.40*10-7 - 
Cisplatin + N7-Me-Gua - 148.65 15.3 3.79*101 3.20*101[133] 
 
The RA structures shown in Figure 16 are more stable than those shown in the Figure 14. 
As a result, the formation of -interaction could be observed in solution. Moreover, a 
noticeable decrease in rate constants (Table 5) can be observed.[110] Similar results were 
obtained using M06-D3 and B3LYP-D3 functionals; here too, the RA for the reaction with 
adenine shows a proton transfer, while no such behaviour is observed for the reaction 
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with guanine; the same formation of H-bonds between bases and Pt-complex is observed. 
Again, the RAs interacting via -are more stable than the RAs that do not interact in this 
manner (see Table 5). However, the data reported in table 5 show that the introduction 
of the dispersion correction leads to values of the rate constants that are in better 
agreement with the experimental ones compared to the values calculated with pure M06 
functional, highlighting the importance of such contribution. Moreover, the rate constants 
obtained with B3LYP-D3 functional result to be closer to the experimental ones compared 
to the constants obtained with M06-D3, indicating that B3LYP-D3 is better than M06-D3 
for studying the reaction between phenanthriplatin and DNA bases. In fact, the Ga values 
are slightly higher than those calculated with M06-D3 functional. However, the rate 
constant for the reaction with the N7-Me-Gua, calculated with the M06-D3, is closer to 
the experimental one than that obtained with B3LYP-D3. Finally, the Ga values for cisplatin 
calculated with M06-D3 and B3LYP-D3 are similar to that calculated with M06, since in 
this case there is no - interaction. 
Although this type of - interaction between bases and phenanthridine rings may be 
observed in solution, it does not occur when adding phenanthriplatin to DNA; indeed, the 
DNA structure makes this kind of interaction unlikely to form. In addition, the reaction 
rate follows the order N7-Me-Gua > N7-Me-Ade > N1-Me-Ade with all the used 
functionals. In conclusion, the addition of only one nitrogen base in complexes having 
aromatic ligands could provide constant rates not consistent with those obtained using 
DNA fragments. However, there is still a difference between the calculated and 
experimental rate constants, possibly due to the formation of H-bonds between bases and 
water, which decreases the possibility of a nucleophilic attack of the N atom to the Pt 
atom. 
The comparison between the energies profiles (at M06 level of theory, see Figure 15, 
Table A19 in appendix A) of cisplatin and isomer P and isomer M for the reaction with 
guanine shows that the RA for cisplatin lie above the reactant molecules and presents a 
value which is similar to the values obtained for isomer M (see table A19 in appendix A). 
Moreover, cisplatin has a Ga value higher than both isomers. The k for the addition of N7-
Me-Gua to cisplatin is one order of magnitude lower than phenanthriplatin and in good 
agreement with the experimental one (see table 4). The difference in reaction rates can 
be explained by observing the structures of the transition states in cisplatin and in isomer 
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M. In the transition states cisplatin presents two H-bond; the O atom of guanine forms 
one H-bond with the H atom of the coordinated water and the other one with the H atom 
of the amino group of the Pt fragment, where the distance is 1.955 Å and 1.932 Å 
respectively. Isomer M shows only one H-bond, but the distance between O and H is 1.756 
Å. Furthermore, the PA for cisplatin is less stable than the PAs for isomer P and isomer M, 
while the final products have values that are similar to those obtained for isomer M 
(Figure 15 and table A19 in appendix A).  
 
3.3.4.3 Rotation of the phenanthridine ligand in [Pt(NH3)2(Ade)(phenanthridine)]2+ 
As reported in Riddell's work[110], the reaction products between aqua-activated 
phenanthriplatin and 9-methyladenine can potentially exist as a mixture of rotational 
diastereoisomers, or rotamers. Rotamers derive from the rotation of the adenine and 
phenanthridine ligands about their Pt-N bonds. Furthermore, an investigation of the rate 
and energetics of diastereomer interconversion was carried out, obtaining a G value for 
the interconversion of 16.1 kcal mol-1 for N7-Me-Ade adduct and 16.6 kcal mol-1 for N1-
Me-Ade.  
In our work, the interconversion from the isomer P to the isomer M due to the rotation of 
the phenanthridine ligand has been studied in water at M06 level of theory. The starting 
structure was obtained by fixing the N3-Pt-N2-C1 dihedral angel at an intermediate value 
between the values of isomers P and M (see Figure 17). From this point, additional 
structures were obtained by rotating the phenanthridine ligand in a clockwise and 
anticlockwise direction with 15° increments until the configuration of isomer P and M was 
obtained. In Figure 17 the optimized structures for the maximum (TS) obtained by the 
rotation of the phenanthridine ligand are reported together with the Gibbs free energy 
profile due to the rotation of the aromatic ligands. Relevant bond distances and angles of 
optimized TS are reported in Table A22 in appendix A.  
The calculated activation G energy barriers for the interconversion are 16.0 kcal mol-1 for 
N7-Me-Ade adduct and 18.5 kcal mol-1 for N1-Me-Ade, in excellent agreement with the 
values obtained experimentally. However the values for N7-Me-Ade adduct (curve blue) 
are negative at about -45° which may be due to the fact that the complex has not been 
fully relaxed during the optimization; in fact, the value of N3-Pt-N2-C1 dihedral angle was 
fixed. Studying such interconversion is very important, because, experimentally, 
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phenanthriplatin could present two orientations of the phenanthridine ligands when 
binding to DNA, isomer P and M.[134] Isomer M seems to be the major configuration, while 
isomer P seems to be the minor configuration, which is also in good agreement with the 
values calculated in this work; in fact, isomer M forms faster than isomer P for the reaction 
with N7-Me-Gua and N7-Me-Ade. 
 
Figure 17 a) Gibbs free energy profile due to the rotation of the aromatic ligands for [Pt(NH3)2(N7-Me-
Ade)(phenanthridine)]2+ (blue line) and for [Pt(NH3)2(N1-Me-Ade)(phenanthridine)]2+ (green line). 
Optimized structures for the maximum (TS) obtained by the rotation of the phenanthridine ligand in b) 
[Pt(NH3)2(N7-Me-Ade)(phenanthridine)]2+ and in c) [Pt(NH3)2(N1-Me-Ade)(phenanthridine)]2+. 
 
3.3.4.4 Reaction with cysteine 
Aqua-activated platinum complexes are very reactive species, which can react with 
molecules containing sulfur atoms such as MT, characterized by a high presence of the 
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cysteine amino acid, which eventually causes the inactivation of this drugs.[3] In this thesis 
the activation energies for reactions between cysteine and isomer P and M were been 
calculated at M06 Level of theory. In Figure 18 the optimized structures of R, RA, PA, P 
and TS are shown for both complexes of phenanthriplatin, while the structure of cisplatin 
is reported in Figure A6. Relevant bond distances and angles of optimized complexes and 
cisplatin are reported in Table A24-A25 in appendix A. The reaction G energy profiles are 
shown in Figure 19 (Table A26 in appendix A).  
 
  
Figure 18 Optimized structures for the reaction between cysteine and isomer P (a) and isomer M (b) at M06 
level of theory. 
 
 
Figure 19 Activation Gibbs free energy profiles for the reaction between cysteine and isomer P (blue line), 
and between isomer M (green line) and cisplatin (red dot line) in PCM water. At M06 level of theory. 
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The G energy profiles (Figure 19) show that the RAs of isomers P and M of 
phenanthriplatin lie above the reactant molecules, and that the RA of isomer M (0.6 kcal 
mol-1) seems to be more stable than the RA of isomer P (2.3 kcal mol-1). In both cases, a 
proton transfer from the N atom of the amino group to the O atom of the carboxyl group 
of cysteine (transforming the amino acid from the zwitterionic form to the neutral form). 
Moreover, the H atom of the coordinated water form two H-bonds with the S atom and 
the O atom of the cysteine (Figure 18). 
Transition states show a penta-coordinated structure. The imaginary frequencies 
observed are 133.46i cm-1 for isomer P and 127.32i cm-1 for isomer M. The analysis of the 
vibrational modes clearly indicates the rupture of the bond between platinum and the 
water ligand (Pt-Ow) and the simultaneous formation of the metal-sulfur (Pt-S) bond. The 
Ga value for isomer P is 15.1 kcal mol-1, which corresponds to a k of 5.32*101 s-1 at 298.15 
K, whereas for isomer M a Ga 20.4 kcal mol-1 was obtained with a k of 6.94*10-2 s-1 at 
298.15 K (see Table A26 in appendix A). Transition states present an H-bond between the 
O atom of the cysteine ligand and the H atom of the amino group in the Pt fragment (see 
Figure 18). The distance between O and H is 1.991 Å for isomer P, and is 2.002 Å for isomer 
M. Furthermore, the O atom of the cysteine seems to interact with a second H atom of 
the amino group in the Pt fragment. In fact, the distance between the two atoms is 2.218 
Å for isomer P while is 2.237 Å in isomer M, this could explain the difference in Ga values. 
According to the results, the release of Cl- ligands is kinetically preferred in isomer P. 
Moreover, isomer P conduces to the most stable PA. An opposite behaviour is observed 
for the final products; isomer M is more stable than isomer P, but the reaction seems 
thermodynamically favoured in both cases.  
The comparison between the energy profiles for the reaction between cysteine and 
cisplatin and the reaction of isomer P and isomer M shows that the RAs for cisplatin lie 
above the reactant molecules and are similar to those obtained for isomer P (see Table 
A26 in appendix A). Ga is 13.5 kcal mol-1, which corresponds to a k of 7.92*102 s-1, in 
agreement with the experimental ones (3.2*103 s-1[135]). The Ga value is lower than the 
values obtained for isomer P and M (Ga = = 1.6 kcal mol-1 for isomer P, Ga = 6.9 kcal 
mol-1 for isomer M, see table A26 in appendix A). Moreover, both PA and P are more stable 
for cisplatin than for isomer P and M (Figure 20 and table A26 in appendix A). In 
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conclusion, phenanthriplatin shows higher activation barriers Ga than those obtained for 
cisplatin, a behaviour that could be related to the high cytotoxicity shown by such 
complex. Indeed, the reaction in phenanthriplatin seems disadvantageous compared to 
cisplatin, especially for the M isomer. Cisplatin seems to show a greater reactivity towards 
this class of molecules; indeed, the reaction in cisplatin seems to be favoured from a 
thermodynamic as well as a kinetic point of view. 
 
3.3.5 Conclusions  
In summary, the reactivity of the two phenanthriplatin diastereoisomers (isomer P and 
isomer M) was investigated using the DFT theory combined with the PCM method. In 
particular, the hydrolysis reaction, the reaction with bases such as 9-methylguanine and 
9-methyladenine and the reaction with cysteine were studied. This work allowed us to 
make a direct comparison between the reactivity of phenanthriplatin and cisplatin, one of 
the most used chemotherapeutic agents.[44]  
The study of the hydrolysis reaction, a key step for the activation of such species,[3] 
showed that phenanthriplatin has Ga (22.4 kcal mol-1 for isomer P and 23.9 kcal mol-1 for 
isomer M) close to those obtained for the first hydrolysis of cisplatin (23.4 kcal mol-1). The 
high toxicity of phenanthriplatin may be partly due to the hydrolysis reaction, a low Ga, 
and the consequent high hydrolysis reaction rate, which might submit the complexes  to 
fast degradation, causing potentially poor pharmacological activity.[76,99] Moreover, the 
hydrolysis process is the rate determining step (RDS) of the whole process.  
Unlike cisplatin, phenanthriplatin reacts with both guanine and adenine; with the latter 
the formation of two products; N7 and N1, occurs. Guanine as a target for platination 
process is confirmed to be preferred over adenine for all the investigated compounds. In 
addition, the reaction rate follows the order N7-guanine > N7-adenine > N1-adenine. The 
dominating preference for guanine seems to be a hydrogen-bond-controlled process, 
confirming that H-bonds are important in imposing both structural and kinetic control on 
the purine platination processes. The comparison between the Ga of cisplatin and 
phenanthriplatin for the reaction with guanine shows that the reaction is kinetically 
favoured for phenanthriplatin. The calculated reaction rates differ considerably from the 
experimental ones, maybe due to the formation of a - interaction between the bases 
 pag. 85 
 
Chapter 3 
and the phenanthridine ligand. Although this type of structure may be observed in 
solution, it cannot be observed in DNA. The addition of only one nitrogen base to 
complexes having aromatic ligands could provide constant rates not consistent with those 
obtained using DNA fragments. In addition, the reaction products between 
phenanthriplatin and adenine can potentially exist as a mixture of rotational 
diastereoisomers.[110] The calculated activation G energy barriers for the interconversion 
are in agreement with those obtained experimentally. 
Finally, the study of the reaction between phenanthriplatin and cysteine has shown that 
such reaction is disadvantageous, both kinetically and thermodynamically, in 
phenanthriplatin in respect to cisplatin. In conclusion, phenanthriplatin seems to have 
hydrolysis rate comparable to cisplatin and to react faster with guanine than with sulfur 
molecules. 
 
3.4 Nano-delivery of Cisplatin: Interactions with Graphene 
Prototypes  
3.4.1 Introduction  
In recent years, the nano-delivery of biologically active agents has been one of the most 
studied fields,[136] including different subjects such as material science, engineering, 
medicine and chemistry. 
Nanoscale drug delivery is the administration of drugs using objects with dimensions in 
the nanometer regime for the transport of pharmacologically active agents. In the nano-
delivery of anticancer agents, the main advantages of using nanoparticles relate to their 
ability to target tumour tissue in either an active or a passive manner.[137,138] These 
systems could be used as a possible solution to resolve the inconvenience of Pt-based 
drugs, being the nano-delivery able to reduce the systemic dose while increasing the 
amount of active molecule that reaches the target site.[136] Graphene-based nano-carries 
is a new class of compounds that are emerging as optimal candidates in the delivery of 
various active compounds.[139] 
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3.4.2 Graphene based materials 
In 2004 Geim et al.[140] discovered graphene, the thinnest known material (see Figure 20), 
and won the Nobel Prize. The research on graphene has increased exponentially and finds 
applications in different sectors such as electronic and optoelectronic devices, 
photoconductive materials in solar cells, medical imaging, drug delivery and tissue 
engineering.[141] 
 
 
Figure 20 Structures of a) graphene and b) graphene multilayer. 
 
Graphene-based materials are two-dimensional (2D) structures where each carbon is 
bound to other three carbons in the same plane in a sp2-hybridized flat structure. Their 
surfaces represent ideal adsorption platforms for a wide variety of molecules through 
covalent and  non-covalent interactions, thanks to their high surface/volume ratio and 
ease of functionalization, which make them attractive as carriers for removal and delivery 
of bioactive agents.[142–145] The presence of strong carbon-carbon bonding, aromatic 
structure, reactive sites for surface reactions and free  electrons makes graphene a 
unique material with exceptional proprieties. Indeed, high electron density above and 
below the 2D graphene plane, provided by the  electron, could interact with the 
molecular orbitals of different compounds, thus facilitating reactions such as electrophilic 
substitution.[146] Moreover, the structure provides excellent thermal and electrical 
conductivity with a low coefficient of thermal expansion[147,148] and makes graphene one 
of the strongest tested materials; the breaking strength of single layer defect-free 
graphene is approximately 200 times higher than steel.[149] 
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Graphene-family nanomaterials are classified based on the number of layers in the sheet 
and chemical modification. The most used graphene systems are single-layer graphene, 
bi-layer graphene, multilayer graphene (see Figure 20), graphene oxide (GO) and reduced 
graphene oxide (rGO). Single-layer graphene is synthesized by repeated mechanical 
exfoliation[140] or extremely controlled growth on substrates like silicon carbide[150] via 
chemical vapor deposition (CVD).  
Graphene oxide (GO) is a highly oxidized form of graphene, chemically modified with 
carboxylic acid, epoxide and hydroxyl groups in the plane. The carboxylate group provides 
colloidal stability and pH dependent negative surface charge,[151] while epoxide (-O-) and 
hydroxyl (-OH) can interact by hydrogen bonding.[152] GO is an amphiphilic sheet-like 
molecule, which can be used as a surfactant to stabilize hydrophobic molecules in a 
solution.[153,154] Reduced graphene oxide (rGO) can be obtained by thermal, chemical and 
UV treatment of GO under reducing conditions.[151] rGO is mainly produced to restore the 
electrical conductivity and optical absorbance in GO while reducing the oxygen content, 
surface charge, and hydrophilicity.[155]  
One of the field in which graphene-based materials are used is biomedical 
applications,[141,156,157] because its unique properties make this material an excellent 
candidate for drug delivery. 
 
3.4.3 Graphene-based materials as drug delivery systems 
The main property of a delivery vehicle is the ability to carry drugs on the site of action 
and protect them from degradation, leading to a potential increase of efficacy.[158–162] In 
these respects, graphene-based nano-carriers have emerged as excellent candidates for 
drugs delivery because, as recent studied have demonstrated, they are less toxic 
compared to other carbon materials, and a proper functionalization of the surface can 
improve their biocompatibility in live organisms.[139] Different molecules can be 
transported by graphene-based materials[163–165] and different methods can be used to 
load the drugs (cargo) to graphene delivery systems. The cargo can interact directly with 
graphene sheets by hydrophobic interactions, - stacking, hydrogen bonding (if the 
graphene surface is functionalized with carboxylic acid, epoxide and hydroxyl groups) or 
by covalent bonding. After the drug loading, the cargo must be transported to its target 
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cell or target tissue and, generally, nano-carriers enter the cells by endocytosis. After 
entering the target cell, the cargo should be effectively released. Cargo release can be 
activated by a change in the local environmental conditions, such as the pH or the 
temperature, or through the recognition by a target receptor.[139] 
Recently, cisplatin loading on graphene has been attempted through the formation of a 
covalent bond between the platform and cisplatin.[166,167] However, the square planar 
structure and the low solubility of cisplatin suggests that this species may have a certain 
affinity with the graphene surface; therefore, a favourable adsorption of cisplatin on 
graphene can be predicted. Even from a theoretical point of view, the study of non-
covalent interactions between cisplatin and graphene is rather poor. However, Cuevas-
Flores et al.[168] did study the interaction between cisplatin and graphene prototypes in 
gas-phase. They chose the cisplatin-pyrene complex as graphene prototype and 
considered different orientations of cisplatin. They performed scan at MP2C level of 
theory, finding that parallel geometries show the largest attraction. The calculations were 
used as reference data to validate selected DFT levels, in particular, the best DFT 
functional reproducing MP2C energy is PBE-D3(BJ). This functional was finally used to 
study the interaction between cisplatin and larger graphene prototypes; the best 
prototypes seem to be ovalene (C32H14), because it represents the best compromise 
between computational cost and accuracy. 
 
3.4.4 Aim of this work  
The purpose of this work is to provide more details about the interactions between 
cisplatin and graphene by means of MP2 and DFT calculation and to introduce the solvent 
effect, since no works considering the solvent effect can be found in literature. 
 
3.4.5 Computational details 
Circumcoronene (C54H18) was chosen as the representative model of graphene, as Cuevas-
Flores[168] observed that the change in the interaction energy for large surfaces of 
circumcoronene is small. In this work, different orientations of cisplatin were taken into 
account, four to be precise (Figure 21): one parallel (P) and three perpendicular (N, Cl, N-
Cl) geometries. The interaction between cisplatin and graphene was studied by 
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performing scans as a function of the distance (r) between the Pt atom and the centre of 
mass (COM) of circumcoronene. The r coordinate varied from 2.6 Å to 10.5 Å for P 
orientation, from 3.8 Å to 10.5 Å for N orientation and from 4 Å to 10.5 Å for Cl and N-Cl 
orientation. The interaction energy (Eint) was calculated following this equation: 
 ��௡� = ��௢� − ሺ�௖�௥௖௨௠ +  �௖�௦ሻ 
(eq2) 
where Etot is the potential energy for the cisplatin-circumcoronene dimer, Ecircum is the 
potential energy of circumcoronene at infinitive distance, and Ecis is the potential energy 
of cisplatin at infinitive distance. All Eint were corrected for the basis set superposition 
error (BSSE) by the counterpoise method of Boys and Bernardi.[168] 
Quantum-mechanical calculations were carried out at MP2 and DFT level of theory. 
Geometry optimizations of isolated molecules were carried out at MP2 level of theory in 
vacuum with a 6-31+G(d,p) basis set for all atoms except the platinum atom, which was 
described by the quasi-relativistic Stuttgart-Dresden pseudopotential (SDD). Improved 
energies for the cisplatin-circumcoronene dimer were obtained by single-point 
calculations using a 6-311+G(d,p) basis sets for all elements, while platinum was described 
by the Stuttgart-Dresden pseudopotential. Several DFT functionals were considered for 
the Eint calculation, from standard GGA functional such as BPBE and BP86[169] to hybrid-
GGA functional such as B97[169] (19.4% Hartree Fock (HF) exchange), B3PW91[170,171] (20% 
HF exchange), PBE1PBE[172] (25% HF exchange), BMK[173] (42% HF exchange), M062X[121,122] 
(54% HF exchange) and M06HF[121,122] (100% HF exchange). Moreover, the range-
separated hybrid GGAs functionals such as CAM-B3LYP[174] and LC-wPBE[174] were also 
tested. In such functionals, the fraction of exact exchange varies as a function of the 
interelectronic distance, by partitioning the Coulomb operator. All DFT functionals include 
the latest dispersion contribution correction (D3) of Grimme,[130] and the damped 
dispersion scheme of Becke-Johnson (BJ)[175], as it has been observed that the inclusion of 
the dispersion correction allows to obtain a better agreement with the reference MP2 
energy.[168] The solvent effect was taken into account using the method reported in the 
work of Melchior and collaborators,[176] and water was chosen as a solvent, considering 
that the drugs are administered in aqueous solutions.[177] All calculations were performed 
using the Gaussian 16 program.[178] 
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Figure 21 Orientation of cisplatin studied in this work: a) parallel P b) perpendicular N, c) perpendicular Cl 
d) perpendicular N-Cl. 
 
3.4.6 Results and Discussion 
3.4.6.1 Comparison between MP2 and DFT in the calculation on Eint 
The work started by evaluating which DFT functional best reproduces MP2 Eint. The MP2 
method can properly describe non-covalent interactions such as dispersion forces, but it 
implies an overestimation of - stacking interactions in complexes such as the benzene 
dimer and has a higher computational cost.[179–182] For this reason, only 3 point were 
calculated at the MP2 level, where cisplatin is parallel to the surface (Figure 21a) and in 
proximity of the minimum (an idea of the minimum position was obtained from MP2 
calculations on coronene (C24H12) cisplatin dimer, not reported in this thesis). Table 6 
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shows the comparison between the Eint calculated at MP2 level and the Eint calculated with 
the selected DFT functionals. 
 
Table 6 Comparison between MP2 and DFT; Eint (kcal mol-1), r (Å) is the distance between the Pt atom and 
the COM of circumcoronene. 
 Eint 
Functional r 2.8 r 3.2 r 3.6 
MP2 1.8 -17.2 -15.1 
BPBE-D3 -11.5 -28.8 -23.1 
BPBE-D3(BJ) -13.5 -27.9 -24.1 
BP86-D3 -7.9 -26.3 -21.9 
B97-D3 0.9 -19.8 -17.6 
B3PW91-D3 -7.1 -25.9 -21.8 
B3PW91-D3(BJ) -8.2 -24.4 -21.6 
PBE1PBE-D3(BJ) 2.1 -17.0 -17.1 
BMK-D3 -8.9 -29.3 -22.1 
M062X-D3 3.5 -17.5 -16.6 
M06HF-D3 -4.9 -20.7 -18.1 
CAM-B3LYP-D3 4.4 -18.2 -17.4 
LC-wPBE-D3(BJ) -3.6 -21.3 -19.8 
 
On the one hand, standard GGA functionals, BPBE-D3, BPBE-D3(BJ) and BP86, together 
with hybrid-GGA functional, BMK-D3, are the worst at reproducing MP2 Eint, because they 
overestimate the Eint from 7.1 to 12.1 kcal mol-1; on the other hand, the best DFT 
functionals are the hybrid-GGA M062X-D3 and the range-separated hybrid GGAs CAM-
B3LYP-D3. The difference between the MP2 and DFT energy (Eint) calculated according 
to this equation: ∆��௡� =  ��௡�ሺ��2ሻ − ��௡�ሺ���ሻ 
(eq3) 
shows that M062X-D3 reproduces the Eint better than CAM-B3LYP-D3:Eint for M062X-D3 
functional is -1.7 kcal mol-1 at 2.8 Å, 0.3 kcal mol-1 at 3.2 Å, 1.5 kcal mol-1 at 3.6 Å, Eint for 
CAM-B3LYP-D3 functional is -2.6 kcal mol-1 at 2.8 Å, 1.0 kcal mol-1 at 3.2 Å, 2.3 kcal mol-1 
at 3.6 Å. In both cases, there are more marked deviations in the repulsive part of the Eint 
profile (where the Eint is positive) compared to MP2 energies. It is interesting to note that 
even the Eint values of PBE1PBE-D3(BJ) functional are very close to MP2 energy, although 
a slight increase in such energy, going from 3.2 Å to 3.6 Å, is observed; hence, comparing 
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the Eint on more than one point is very important. In conclusion, M062X-D3 is the 
functional that provides the best agreement with MP2 energy, so it was used to obtain 
complete scans for all the studied orientations. 
 
3.4.6.2 Cisplatin interaction with circumcoronene 
The Eint profiles, represented as a function of the r of the Pt atom from the COM of 
circumcoronene, obtained at the M062X-D3 level of theory in vacuum and in water, are 
reported in Figure 22, together with points calculated at an MP2 level of theory. 
 
 
Figure 22 Eint as a function of the r (Å) obtained at the M062X-D3 level for the different configurations of 
the cisplatin circumcoronene dimer. The black curve is the Eint in vacuum, the blue curve is Eint in water and 
the red dot is Eint at MP2 level in gas phase. 
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The Eint calculated at an MP2 level of theory in vacuum, reported in table 7, are in good 
agreement with the energy calculated at M62X-D3 for P, N, and N-Cl orientations. Marked 
differences are observed in the repulsive part of the Eint profile, while the energies are in 
good agreement in proximity to the minimum, confirming the reliability of the DFT 
computational protocol used. However, more marked deviations between MP2 and 
M062X-D3 energies are observed for Cl orientation (see Figure 22, table 7). 
 
Table 7 Comparison between MP2 and M062X-D3 Eint (kcal mol-1) in gas phase. 
 
Eint 
Orientation r (Å) M062X-D3 MP2 
P 2.8 3.5 1.8 
 3.2 -17.5 -17.2 
 3.4 -18.2 -18.1 
 3.6 -16.6 -15.1 
N 4 6.8 4.9 
 4.6 -13.1 -12.9 
 5.2 -10.8 -10.3 
N 4.4 2.0 0.7 
 4.8 -8.1 -8.5 
 5.6 -5.6 -6.4 
Cl 4.2 12.6 9.4 
 4.8 -4.4 -6.4 
 5.4 -2.4 -4.5 
 
The largest Eint in vacuum was observed when cisplatin is parallel to the surface of the 
circumcoronene (Figure 21a); the minimum is located at about 3.4 Å and Eint is -18.2 kcal 
mol-1. The values are similar to those obtained by Cuevas-Flores,[168] who reported an Eint 
value of -16.5 kcal mol-1 at a distance of 3.5 Å. Among the perpendicular orientations, the 
most negative Eint was observed when the NH3 groups of cisplatin are oriented towards 
the circumcoronene plane (Figure 21b). The minimum is located at about 4.6 Å and the 
Eint is -13.1 kcal mol-1; a shift of the energy minimum of 1.2 Å and an Eint reduction of 5.1 
kcal mol-1 compared to the parallel orientation can be observed. Again, the values are 
similar to those reported by Cuevas-Flores (12.4 kcal mol-1 at 4.7 Å).[168] The results for the 
N-Cl and Cl perpendicular configurations show that the minima of the energy profiles are 
located an even wider distances (around 5.0 Å and 4.8 Å respectively); furthermore, the 
Eint are smaller than the other two configurations (-8.5 kcal mol-1 and -4.4 kcal mol-1 
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respectively). It is interesting to note that the Eint profiles obtained for Cl orientation are 
different compared to all other cases; in fact, at a distance of 6.4 Å, Eint starts to assume 
positive values, with a maximum localized at 8.5 Å where the  Eint is 1.1 kcal mol-1; the 
same behaviour was observed in Cuevas-Flores work.[168]  
With the aim of further understanding of the interaction properties of cisplatin on 
circumcoronene, the total electronic density of states (DOS) for the cisplatin 
circumcoronene dimer, circumcoronene and cisplatin, together with the partial DOS 
(PDOS) for adsorbed cisplatin molecule and for circumcoronene (red curve) were 
calculated at the minimum of the Eint in vacuum and are reported in Figure 23. 
 
 
Figure 23 DOS for the cisplatin circumcoronene dimer (black curves), DOS for circumcoronene (green dash 
curve) and the DOS for cisplatin (magenta dash curve), PDOS for adsorbed cisplatin molecule (blue curves), 
PDOS for circumcoronene (red curve), for the different orientation of cisplatin. The Fermi level, indicated 
with a dash line, was set as zero. 
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In comparison with the DOS of the non-adsorbed cisplatin molecule (magenta dash curve), 
the DOS of the adsorbed cisplatin (blue curve) moved left. The electrons for adsorbed 
cisplatin comprised between 0 and -100 kcal mol-1 shifted by about -32 kcal mol-1 below 
the Fermi level, which implied that the adsorption state favoured the stability of the 
electronic structure of cisplatin. Furthermore, when cisplatin was parallel to the surface 
of the circumcoronene electrons between -200 and -300 kcal mol-1 shifted by about -29 
kcal mol-1 below the Fermi level, while in other cases such behaviour was not observed. 
The observations are in agreement with the trend of Eint, as the parallel orientation of 
cisplatin appears to be the most stable orientation. No difference was observed in the 
DOS of circumcoronene after cisplatin adsorption when it was parallel to the surface. 
However, In comparison to the DOS of the circumcoronene without cisplatin (green dash 
line in Fugure 23), the DOS of the circumcoronene with cisplatin (red curve) moved right; 
the electrons for free circumcoronene comprised between -100 and -200 kcal mol-1 are 
shifted by about 13 kcal mol-1 for N orientation, about 25 kcal mol-1 for N-Cl orientation 
and about 32 kcal mol-1 for Cl orientation, implying that, when cisplatin is adsorbed with 
such orientations, a destabilization of the circumcoronene electronic structure occurs. 
Moreover, such behaviour is also in good agreement with the trend of interaction 
energies that follow the order P > N > N-Cl > Cl, and is further confirmed by the calculation 
of the electron density overlap reported in Figure 24, where the electron density of the 
two monomers overlap with each other evidently. From the Figure 24 we can observe that 
the electron density overlaps are always distributed below the cisplatin molecule; 
furthermore, the configuration P seems to have the highest electron density. 
 
Figure 24 Electron density (in red) overlap between circumcoronene and cisplatin. Isovalue 0.0006 a.u. 
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Even with the introduction of the solvent (see Figure 22, blue curve) the largest Eint was 
observed when cisplatin was parallel to the graphene surface. However, Eint value is -18.1 
kcal mol-1, similar to what was calculated in vacuum, and no variation in the minimum 
point is observed. Even in this case, the N orientation is the most favoured among 
perpendicular orientations, no variation in the minimum point is observed, although a 
descries in Eint of -4 kcal mol-1 is observed (from -13.1 kcal mol-1 in vacuum to -17.2 kcal 
mol-1 in water). The results for the N-Cl and Cl perpendicular configurations show that the 
minima of the energy profiles do not change in comparison to vacuum calculation, and in 
both cases an increase in Eint is observed (from -8.5 to -7.7 kcal mol-1 for N-Cl orientation 
and from -4.4 to -2.8 kcal mol-1 for Cl orientation). Also in this case, the Eint for Cl 
orientation starts to assume positive values at the distance of 5.4 Å, and the maximum is 
localized at 7.0 Å where Eint is 3.4 kcal mol-1. In conclusion, the introduction of the solvent 
does not drastically change the Eint profiles between cisplatin and circumcoronene. 
However, there is a decrease in Eint for N orientation, which is now similar to the Eint 
calculated for P orientation. 
 
3.4.7 Conclusions 
In summary, the interaction energy profiles between cisplatin and circumcoronene were 
carried out at DFT level in vacuum and with the introduction of the solvent (water). 
Different orientations of cisplatin in respect to circumcoronene were taken into account. 
Different DFT functional, from standard GGA functional to hybrid-GGA, were tested and 
compared with the interaction energy obtained from MP2 calculations. The functional 
that best reproduces MP2 energies is M62X-D3, which was used to obtain the energy 
profiles. The Eint in vacuum followed the order P > N > N-Cl > Cl. The density of states 
analysis showed that when cisplatin is adsorbed with perpendicular orientations (N, N-Cl, 
Cl), a destabilization of the circumcoronene electronic structure occurs. Finally, the 
introduction of the solvent does not drastically change the Eint profiles between cisplatin 
and circumcoronene; the Eint in water followed the order P > N > N-Cl > Cl. However, a 
decrease in Eint was observed for N orientation, which is now similar to the one calculated 
for P orientation. 
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Fluoroquinolones: Study of 
the Chemical Properties and 
the Adsorption Mechanism 
on Carbon Nano Tube 
 
 
One sometimes finds what one is not looking for.  
When I woke up just after dawn on Sept. 28, 1928, 
I Đertainly didn’t plan to revolutionize all ŵediĐine  
ďy disĐovering the ǁorld’s first antiďiotiĐ.  
But I guess that was exactly what I did. 
Cit. ͞Alexander Fleming” 
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4.1 Introduction 
4.1.1 A brief history of the quinolones 
The history of quinolone antibacterial compounds started in 1962 with nalidixic acid. The 
compound showed a modest Gram-negative activity and a low oral absorption, therefore 
it was not a good candidate for the treatment of systemic infections. Its urinary 
concentrations, however, were found to be high, so the compound was (and continues to 
be) used for the treatment of urinary tract infections, although after its introduction into 
clinical use a number of organisms were found to possibly develop resistance.[1] The 
compound was used as a starting model to obtain new drugs that would improve the 
unsatisfactory tolerance and increase the activity spectrum.[2] Structure-activity studies 
have shown that the 1,4-dihydro-4-oxo-3-pyridinecarboxylic acid moiety is essential for 
antibacterial activity, and that such system must be bound with an aromatic ring; the 
structure is called ͞4-Ƌuinolone͟ skeleton (Scheme 1).[1]  
 
 
Scheme 1 4-Ƌuinolone’ skeleton ;4-oxo-1,4 dihydroquinolone). 
 
Marginal structural modifications were initially made in order to develop some of the early 
second-generation compounds such as oxolinic acid and cinoxacin. More substantial 
structural changes were obtained by adding the piperazine ring to position R7 (see Scheme 
1), thereby leading to the development of the pipemidic acid, which showed an increase 
in the activity against Gram-negative bacteria. Third-generation quinolones were marked 
by fluorination at the R6 position (see Scheme 1), giving rise to the classification of future 
compounds, such as fluoroquinolones (FQs). Carbon for nitrogen substitution at the X 
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position and alkyl substitution at the R1 position (see Scheme 1) is essential for activity, 
with lower alkyl (methyl, ethyl, cyclopropyl) compounds generally having progressively 
greater potency. Norfloxacin was the first quinolone to be used in the treatment of ocular 
infectious diseases, because it demonstrated activity against Gram-negative and Gram-
positive bacilli. The addition of a cyclopropryl ring at the R1 position (see Scheme 1) led to 
the development of ciprofloxacin, while the addition of a six-member (pyridobenzoxazine) 
ring between the R1 and R8 positions led to the development of ofloxacin. Levofloxacin, 
created by means of isolation of the active enantiomer of ofloxacin, further improved 
susceptibility against Gram-positive bacteria. Emerging resistance among Gram-positive 
organisms led to the development of newer agents. The addition of a methoxy sidechain 
at the R8 position (see Scheme 1) led to the development of fourth-generation 
compounds, including moxifloxacin. FQs now exhibit an extended spectrum of activity, 
including effectiveness against additional Gram-negative pathogens (e.g., P. aeruginosa, 
H. influenzae, N. gonorrhoeae), Gram-positive cocci (e.g., S. aureus) and some 
streptococci, and they are by far the most frequently used antibacterial quinolones. [2–6] 
Nowadays, numerous representatives are used in both human (Scheme 2) and veterinary 
(Scheme 3) medicine.[6]  
 
 
Scheme 2 Antibacterial quinolone derivatives commonly used in human medicine. 
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Scheme 3 Antibacterial quinolone derivatives commonly used in veterinary medicine. 
 
4.1.2 Mechanism of action and resistance 
FQs act by inhibiting two type of topoisomerases enzymes that human cells lack, DNA 
gyrase and topoisomerase IV (Topo IV), essential for bacterial DNA replication, thereby 
enabling these agents to be both specific and bactericidal.[7,8] DNA gyrase introduces 
negative superhelical twists in the bacterial DNA double helix ahead of the replication 
fork, thereby catalysing the separation of daughter chromosomes. Such activity is 
essential for the initiation of DNA replication and allows the binding of initiation proteins. 
DNA gyrase is an excellent target for FQs, because it is not present in eukaryotic cells and 
it is essential for bacterial growth.[9–11] Topo IV has two functions in the cell: firstly, it 
serves as a decatenating enzyme that resolves interlinked daughter chromosomes after 
DNA replication (Topo IV is required at the terminal stages of DNA replication to unlink 
newly replicated daughter chromosomes); secondly, it relaxes positive supercoils (a 
function shared with the DNA gyrase).[9–13] The mechanism of quinolone inhibition occurs 
via formation of a ternary cleavage complex with the topoisomerase enzyme and DNA 
(see Figure 1). FQs bind in a noncovalent manner to the enzyme−DNA interface in the 
cleavage−ligation active site. Drugs interact with the protein and intercalate into the DNA 
at both cleaved scissile bonds. As a result of their intercalation, FQs increase the steady-
state concentration of cleavage complexes by acting on ligation as physical blocks. When 
replication forks, transcription complexes or other DNA tracking systems collide with 
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drug-stabilized gyrase or Topo IV−DNA cleavage complexes, which are converted to 
permanent chromosomal breaks. In turn, the generation of DNA breaks triggers the SOS 
response and other DNA repair pathways. If the strand breaks overwhelm such processes, 
they can lead to cell death.[14–17] 
 
 
Figure 1 Schematic representation of mechanism of action for FQs. 
 
In general, bacterial resistance to antibiotics occurs in two ways. The first way is known as 
the ͚͚natural’’ ǁay, ǁhen all the strains of the saŵe ďacterial species are resistant to a 
particular drug. This type of antibiotic resistance is known as intrinsic resistance. The 
second ǁay is ͚͚acƋuired’’, and occurs when resistant strains have evolved from 
susceptible ones through a selection after mutation or lateral genetic transfer events. FQs 
have been extensively used in medicine and in the livestock production units,[6] even 
though the prescribing guidelines suggest limiting the use of FQs, since the resistance 
continues to rise and becomes a major problem in the clinical setting.[18] Resistance to the 
fluoroquinolones can occur via a range of mechanisms (see Figure 2). The most common 
mechanism of FQs resistance is due to a mutation of the genes that encode the primary 
and secondary targets of these drugs, the DNA gyrase and Topo IV. The region where 
mutations arise in the genes that encode fluoroquinolone resistance is a short DNA 
sequence, the quinolone resistance-determining region (QRDR). Mutations in the QRDR 
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region, resulting in amino acid substitutions, alter the structure of the target protein and 
subsequently the FQs binding affinity of the enzyme, leading to drug resistance. Other 
resistance mechanisms can be: transmissible quinolone-resistance mechanisms due to 
plasmid-mediated quinolone resistance (PMQR) genes, changes in the permeability of the 
cell membrane, efflux of FQs due to chromosomal multidrug efflux pumps, capable of 
actively removing FQs from the bacterial cell.[3,7,8,19] 
 
 
Figure 2 Schematic representation of mechanisms of resistance for FQs. 
 
4.2 Chemical Properties: Inside the Acidity of Fluoroquinolone 
Antibacterials 
4.2.1 Acid base proprieties 
pH plays an extremely important role on both the activity and the pharmacokinetics of a 
drug and is well known mainly for its acid-base properties. In particular, the activity of FQs 
is reported to be pH-dependent; the binding of the bacterial DNA gyrase and Topo IV 
enzyme is therefore assumed to be dependent on the protonation states of FQs.[20,21] The 
study of the protonation equilibria of FQs has been extensively developed over the last 
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twenty years, and various techniques have been used to obtain both equilibrium 
constants and proton coordination sites.[22–27] Fluoroquinolones (FQs) are ampholyte 
compounds presenting multiple sites that could be protonated depending on pH. 
However, the reported acid–base properties of FQs are highly controversial, particularly 
as regards the values of protonation constants and even the number of basic sites.[26] FQs 
can exist in five different pH-dependent protonation species, namely: di-cation, (H3FQ2+), 
cation (H2FQ+), zwitterions (zHFQ), neutral (nHFQ) species and anion (FQ-). A scheme of 
the equilibria involving such species is reported in scheme 4.  
 
 
Scheme 4 Protonation equilibria involving micro-species and protonation equilibria taking into account only 
the macro-species. 
 
The mole fractions of zHFQ and nHFQ species reach their maximum values at the 
isoelectric point (pH 7), in water. From an experimental point of view, zHFQ seems to be 
the most stable species,[22,23,26,27] although according to some theoretical works 
employing the polarizable continuum model (PCM)[28] to simulate the solvent the most 
stable species should be nHFQ.[25,29] The inconsistency could be related to the fact that 
the PCM model does not take into account the structure of the solvent. Therefore, 
important interactions (hydrogen bond) between the solute and the solvent that could 
stabilize zHFQ form in water can be missed, thereby leading to wrong conclusions.[30,31] 
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The problem could be solved using the discrete-continuum approach, according to which 
some water molecules are placed around the solute to capture strong interactions, and 
the entire system is then immersed in the continuum cavity. In 2007 Lamber et al.[32]  
investigated the relative stability of zHFQ and nHFQ forms of levofloxacin by means of DFT 
calculations, using both the PCM model and the discrete-continuum approach. In their 
work the discrete-continuum approach was performed by placing 5 molecules of water 
near the ionizable groups. Four water molecules were used to stabilize the carboxylate 
(COO-) group, since preliminary calculations with one or two water molecules did not 
show any significant changes with respect to the continuum model results.  The fifth 
molecule is necessary to stabilize the N atom of the piperazine ring. Thanks to the use of 
this approach, the authors revealed that zCFX is slightly more stable than the nCFX form 
in water, and hydrogen bonds were shown to play a key role.  
The H3FQ2+ species (available only in extremely acidic pH) presents another incongruity: 
the protonation may take place at both the piperazine[26,33] ring and the carbonyl 
oxygen.[34,35] 
 
4.2.2 Aim of this work 
In the present thesis Ciprofloxacin (CFX) (scheme 5) has been chosen as a representative 
model, because it is the most prescripted FQ in the world.[6] CFX was patented in 1983 by 
Bayer A.G. and subsequently approved by the United States Food and Drug Administration 
(US FDA) for use in the United States in 1987.[36] CFX is on the World Health Organization's 
List of Essential Medicines, the most effective and safe medicines needed in a health 
system, and[37] has been a very successful drug for Bayer A.G., generating billions of dollars 
in revenue.[36] Ciprofloxacin is the most potent FQ, used for the treatment of bacterial 
gastroenteritis caused by Gram-negative bacilli. It is also used for the treatment of 
respiratory tract infections and it is particularly effective for controlling bronchitis and 
pneumonia and for combating infections of the skin, soft tissues, bones, joints, urinary 
tract infections. It is particularly convenient for the control of chronic infections 
characterized by renal tissue involvement.[5] CFX has also attracted significant interest 
among the scientific community, due to its antiproliferative and apoptotic activities in 
several cancer cell lines; CFX was observed to induce time- and dose-dependent growth 
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inhibition and apoptosis of various carcinoma, osteosarcoma and leukemia cell lines by 
blocking mitochondrial DNA synthesis.[38–41] 
 
 
Scheme 5 Schematic representation of ciprofloxacin (CFX, neutral form). 
 
In our work, DFT calculations were run to provide geometries, relative stability and 
photochemical behaviour of the different protonation states of CFX in gas phase and 
polarized continuum medium (PCM). A discrete-continuum approach was also introduced 
in order to overcome the limit of the PCM method discussed above. To understand how 
many water molecules surround zCFX-N4’ and nCFX molecules, a molecular dynamics 
simulations were performed in order to build a good cluster to be used for the discrete-
continuum approach. Furthermore, calculated UV-Vis absorbance spectra were carried 
out for CFX-, zCFX, nCFX, H2CFX+ and H3CFX2+ species in the various possible tautomeric 
forms, in order to provide detailed information on the effect of protonation on such 
spectra. 
 
4.2.3 Computational details 
4.2.3.1 Molecular dynamics simulation 
The GROMACS 5.1.4 package[42] was used to perform MD simulations in water on systems 
containing nCFX, zCFX, and 1000 water molecules. The united atom GROMOS 54A7 force 
field (G54A7)[43] , used to represent all bonded and non-bonded interactions, has been so 
far one of the most successful; it was developed primarily for the simulation of large 
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organic molecules and has been thoroughly tested.[44] The cross-term Lennard-Jones (12, 
6) parameters were obtained using the Lorenz-Berthelot combination rules. Water was 
described by the SPCE model.[45] United atom (UA) topologies for nCFX and zCFX  were 
obtained from ATB (Automated topology builder).[46] The particle-mesh Ewald method 
was used to calculate long-range electrostatic interactions[47,48], whereas vdW 
interactions were treated with smooth cut-off at a distance of 12 Å. Periodic boundary 
conditions were applied in all directions, the LINear Constraint Solver (LINCS) algorithm[49] 
was applied to constrain all hydrogen bonds. After energy minimization, the systems were 
pre-equilibrated by MD simulations in NVT canonical ensemble and in NPT isothermal-
isobaric ensemble at 1 atm and 298.15 K for 1 ns at the temperature of 298.15 K and 1 
atm with Berendsen coupling methods.[50] The simulation was run with NPT ensemble at 
1 atm and 298.15 K for 10 ns with a time step of 2 fs. The V-rescale[51] algorithm was used 
as temperature coupling method, while the Parrinello-Rahman algorithm[52] was chosen 
as pressure coupling method. Hydrogen bonds were detected by analysing the trajectories 
with the program g_hbond of the GROMACS software. A proton-acceptor distance cut-off 
of 0.35 nm and a hydrogen-acceptor-donor angle cut-off of 30° degrees were used for 
defining the hydrogen bonds. 
 
4.2.3.2 Quantum mechanics calculations 
DFT calculations were performed with the Gaussian 09 program[53] using the B3LYP 
functional.[54] The B3LYP hybrid functional was very successful in the thermochemistry of 
atoms and molecules. The B3LYP hybrid functional has become a standard method used 
to study organic chemistry.[55] All geometries of CFX in different protonation states were 
carried out in vacuum with a 6-311G(d,p) basis set for all atoms. Solvent effects were 
taken into account in two alternative ways: (1) implicit solvent introduced by the PCM 
method[28] using the universal force field (UFF)[56] radius for the spheres centred on each 
atom; (2) discrete-continuum approach, obtained by placing 10 water molecules around 
the protonated groups of the solute to capture the strong interactions and immerse the 
entire system in the continuum cavity. In the latter case, water molecules have been 
selected on the basis of the average number of waters that form hydrogen bonds with the 
ionizable groups, determined by preliminary molecular dynamics simulations.  The cluster 
of 10 water molecules was constructed by taking some representative snapshots, 
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obtained by means of molecular dynamics simulations, and by optimizing the system at 
B3LYP/6-311G(d, p)/H2O/methanol level of theory.  
In order to confirm that stationary points were true minima, an analytical calculation of 
second derivatives of the energy and a vibrational frequency analysis were carried out. 
The same techniques were also used to extract zero-point vibrational energies (ZPVE) and 
thermal corrections to the electronic energy (E), Gibbs free energies (G) at 298 K. 
Excitation spectra of CFX-, zCFX, nCFX, H2CFX+, H3CFX2+ were calculated using the time-
dependent formalism (TD-DFT)[57] at the same level of theory (B3LYP/6-311gG (d, p)/H2O). 
 
4.2.4 Results and discussion 
4.2.4.1 Molecular dynamics simulation 
Molecular dynamics simulations were performed to understand the amount of hydrogen 
bonds (H-bons) formed between water, zCFX-N4’ and nCFX (see Scheme 6). The aim is 
understanding how many water molecules interact with zCFX-N4’ and nCFX, in order to 
build a good cluster formed by z-nCFX and water molecules to be used for the discrete-
continuum approach in the quantum mechanics calculations part. Indeed, constructing a 
cluster of water molecules by randomly inserting them could lead to an inefficient 
arrangement of the molecules and, consequently, of the hydrogen bonds, which could 
affect the relative stability of zCFX-N4’ and nCFX molecules. 
 
 
Scheme 6 Schematic representation of neutral and zwitterion form of CFX. 
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The time evolution of the H-bonds formed between water and zCFX-N4’ or nCFX is 
reported in Figure 3, along with the time evolution of the H-bonds formed between water 
and the inonizable groups presents in CFX. 
 
 
Figure 3 Time evolution (from 4990 to 5020 ps) of the H-bonds formed between ǁater and aͿ CFX, ďͿ N4’ cͿ 
O4, d) O11, e) O12. The blue curve represents zCFX-N4’ and the red curve represents nCFX. The straight line 
represents the average of the number of hydrogen bonds calculated throughout the trajectory. 
 
The analysis of the number of H-bonds revealed that zCFX-N4’ and nCFX form on average 
10.1 and 7.3  hydrogen bonds respectively. A more detailed observation reveals that N4’ 
amino group forms 2.6 H-bonds in zCFX-N4’ and 1.1 in nCFX. The difference can be 
explained by observing that N4' is bound to two H atoms in zCFX-N4’ and has a positive 
charge, while in nCFX it is bound to a single H atom and has no charge. Thanks to its 
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positive charge, the N4 'atom of zCFX-N4’ interacts more effectively with the O atoms of 
water compared to the N4’ atoŵ of nCFX. For O4, the number of H-bonds for zCFX-N4’ is 
very close to the number obtained for nCFX (2.1 and 2.2 respectively). Marked differences 
have been observed in O11 and O12 atoms. For zCFX-N4’, O11 forms 3.1 H-bonds while 
nCFX forms 1.9; similar behaviors are reported for O12, where zCFX-N4’ forms 3.1 H-
bonds and nCFX 1.6. Such behavior can be explained by observing that the carboxyl group 
has a delocalized negative charge in zCFX-N4’, while it is neutral in nCFX; therefore, COO- 
in zCFX-N4’ interacts more strongly with water compared to nCFX. H-bonds for other 
ionizable groups, Nϭ, Nϭ’ and F, are not observed. Such trend is confirmed by the radial 
distribution function (RDF) calculated between the ionizable groups of CFX and H or O 
atoms of water molecules (Figure 4). 
 
Figure 4 Simulated RDFs relative to a) F atom of z-nCFX and H atoms of water molecules; b) N1 atom of z-
nCFX and H atoŵs of ǁater ŵolecules; cͿ Nϭ’ atoŵ of z-nCFX and H atoŵs of ǁater ŵolecules; dͿ N4’-H 
atom of z-nCFX and O atoms of water molecules; e) O4 atom of z-nCFX and H atoms of water molecules; f) 
O11 atom of zCFX and H atoms of water molecules and O11-H atom of nCFX and O atoms of water 
molecules; g) O12 atom of z-nCFX H atoms of water molecules. The blue curve represents zCFX, the red 
curve represents nCFX. 
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RDF curve shows a notable peak, which indicates the most probable distance between the 
ionizable group of z-nCFX and the O or H atoŵ of ǁaters. For F, Nϭ and Nϭ’, RDF presents 
a flat curve (see Figure 4a, 4b, 4c), indicating a weak interaction between these groups 
and the O or H atoms of the water molecules. The RDF curves are in good agreement with 
the results of the analysis of the nuŵďer of hydrogen ďonds. For N4’ ammine group, RDF 
shows a sharp peak at 1.9 Å for both zCFX-N4’ and nCFX, indicating the most probable 
distance ďetǁeen N4’-H and the O atom of waters. The intensity of the peak in zCFX-N4’ 
is more than twice than intensity of nCFX and the magnitude of RDF peak is directly 
proportional to the relative density of O atoms in water, indicating that the density of O 
atoms in zCFX-N4’ is double the density in nCFX. A similar behaviour has been observed 
also for O11 and O12. The peak positions for O11 in zCFX-N4’ are located at 1.8 Å and 1.6 
Å in nCFX, while for O12 the peak is located at 1.8 Å in zCFX-N4’ and at 2.7 in nCFX. On the 
contrary, O4 RDF curves show a similar pattern. The intensity of the peak in zCFX-N4’ is 
equal to the one reported for nCFX, and the peak is located at 1.7 Å for both zCFX-N4’ and 
nCFX. Such behavior has also been confirmed by the calculation of spatial distribution 
functions (SDF, see Figure 5) of O and H atoms of waters. 
 
 
Figure 5 Spatial distribution functions for a) nCFX and b) zCFX-N4’ at isovalue 13.5. SDF of O atoms of waters 
in red, SDF of H atoms of waters in blue. 
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Figure 5 shows that the density of O atoms around the amino group N4 ' is greater in zCFX-
N4’ than in nCFX. A similar pattern has been observed for the carboxy group. It is 
interesting to note that, in nCFX, O12 does not seem to greatly interact with the H atoms 
of the waters. 
In conclusion, zCFX-N4’ appears to form a higher number of hydrogen bonds compared to 
nCFX (10 and 7 respectively). In addition, the differences in the solution properties in zCFX-
N4’ and nCFX seem to be due to the presence of the carboxyl group and the N4 'amine 
group, which present a negative and a positive charge in zCFX-N4’ and a neutral charge in 
nCFX. Dynamic simulations have been useful to understand how many molecules of water 
interact with CFX. This information has served us to get a representative cluster of water 
molecules and CFX to be used for the discrete-continuum approach. In our work we chose 
to use a cluster of 10 water molecules and CFX, obtained from a snapshot of the molecular 
dynamics simulations. 
 
4.2.4.1 Quantum mechanics calculations   
First Protonation 
This part of the work started by analyzing the relative stability of zCFX and nCFX species 
in gas phase, implicit water and with discrete-continuum approach. The experimental data 
show that  nCFX (protonation of O11 oxygen) and zCFX (protonation of N4’ nitrogen, zCFX-
N4’) species (Scheme 7) is formed, and that zCFX-N4’ is the most stable species in 
water.[22,23,26,27] 
 
 
Scheme 7 CFX- nCFX and zCFX-N4’ species of CFX reported in literature. For simplicity, the proton of the first 
protonation reaction is indicated in red. 
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The optimized structures of the different species in implicit water are displayed in Figure 
6. Overall, there are small structural changes in bond lengths and angles values, (see Table 
A1 in appendix B) between CFX- and nCFX, zCFX-N4’ species.  
 
 
Figure 6 Optimized structures of CFX-, nCFX and zCFX-N4’ species in implicit water. 
 
nCFX exhibits an increase of the distance C11-O11 (1.251 Å to 1.336 Å) and a slight 
decrease of the distance C11-O12 (1.261 Å to 1.216 Å); moreover, the formation of a 
hydrogen bond between O11-H and O4 (Figure 6) can be observed. The major change in 
zCFX-N4’ occurred on the piperazine ring, where an increase of the distances Cϯ’-N4’ 
(1.468 Å to ϭ.ϱϬϵ ÅͿ and Cϱ’-N4’ ;ϭ.467 Å to ϭ.ϱϭϬ ÅͿ has been registered. For this species, 
X-Ray diffraction has been obtained. Table 1 shows the most significant atomic distances 
of zCFX-N4’ froŵ X-ray[58] (with relative esd) and optimized structures in PCM. The 
calculated bond lengths and angles are in excellent agreement with the experimental 
ones, confirming the reliability of the computational protocol used (as can be seen from 
MAE and RMSD index[59] calculated on bond lengths, measuring 0.008 Å and 0.014 Å 
respectively). 
The computed Gibbs free energies in gas phase show that nCFX is more stable than zCFX-
N4’ form G = 90.9 kcal mol-1 (G = GzHFQ-4’ – GnCFX).  Such behavior does not change when 
introducing the implicit water: nCFX remains the most stable (G = 24.7 kcal mol-1). 
This result is in agreement with other similar computational works[25,29] but in contrast 
with experimental data.[22,23,26,27]  Therefore, the effect of the presence of explicit water 
molecules solvating the ionisable groups was considered. Water molecules were 
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introduced to obtain a cluster composed by CFX and 10 water molecules. The number of 
water molecules added to CFX was calculated on the basis of the average number of 
waters solvating the MD simulations (see MD parts in results and discussion). The 
obtained cluster was then optimized in PCM water to produce stable final structures 
(Figure 7). 
 
Table 1 Most significant bond lengths (Å) in zCFX-N4’ form from x-Ray[58] (esd are reported in parentheses) 
and optimized structures in implicit water. 
 
 zCFX-N4’ 
Distance Exp.[58] Calc. 
C11-O12 1.251(3) 1.261 
C11-O11 1.254(3) 1.250 
C11-C3 1.504(3) 1.547 
C4-O4 1.251(3) 1.238 
Nϭ’-CϮ’ 1.479(3) 1.460 
CϮ’-Cϯ’ 1.501(3) 1.523 
Cϯ’-N4’ 1.484(3) 1.509 
N4’-Cϱ’ 1.489(3) 1.510 
Cϱ’-C6’ 1.518(3) 1.520 
C6’-Nϭ’ 1.462(3) 1.470 
 
 
Figure 7 Optimized cluster structures of a) nCFX and b) zCFX-N4’ species in implicit water (discrete-
continuum approach). 
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After the introduction of this method, zCFX-N4’ species is now predicted to be slightly 
more stable than the nCFX form with G = -2.1 kcal mol-1 , in nice agreement with 
experimental literature.[22,23,26,27] 
The driving force in the stabilization of zCFX-N4’ species could be related to the energy 
contribution of hydrogen bonds. The hypothesis was verified by calculating the cluster 
energies formation without CFX (X=Xcluster10w-X10w where X is E or G) and the cluster 
energies formation with CFX (X=Xcluser10w-CFX - Xcluster10w+CFX where X is E or G) for nCFX and 
zCFX-N4’; results are reported in Table 2. 
 
Table 2 Cluster energy formation (kcal mol-1). 
 
E  G  
10H2O → Cluster10w (nCFX) -18.6 53.6 
10H2O → Cluster10w (zCFX-N4’) -14.4 63 
nCFX+cluster10w → cluster10w-nCFX -31.7 34.9 
zCFX+cluster10w → cluster10w-zCFX -66.7 8.1 
 
The results show that E cluster formation energy without CFX is negative in both cases, 
but the E of nCFX is about 4 kcal lower than the E of zCFX-N4’. The difference could be 
due to the reduced formation of water-water hydrogen bonds in the case of zHFQ-N4’. In 
fact, we can observe that the E cluster formation energy with CFX (measure of the 
interaction energy between CFX and waters cluster) remains negative, but presents a 
trend that is opposite to the previous case. E for zCFX-N4’ is much more negative 
compared to nCFX (about 35 kcamol-1), possibly due to a greater formation (and thus 
stabilization) of hydrogen bonds between water and zCFX-N4’ compared to nCFX. G 
values, instead, are positive, due to the loss of entropy. In any case, G values confirm 
those reported above. 
Finally, the clusters shown in Figure 7 have been optimized using methanol as implicit 
solvent, in order to understand how the solvent affects the relative stability of the two 
species. The computed energies show that zCFX-N4’ is slightly more stable than nCFX (G 
= -1.6 kcal mol-1). A decrease of 0.5 kcal mol-1 was observed, due to lower polarity of 
methanol in relation to water.   
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Other possible zCFX forms (scheme 8) could be present; in fact, the protonation could take 
place also in N1 (zCFX -N1) and Nϭ’ (zCFX-Nϭ’) nitrogen, as well as in O4 oxygen (zCFX –
O4).  
 
 
Scheme 8 Other possible zCFX forms studied in this work. For simplicity, the proton of the first protonation 
reaction is indicated in red. 
 
Such zCFX forms were analyzed in our work, and their optimized geometries in implicit 
water are shown in Figure 8. 
 
 
Figure 8 Optimized structures of different zCFX forms in implicit water. 
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There are small changes in bond lengths and angles between zCFX-N4’ and other zCFX 
forms (see Table 4). The most significant atomic distances and angles of zCFX-N1 and zCFX-
Nϭ’ are reported in Taďle A2 in appendix B, in comparison with those obtained for zCFX-
N4’. The largest change in zCFX-N1 form was observed in the quinolone ring, with an 
increase of the distances C2-N1 (1.362 A to 1.486 A) and C9-N1 (1.393 A to 1.486 A); 
furthermore, a reduction of the angles C2-N1-C12 (119.9° to 108.7°) and C9-N1-C12 
(120.7° to 111.5°) can be observed. Finally, the carboxyl group is rotated approximately 
90 ° (Figure 8). The major change in zCFX-Nϭ’ form was observed on the piperazine ring, 
where an increase of the distances Nϭ’-C2’ (1.460 A to 1.525 A) and C6’-Nϭ’ (1.470 A to 
1.570 A) and the formation of a hydrogen bond between Nϭ’-H and F (Figure 8) are 
observed. zCFX-O4 form showed a proton transfer from O4 to O11 with reformation of 
nCFX form (Figure 8).  
The relative stability of these forms is summarized in Table 3. G values were calculated 
as difference between zCFX-N4’ (taken as reference) and other zCFX forms (G= GzCFX-n – 
GzHFQ-N4’ where zCFX-n is zCFX-N1, Nϭ’, O4). 
 
Table 3 Relative stability (kcal mol-1) of different zCFX forms in gas-phase, implicit water (PCM). 
 
G Gas-phase G PCM 
zCFX-N4’ → zCFX-N1 -6.8 34.8 
zCFX-N4’ → zCFX-Nϭ’ -11.2 9.3 
 
The results show that, in gas phase, both zCFX-N1 and ZCFX-Nϭ’ forms are more stable 
than zCFX-N4’ form, with zCFx-Nϭ’ being the most stable species. The introduction of 
implicit water leads to a change of this trend, and the more stable species appears to be 
zCFX-N4’. In conclusion, the most stable form appears to be zCFX-N4’, a result in nice 
agreement with experimental literature.[22,23,26,27] 
 
Second protonation 
Experimental data[22,23,26,27] argue that, in the second protonation reaction,  the formation 
of the H2CFX+ species (protonation of O11 oxygen, H2CFX+-O11) reported in Scheme 9a 
occurs. However, there may be additional H2FQ+ forms (Scheme 9b), and the protonation 
could also take place in N1 (H2CFX+-N1) and Nϭ’ nitrogen (H2CFX+-Nϭ’), as well as in O4 
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oxygen (H2CFX+-O4). The optimized structures of different species in water are displayed 
in Figures 9. Overall, there are small changes in bond lengths and angles between zCFX-
N4’ and H2CFX+ species (see Table A3 in appendix B). 
 
 
Scheme 9 a) zCFX-N4’ and H2CFX+-O11 b) Other possible H2CFX+ forms studied in this work. For simplicity, 
the proton of the second protonation reaction is indicated in red. 
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Figure 9 Optimized structures of H2CFX+-O11 H2CFX+-N1, H2CFX+-Nϭ’ and H2CFX+-O4 forms in implicit water. 
 
In the case of H2CFX+-O11, an increase of the distance C11-O11 (1.250 A to 1.336 A), and 
a slight decrease of the distance C11-O12 (1.261 A to 1.216 A) was observed; the 
formation of a hydrogen bond between O11-H and O4 (Figure 9) occurred. H2CFX+-O11 
form was characterized by X-Ray.[60] Table 4 shows the most significant atomic distances 
in H2CFX-O11 from X-Ray (with relative esd) and optimized structures in PCM. 
 
Table 4 Most significant bond lengths (Å) in H2CFX+-O11 form from x-Ray[60] (esd are reported in 
parentheses) and optimized structures in implicit water. 
 H2CFX+-O11 
Distance Exp.[60]  Calc. 
C11-O11 1.213(6) 1.216 
C11-O12 1.319(6) 1.336 
C11-C3 1.477(7) 1.489 
C4-O4 1.265(6) 1.255 
O11-O4 H-bond 2.535(5) 2.563 
 
The calculated bonding distances reported in the table 7 are in excellent agreement with 
the experimental ones; the MAE and RMSD index is of 0.007 Å and 0.001 Å respectively. 
The biggest change in H2CFX+-N1 was observed in the quinolone ring (see Table A3 in 
appendix B), with an increase of the distances C2-N1 (1.362 A to 1.486 A) and C9-N1 (1.393 
A to 1.484 A); furthermore, a reduction of the angles C2-N1-C12 (119.9° to 108.8°) and 
C9-N1-C12 (120.7° to 111.6°) was registered. Finally, carboxyl group rotated 
approximately 90 ° (Figure 9). The major change in H2CFX+-Nϭ’ was observed on the 
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piperazine ring, with an increase of the distances CϮ’-Nϭ’ (1.470 A to 1.521 A) and C6’-Nϭ’ 
(1.460 A to 1.519 A); we also observed the formation of a hydrogen bond between Nϭ’-H 
and F (Figure 9). H2CFX+-O4 form showed a proton transfer from O4 to O11, with 
reformation of H2CFX+-O11 form (Figure 9).  
The relative stability of the forms is summarized in Table 5. G values were calculated as 
difference between H2CFX+-O11 (taken as reference) and the other H2CFX+ forms (G= 
GH2CFX+-n – GH2CFX+-O11, where H2CFX+-n is H2CFX+-N1, Nϭ’). 
 
Table 5 Relative stability (kcal mol-1) of the different H2FQ+ forms in gas-phase and implicit water. 
 
G Gas-phase G PCM 
H2CFX+-O11 → H2CFX+-N1 92.4 59.9 
H2CFX+-OϮ → H2CFX+-Nϭ’ 119.8 45.4 
 
The results in gas-phase and in implicit water show that H2CFX+-O11 is always much more 
stable than the other possible forms. The most stable form between H2CFX+-N1 and 
H2CFX+-Nϭ’ in gas phase results to be the first one. A different behavior occurs with the 
introduction of implicit water; in fact, H2CFX+-Nϭ’ becomes the most stable form. Such 
behavior could be explained by assuming that the piperazine ring is more exposed to the 
solvent than N1 nitrogen, leading to a stabilization of the system. In this case we did not 
use the discrete-continuum approach, considering that the data in gas-phase and in PCM 
confirm what is reported in literature.[22,23,26,27]  
 
UV-VIS Spectra for first and second protonation 
The UV-vis spectra were simulated to have a comparison with the experimental ones.[61] 
The characteristic absorption bands of CFX in different protonation states were found in 
the range of 280-290 nm and 320-360 nm. Calculated absorption spectra are showed in 
Figure 10. The main absorption peak of these species is located in the UV region of the 
spectrum, at 260-280 nm. All species also display a weaker absorption in the 300-400 nm 
range, extending toward the visible region; more bands are obtained at wavelengths of 
less than 250 nm for all species. The findings are in good agreement with experimental 
spectra[61] and previous computational works.[25] Musa et al.[25] calculated the absorption 
spectra for different species of norfloxacin (NOR) at the TD-B3LYP/6-31G(d,p) level of 
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theory, finding that the main absorption peak of such species is located in the 260-280 nm 
wavelength range. 
 
 
Figure 10 Computed UV-VIS spectra in implicit water of CFX- (black line), nCFX (red line), zCFX-N4’ (blue line) 
and H2CFX+-O11 (green line) species. 
 
The major variations in experimental spectra, going from the CFX- to the H2CFX+-O11 
species (decreasing the pH), are the increase of the intensity of the principal band at 280-
290 nm, accompanied by its shift to higher wavelengths, and the decrease of the intensity 
of the bands between 320 and 360 nm. To understand the effect of the protonation site 
on the absorption spectra, the relevant frontier molecular orbitals, which play a dominant 
role in electronic transitions of FQs, have been reported in Figure 11; the main transitions 
are reported in Table 6. 
 
Table 6 Wavelengths () in nm, molecular orbitals and relative percentage contribution (%), oscillator 
strength (f(osc)) of FQ-, nHFQ, zHFQ-N4’ and H2FQ+-O11 species. 
Species   Orbital % f(osc)   Orbital % f(osc) 
CFX- 260 HOMO-ϱ → LUMO 41 0.5156 311 HOMO →LUMO+ϭ 55 0.1144 
nCFX 275 HOMO-ϭ → LUMO+ϭ 46 0.4026 342 HOMO → LUMO 95 0.1389 
zCFX-N4’ 268 HOMO-Ϯ → LUMO+ϭ 46 0.4704 310 HOMO→ LUMO 54 0.0877 
H2CFX+-O11 268 HOMO-ϭ →LUMO+ϭ 52 0.778 309 HOMO → LUMO 81 0.1637 
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With the first protonation step (CFX- → nCFX + zCFX-N4’Ϳ, a shift of the main maximum 
towards higher wavelengths is observed (+15 nm in the case of nCFX, +8 nm for zCFX-N4’ 
and H2CFX+-O11), in agreement with the experimental trend. According to Figure 10, an 
absorption peak relative to nCFX should be obtained in the high wavelength range by 
lowering the pH. On the contrary, the experimental spectra[61] only show a weak shoulder 
in the 360-400nm range: therefore, nCFX species is argued to form only in small amounts. 
The formation of a small shoulder in the low wavelength range (~210 nm)[61] is compatible 
with the formation of H2CFX+-O11 species (green line in Figure 10). It is interesting to note 
that the bands placed at a higher wavelength, corresponding to the HOMO → LUMO 
excitation, are useful to distinguish zCFX (= 310 nm) from nCFX (= 342 nm); an 
explanation can be provided by observing the structure of the orbital (Figure 11).  
HOMO and HOMO-1, orbitals of CFX- and zCFX-N4’ localized on the carboxyl group, are 
very similar. HOMO-2 in CFX- form is slightly different, because a localization is observed 
on the piperazine ring, while in zCFX-N4’ form the orbital is localized on the carbonyl 
group. In both species LOMO is localized on the quinolone ring. LUMO+1 orbital has minor 
components on the Nϭ’ atom of the piperazinyl ring and on the carboxyl group too. 
For nCFX, HOMO, HOMO-1 and HOMO-2 are localized on the quinolone ring and on the 
piperazinyl ring. LUMO and LUMO + 1 are very similar to those obtained for CFX- and zCFX-
N4’ species, ǁhich could eǆplain the difference in  in nCFX and zCFX-N4’. 
Finally, HOMO and HOMO-1 of H2CFX+-O11 are localized on the quinolone ring, while 
HOMO-2 is localized on the carbonyl and carboxyl group. LUMO and LUMO+1 are very 
similar to those obtained for CFX- and zCFX-N4’ species. On the basis of the orbital 
structures, we can hence assume that the photochemical behavior between nCFX and 
zCFX-N4’ species is governed by HOMO -> LUMO excitation. The difference in the 
photochemical behavior can be explained considering that, for this species, the HOMO 
orbitals are localized in different parts of the molecule. 
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Figure 11 Ground-state orbitals of CFX-, nCFX, zCFX-N4’ and H2CFX+-O11 species (isovalue=0.03). 
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Third protonation and relative UV-Vis spectra. 
The experimental data suggest that the formation of the H3CFX2+ species occurs only in 
extremely acidic conditions.[26] However, the literature is not unanimous: this last 
protonation, in fact, could take place either in Nϭ’ nitrogen of the piperazine ring (H3FQ2+-
Nϭ’)[26,33] or in carbonyl oxygen (H3FQ2+-O4).[34,35] Moreover, there may be an additional 
H3CFX2+ form, and the protonation could take place also in N1 nitrogen (H3CFX2+-N1).  The 
forms are reported in Scheme 10. 
 
 
Scheme 10 Possible H3CFX2+ form. For simplicity, the proton of the third protonation reaction is indicated in 
red.  
 
The optimized structures of the different species are displayed in Figure 12. Overall, there 
are small changes in bond lengths and angles between H2CFX+ and H3CFX2+ species (Table 
A4 in appendix B). 
 
 
Figure 12 Optimized structures of H3CFX2+ forms in implicit water. 
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The major change for H3CFX2+-Nϭ’ form was observed on the piperazine ring, with an 
increase of the distances Nϭ’-CϮ’ (1.461 A to 1.521 A) and C6’-Nϭ’ (1.471 A to 1.523 A); 
the formation of a hydrogen bond between Nϭ’-H and F (Figure 12) was also observed. 
For H3FQ2+-O4 form, an increase of the distance C4-O4 (1.255 A to 1.334 A) and the 
formation of a hydrogen bond between O11-H and O4 (Figure 12) were observed. The X-
Ray structure for di-cationic form of NOR (H3NOR2+-O4) was obtained.[34] Table 7 show the 
most significant atomic distances of NOR from X-ray with relative esd and CFX optimized 
structures.  
 
Table 7 Most significant bond lengths (Å) in H3NOR2+-O4 form from X-ray[34] (esd are reported in 
parentheses) and H3CFX2+-O4 optimized structures in implicit water. 
 H3FQ2+-O4 
 NOR CFX 
Distance (A) Exp.[34]  Calc. 
C11-O12 1.226(2) 1.208 
C11-O11 1.313(2) 1.336 
C11-C3 1.479(3) 1.505 
C4-O4 1.319(2) 1.334 
 
The calculated bonding distances reported in the table 7 are in excellent agreement with 
the experimental data; the MAE and RMSD index are of 0.001 Å and 0.015 Å respectively. 
The largest change in H3CFX2+-N1 form was observed on the quinolone ring, with an 
increase of the distances C2-N1 (1.346 A to 1.462 A) and C9-N1 (1.402 A to 1.486 A), 
accompanied by a reduction of the angles C2-N1-C12 (119.7° to 112.3°) and C9-N1-C12 
(120.4° to 109.6°). 
G values,  calculated as difference between the H3CFX2+-O4 (taken as reference) and 
other H3CFX2+ forms (G= GH3CFX2+-n – GH3CFX2+-O4 where H2CFX2+-n is H3CFX2+-N1 and Nϭ’),  
are reported in Table 8. 
 
Table 8 Relative stability (kcal mol-1) of the different H3CFX2+ forms in gas-phase and implicit water. 
Form G gas-phase  G PCM  
H3FQ2+-N1 39.5 33.2 
H3FQ2+-Nϭ’ 41.0 3.7 
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The results show that the H3CFX2+-O4 form is always more stable than the other possible 
forms. As already observed for the second protonation reaction, the most stable form 
between H3CFX2+-N1 and H3CFX2+-Nϭ’ in gas phase is the former; conversely, the most 
stable form with implicit solvent is the latter. In order to evaluate the electronic 
transitions of CFX in different protonation H3CFX2+ form, UV-vis spectra were simulated 
(Figure 13). The main absorption maxima wavelengths, the orbitals involved, the relative 
percentage contribution and the oscillator strength are reported in Table 9. The molecular 
orbitals involved in the electronic transitions are shown in Figure 14. 
 
 
Figure 13 Computed UV-VIS spectra in implicit water of H3CFX2+-N1 (black line), H3CFX2+-N1’ (red line), H3CFX2+-O4 (blue 
line), H2CFX+-O11 (green dot line, for comparison) forms. 
 
Table 9 Wavelengths () in  nm, orbitals and relative percentage contribution (%), oscillator strength (f(osc)) 
of possible H3CFX2+ form. 
Form   Orbital % f(osc)  (nm) Orbital % f(osc) 
H3CFX2+-N1 293 HOMO → LUMO+ϭ 95 0.3279 426 HOMO → LUMO 98 0.2151 
H3CFX2+-Nϭ’ 251 HOMO-ϯ → LUMO 82 0.2178 321 HOMO → LUMO 96 0.1024 
H3CFX2+-O4 285 HOMO → LUMO+ϭ 50 0.4092 361 HOMO → LUMO 93 0.3207 
 
The main experimental absorption peak[61] of these species is located in the 250-290 nm 
spectral range. The major variation in experimental spectra, going from H2CFX+ to H3CFX2+ 
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species (decreasing the pH), is the appearance of the band at 360-400 nm, accompanied 
by a decrease of the intensity of the other bands. The computed spectrum that best 
reproduces such trend seems to be H3CFX2+-O4 form (Figure 13, Table 9), in which a 
decrease of the intensity of the principal bands and the appearance of the band at 361 
nm are observed. Moreover, in this region H3CFX2+-O4 has a higher probability (oscillator 
strength) of absorption in respect to H3CFX2+-Nϭ’ and H3CFX2+-N1. The computed spectra 
for H3CFX2+-N1 and H3CFX2+-N1’ are very different from the experimental spectra. In order 
to understand the effect of the protonation on the absorption spectra, it is useful to 
examine the relevant frontier molecular orbitals (Table 9). 
 
 
Figure 14 Ground-state orbitals of possible H3CFX2+ form (isovalue=0.03).  
 
For H3CFX2+-N1 and H3CFX2+-O4 forms, HOMO is very similar and localized on the 
quinolone ring and to less extent on Nϭ’ of the piperazinyl ring, while for the H3CFX2+-Nϭ’ 
form the orbital is localized only on the quinolone ring. LUMO is localized on the carboxyl 
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group for H3CFX2+-N1 form and on quinolone ring for H3CFX2+-Nϭ’ form. For H3CFx2+-O4, 
LUMO is localized on the quinolone ring and on the carbonyl group.  
 
4.2.6 Conclusions 
In our work, the relative stability of the possible forms of CFX was studied from a 
theoretical point of view. Molecular dynamics simulations were conducted to obtain 
information on the amount of H-bonds formed between water, zCFX-N4’ and nCFX. The 
results showed that zCFX-N4’ forms on average 10 H-bonds, while the H-bonds formed by 
nCFX are on average 7. The amino group N4' and the carboxy group are responsible for 
the various properties of zCFX-N4’ and nCFX. This information has been used to build a 
representative cluster formed by z-nCFX and 10 water molecules. The cluster has been 
used for the discrete-continuum approach in the quantum mechanics calculations. In the 
second part of our work, the geometries, relative stability and photochemical behaviour 
of the different protonation states of the antibiotic compound ciprofloxacin have been 
studied by DFT calculation. Our computations confirm the predominance of the zCFX-N4’ 
form in water, thanks to the introduction of a discrete-continuum approach; the result 
was further confirmed through calculated absorption UV-Vis spectra. A slight decrease of 
stability of the zCFX-N4’ species with respect to nCFX was observed by using from water 
instead of methanol as implicit solvent, due to lower polarity of such solvent. The 
protonation sequence N4’→O11→O4 was firstly confirmed through the comparison with 
crystalline structures present in the literature; secondly, by means of the calculation of 
the relative stability for such species; thirdly, through calculated absorption UV-Vis 
spectra.  
 
4.3 Antibacterial Fluoroquinolones as Pollutants: Adsorption on 
Carbon Nano-tube, a Molecular Dynamics Simulation Study 
4.3.1 FQs pollution 
In addition to being used in human and veterinary medicine, FQs are also used in 
agriculture and aquaculture. The unreasonable use of such antibiotics has led to the 
emergence of a global environmental pollution problem, namely the environmental 
pollution with FQs.[62] This class of compounds was known to have a low antimicrobial 
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resistance. In recent years, however, an increase in the antimicrobial resistance has 
alerted the international authorities;[63] the presence of such phenomenon has already 
been demonstrated and is known to be gradually increasing. To understand the problem, 
we need to know how FQs can enter the environment (Figure 15). 
 
 
Figure 15 Pollution with FQs. The FQs and their metabolites end up in the sewage, manure and domestic 
waste, then in soil and waters. In addition, the presence of fluoroquinolones residues in food of animal 
origin causes the emergence of bacterial resistance. 
 
The excretion of FQs by animals and humans through faeces and urine is the principal 
pathway by which they can enter the environment. FQs can be excreted unchanged or as 
the product of   conjugation, oxidation, hydroxylation, dealkylation, or decarboxylation 
processes.[62] Original compound residues are defined as the amount of antibiotic not 
absorbed by a human or animal digestive system and excreted through faeces into the 
external environment, or the detectable level of antibiotics remaining in the muscle fibres 
of animals.[64–66] In turn, the amount of antibiotic residue has implications on the bacterial 
ecology, as well as on the invertebrate and vertebrate ecology in soil matrices and 
surrounding surface water. Moreover, the formation of metabolites is also possible. 
Metabolites are molecules transformed from a parent compound through a biochemical 
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transformation process. The transformation can occur within the body, or in sewage, 
manure, soil, and the environment.[67] In addition, the degradation of FQs can lead to the 
formation of metabolites resembling other FQ drugs; for example, a metabolite of 
enrofloxacin, a FQ used only in veterinary medicine, closely resembles CFX, which is used 
only in human medicine, so the enrofloxacin metabolite has to be distinguished from true 
CFX.[68] Another possible pathway through which FQs enter the environment is 
photochemical degradation.[69–71] The studies on products resulting from photochemical 
degradation are limited, and both the presence of antibacterial activity in such products 
and their potential threat to the environment and human health remain to be 
determined. Chemical changes occur in the structure by irradiation, but usually the 
quinolone ring remains intact and the antibacterial activity of the compounds is generally 
high. 
 
4.3.2 Water pollution with FQs and remediation 
Surface water plays an important role in the emergence and spread of antibiotic 
resistance, so the development of strategies to improve water quality has become a 
permanent necessity. Pharmaceutical industry waste, hospital waste and therapeutic 
drugs contribute to the excretion of unchanged fluoroquinolones and their metabolites in 
the domestic wastewater.[72] Considering their serious threat to the environment and their 
inherent health threat to human beings, the development of efficient removal techniques 
is becoming an urgent matter to be addressed. Accordingly, it is necessary to implement 
techniques to effectively remove FQs in aquatic environments. Thus, different treatment 
techniques including adsorption,[73] advanced oxidation process and bioremediation[74] 
were investigated. Among those techniques, adsorption seems to have interesting 
potentialities for emerging organic pollutants remediation, considering its versatility and 
removal efficiency.[73] Adsorption may be defined as an accumulation of compounds 
(adsorbate) on the surface provided by solid materials (adsorbent), and it is widely used 
to remove substances from fluid phases.[75,76] Due to their high specific surface area, nano-
adsorbents show a rate of adsorption for organic compounds which is considerably high 
compared with macroscopic adsorbents systems. They have a great potential for novel, 
more efficient, and faster decontamination processes aimed at removing organic and 
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inorganic pollutants like heavy metals and micropollutants. Current research activities 
mainly focus on the following types of nano-adsorbents:[73] 
 Carbon nanotubes (CNTs) 
 Metal-based nanoadsorbents 
 Polymeric nanoadsorbents 
 Zeolites. 
 
4.3.3 Carbon nanotubes 
In this thesis, I will focus my attention on carbon nano-tubes (CNTs). CNTs were originally 
discovered and fully described by Sumio Iijima in his TEM observation,[77] even though 
some scientists believe that the discovery was made earlier by Bacon.[78] CNTs, like 
graphene (see chapter 3), are allotropes of carbon with a cylindrical three-dimensional 
(3D) structure where carbon is bound to other three carbons in a sp2 bond formed by 
rolling single or multiple layers of graphene sheets into seamless cylinders.[79] These 
cylindrical structures haǀe tǁo forŵs: single‐ǁalled CNTs (SW-CNTs) and multi-walled 
CNTs (MW-CNTs) reported in Figure 16.  
 
 
Figure ϭ6 “tructures of single‐ǁalled CNTs ;“W-CNTs) and multi-walled CNTs (MW-CNTs). 
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SW-CNTs are composed of a single cylindrical graphene layer, while MW-CNTs comprise 
several concentric cylinders of graphitic shells, each forming a SW-CNT. Moreover, MW-
CNTs generally have a larger outer diameter (2.5 - 100 nm) compared to SW-CNTs (0.6 - 
2.4 nm).[80] As observed for graphene (see chapter 3), the sp2 structure, which is stronger 
than the sp3 bond found in diamonds, gives the CNTs unique properties, such as high 
tensile strength, ultra‐light ǁeight and eǆcellent cheŵical and therŵal staďility. Another 
amazing property of CNTs is elasticity: when a high pressure is exercised, it can bend, 
twist, kink, and in the end the nanotube will return to its original structure. However, its 
elasticity presents a limit and, under very physically powerful forces, the shape of a CNT 
can be temporarily deformed. Moreover, some of the structure defects can weaken CNTs 
strength.[81] Several techniques have been developed to synthetizing CNTs; the most 
commonly procedure are: arc-discharge technique,[82,83] laser-ablation technique[84] and 
catalytic chemical vapor deposition (CVD) technique.[85,86]   
CNTs can be functionalized in different ways, and various functional groups can easily be 
attached on the surface of CNTs by chemical modification, which enhances its aqueous 
solubility with reduced tendency of agglomeration. Chemical modification can be 
accomplished by adsorption and other interactions (electrostatic, hydrophobic, or 
covalent and non-covalent bonding). As observed for graphene based materials, the 
unique structure of CNTs is characterized by highly assessable adsorption sites, adjustable 
surface chemistry and the presence of delocalized  electrons, rendering this material an 
excellent candidate for environmental remediation. However, their use on an industrial 
scale for large municipal water and wastewater treatment plants is not expected in the 
midterm, because of high production costs.[87] Point-of-use applications that require small 
quantities of CNTs are more competitive; for example, the elimination of heavily 
degradable contaminants such as many antibiotics and pharmaceuticals.[73] 
 
4.3.4 CNTs as adsorbents system in wastewater treatment 
The adsorption of synthetic organic compound by CNTs has been rapidly growing.[77,88,89] 
The studies included the adsorption of a multitude of organic contaminants such as 
polycyclic aromatic hydrocarbons (PAHs), benzene derivatives, phenolic compounds, 
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pharmaceuticals, polychlorinated biphenyls, proteins, insecticides, herbicides, organic 
dyes, and dioxin by CNTs.[90] 
Moreover, CNTs have demonstrated potential as adsorbent systems applied in water and 
wastewater treatment for the removal of FQs. 
Several experimental studies of adsorption of FQs on CNTs are reported in the literature. 
For example, Li et al.,[91] found that the adsorption of CFX on SW and MW-CNTs was 
greatly affected by pH and proposed that hydrophobic interactions controlled sorption for 
neutral and zwitterionic CFX, while electrostatic interactions were the dominant 
mechanism for ionic CFX sorption.  
The CFX sorption was thermodynamically favourable for all CNTs used, although in the 
case of SW-CNTs the sorption process is an entropy driven process (i.e. positive H of 
adsorption), while the opposite behaviour was observed for CFX sorption on MW-CNTs. 
SW-CNTs present the highest sorption for CFX, due to the fact that they have the largest 
surface area among all CNTs.[91] The adsorption of the FQs Norfloxacin (NOR) and 
Ofloxacin (OFL) on CNTs has been studied by Peng et al.[92] to evaluate the role of 
structural and hydrophobic properties in regulating their adsorption. They concluded that, 
even though OFL and NOR showed one order of magnitude difference in their solubilities, 
their adsorption coefficients were similar. The major difference between the 
hydrophobicities of NOR and OFL did not result in their difference regarding adsorption 
on CNTs. The similar structures of OFL and NOR indicated that their adsorption on CNTs 
was also a structural-controlled process. 
In 2015 Ncibi et al.[93] conducted some experiments to investigate the use of SW-CNTs, 
double-walled (DW-CNTs) and MW-CNTs agglomerates for the removal of two antibiotics, 
Oxytetracycline (OXY) and CFX, from aqueous solution by means of UV-Vis 
spectrophotometry. The experimental results revealed that a moderate increase in 
adsorption between pH 3 and 7 for both antibiotics. The highest removal capacities were 
registered using SW-CNTs for both antibiotics.  
In recent years, the interaction between drugs and CNT has been studied by means of MD 
simulations, allowing to have a detailed picture of the adsorption/release mechanisms 
and thermodynamics thanks to the calculation of the binding free energy, obtained 
through the combination of the potential of mean force (PMF) with umbrella sampling 
(US) technique.[94–105] 
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While numerous experimental studies have been conducted on the adsorption of CFX to 
CNT,[91,93,106–111] only one computational work related to the interactions between CFX and 
CNT is present in the literature.[112] In that work, the heat-driven release of CFX from CNT 
was studied by means of molecular dynamics (MD) simulations[112], although only  neutral 
CFX was considered and no free energy data the CFX adsorption were obtained.  
 
4.3.5 Aim of this work 
In this work, MD simulations have been used to study the adsorption of both neutral and 
zwitterionic forms of CFX (see Scheme 6) on SW-CNT in vacuum and in water. 
Furthermore, we determined the free energy profile of CFX for the adsorption using the 
Umbrella sampling technique (US)[113], and we used it to discuss the difference between 
neutral and zwitterionic form. US technique is a useful method to analyse the 
macromolecular interaction. The understanding of adsorption mechanisms at a molecular 
level can help to improve the efficiency of CNTs as adsorbent systems in wastewater 
treatment.  
 
4.3.6 Computational details 
4.3.6.1 Force fields and models 
The GROMACS 5.1.4 program[42] was used to perform MD simulations in vacuum and in 
presence of water on several systems containing nCFX, zCFX, SWCNT and water. The 
united atom GROMOS 54A7 force field  (G54A7)[43] was used to represent all the bonded 
and non-bonded interactions. The cross-term Lennard-Jones (12,6) parameters were 
obtained using the Lorenz-Berthelot combination rules. Water was described by the SPCE 
model.[45] LINCS algorithm[49] was applied to constrain all hydrogen bonds. The (14,14) 
armchair SW-CNT, with terminal hydrogen atoms, was created using  VMD.[114] The CNT 
diameters has been set to 1.9 nm and the length to 6 nm. The diameter is typical of CNTs 
used experimentally, indeed, the typically diameters are from 0.6 to 2 nm [87] while the 
lengths range is from less than 100 nm to several centimeters, thereby bridging molecular 
and macroscopic scales.[87] United atom (UA) topologies for nCFX, zCFX and SW-CNT, 
obtained from ATB (Automated topology bulider),[46] were used. MK charges[115] 
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calculated at B3LYP/6-31G level of theory (reported in Table A5 in appendix B) has been 
used for nCFX and zCFX, instead, for SW-CNT the charges have been set to zero. 
 
4.3.6.2 MD simulations in vacuum 
The simulated systems consisted of a SW-CNT located in the center of the MD simulation 
cell (X = 10.0 nm, Y = 10.0 nm and Z = 10.0 nm) and 1, 2, 4 and 8 CFX molecules were 
located to the outer surface and in the inner surface of the SW-CNT.  The simulations were 
conducted in microcanonical (NVE) ensemble. The total length for each simulation was 5 
ns and the time step was 2 fs. Periodic boundary conditions, non-bonded interaction 
cutoffs, temperature coupling and pressure coupling were all turned off. The interaction 
energy (Eint) was calculated by following equation: 
 ��௡� = ��௢� − ሺ�ௌௐ−�ே� + �௭−௡��௑ሻ 
(eq1) 
where Etot is the potential energy for the SW-CNT-z-nCFX system minimum geometry 
configuration, Ez-nCFX is the potential energy of the adsorbed zCFX or nCFX in a vacuum 
with the geometry unchanged, and ESW-CNT is the potential energy of the surface.[116] 
Moreover, the relaxed interaction energy (Eint-relax) was calculated taking into account the 
relaxation (minimum geometry configuration) of CFX and SW-CNT. 
 
4.3.6.3 MD simulations in water 
The simulated systems consisted of a SW-CNT located in the center of the MD simulation 
cell, 1, 2, 4 and 8 CFX molecules were located to the outer and inner surface of the SW-
CNT with 11100 water molecules. 
The particle-mesh Ewald method was used to calculate the long-range electrostatic 
interactions[47,48], whereas the van der Waals interactions were treated with smooth cut-
off at a distance of 12 Å. Periodic boundary conditions have been applied in all directions. 
After energy minimization, the systems were pre-equilibrated by MD simulations in NVT 
ensemble at the temperature of 298.15 K and in NPT ensemble at 1 atm and 298.15 K for 
1 ns with Berendsen coupling method.[50] The simulation was run with NPT ensemble at 1 
atm and 298.15 K for 5 ns with a time step of 2 fs where the V-rescale[51] algorithm was 
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used as temperature coupling method, while, the Parrinello-Rahman barostat was 
employed.[52]    
Simulations of zCFX and nCFX in water, without SW-CNT, have been conducted to obtain 
the hydration energy (Ehyd) of CFX. The simulated systems consisted of one CFX molecule 
and 1000 waters molecules. The system was simulated for 5 ns in NPT ensemble at 1 atm 
and 298.15 K. Ehyd was calculated according to the following equation: 
 �ℎ௬� = ���௑−�2ை − ሺ���௑ + ��2ைሻ 
(eq2) 
where ECFX-H2O is the potential energy of the CFX immersed in a box of water, ECFX is the 
potential energy of CFX in vacuum (in NPT ensemble) and EH2O is the potential energy of 
the box of water without the CFX molecules.  
 
4.3.6.4 Free energy calculation 
Free energy calculations were carried out using the umbrella sampling technique.[113] This 
technique requires the prior generation of initial configurations along a reaction 
coordinate ;ξͿ, ďetǁeen tǁo interacting species. The position of one of these species is 
kept constant in order to have a reference point, while the other group is placed at 
increasing center-of-mass (COM) distance from the reference with its position maintained 
ďy an ͚uŵďrella’ potential. These COM distances represent ͞saŵpling ǁindoǁs͟ ǁherein 
independent simulations are conducted to generate a set of structures along the reaction 
coordinate. The values of the potential of mean force (PMF) can be calculated from of 
these windows. To assemble a PMF curve as a function of the entire reaction coordinate, 
energy values in adjacent windows are reassembled such that they produce a continuous 
function.[113]  
The free energy profiles have been calculated for the adsorption of nCFX and zCFX to the 
outer and inner surface of SW-CNT. To generate equilibrated starting structures for the 
pulling simulations, one molecule of nCFX or zCFX were placed respectively 2.5 Å out of 
the external surface and in the middle of the inner surface of SW-CNT. The rectangular 
box size for the adsorption on the outer surface was X = 8.0 nm, Y = 13.6 nm and 
Z = 8.0 nm with 28050 water molecules. Instead, for the adsorption on the inner surface 
the box size was X = 5.0 nm, Y = 6.0 nm and Z = 20.0 nm with 19050 water molecules.  
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As regards the non-bonded interactions, periodic boundary conditions, constraint 
algorithm and simulation protocol, the same conditions of the simulations in water have 
been used. The position restraint algorithm was employed to restrain the position of SW-
CNT in order to obtain an immobile reference. The starting configurations were obtained 
by pulling the CFX molecule from the outer/inner surface of SW-CNT to the bulk water 
phase with an umbrella potential,[117] along the Y axis for the adsorption on the outer 
surface and along the Z axis for the adsorption on the inner surface (see Figure 17). 16 
configurations have been selected as umbrella sampling windows for the adsorption on 
the outer surface, while 22 configurations have been selected as windows for the 
adsorption on the inner surface, with a spacing of 0.2 nm. After a short equilibration (0.5 
ns) each window was simulated for 10 ns in NPT ensemble at 1 atm and 298.15 K where 
the V-rescale algorithm[118] was used as temperature coupling method, while the 
Parrinello-Rahman algorithm[52] was chosen as pressure coupling method. During this 
simulation an Umbrella potential has been applied between nCFX or zCFX and SW-CNT, 
with a force constant of 1000 kJ mol-1 nm-2. The value of the force experienced by zCFX 
and nCFX was saved every 4 ps. To determine the PMF for the systems studied, we 
processed the results from all windows of the restrained MD simulations for each system 
using the Weighted Histogram Analysis Method (WHAM).[119] 
 
 
Figure 17 Pulling direction of CFX molecules. 
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4.3.7 Results and discussion 
4.3.7.1 MD simulation in vacuum 
In the first simulations, 1, 2, 4, 8 CFXs molecules were placed close to the surface of SW-
CNT. CFX molecules remain adsorbed to the SW-CNT surface by - interactions in all 
cases.[112] Both nCFX and zCFX show similar structures as regards the adsorption of one 
molecule on the outer surface of SW-CNT. The minimum geometry configuration of SW-
CNT-CFX systems for the adsorption of one molecule in vacuum are reported in Figure 18. 
As regards the adsorption on the inner surface, zCFX assumes a cyclic conformation due 
to the formation of an intramolecular hydrogen bond between the carbonyl group and 
the amino group of the piperazine ring, while the minimum geometry of nCFX is parallel 
to the SW-CNT surface (Figure 18c and 18d).  The formation of hydrogen bonds (H-bonds) 
between the carbonyl group or carboxylic acid group and the amino group of the 
piperazine ring (see Figure 19-22) is observed when multiple CFX molecules (2, 4 and 8) 
are adsorbed to the SW-CNT surface. 
 
 
Figure 18 Minimum geometry configuration of a) zCFX and b) nCFX adsorbed on the outer surface of SW-
CNT in vacuum, and c) zCFX, d) nCFX adsorbed on the inner surface of SW-CNT in vacuum. 
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To better understand this phenomenon, an analysis of the H-bonds between CFX 
molecules has been performed. The average number of H-bonds between CFX and CFX, 
calculated over the duration of the simulation, is shown in the Table 10. 
 
Table 10 Average number of H-bonds between CFX molecules for the adsorption of 2, 4 and 8 CFX molecules, 
where nads is the number of CFX molecules adsorbed. 
Average of H-bond 
nads CFX zCFX out nCFX out zCFX in nCFx in 
2 2.5 2.6 2.1 3.0 
4 7.4 6.3 5.8 5.8 
8 14.0 13.1 12.7 12.0 
 
The data in Table 10 show that the number of H-bonds increases with the increase in the 
number of adsorbed molecules. The average number of H-bonds for adsorption on the 
inner and outer surface is comparable to zCFX and nCFX; when four and eight CFX 
molecules are adsorbed they tend to form more H-bonds if located on the outer surface, 
while for the adsorption of two molecules the number of H-bonds on the inner and outer 
surface is comparable. H-bonds influence the adsorption geometry of CFX molecules on 
the SW-CNT surface.  
 
 
Figure 19 Minimum geometry configuration of a) two zCFXs and b) two nCFXs adsorbed on the outer surface 
of SW-CNT and c) two zCFXs, d) two nCFXs adsorbed on the inner surface of SW-CNT in vacuum. 
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Indeed, the adsorptions of two zCFX molecules are not perfectly parallel to outer surface, 
as reported in Figure 19a. However, the two nCFX molecules are parallel to the SW-CNT 
surface (see Figure 19b), and the same behaviour is observed for both zCFX and nCFX for 
adsorption to the inner surface (Figure 19c and 19d). The adsorption of four CFX molecules 
to the outer surface highlights the fact that they remain parallel to the CNT surface for 
both zCFX and nCFX (see Figure 20a and 20b) the same behaviour is reported  for nCFX, 
adsorbed to the inner surface (see Figure 20d). For the adsorption on the inner surface, 
the four zCFXs present a ͞sandǁich͟ configuration ;Figure ϮϬc), where CFX molecules 
interact with each other via - through their own aromatic rings. 
 
 
Figure 20 Minimum geometry configuration of a) four zCFXs and b) four nCFXs adsorbed on the outer surface 
of SW-CNT, and c) four zCFXs, d) four nCFXs adsorbed on the inner surface of SW-CNT. 
 
Such type of conformation, reported in detail in Figure 21, can lead to a decrease in the 
interaction between the aromatic ring of SW-CNT and the quinolone ring of zCFX. The 
͞sandǁich͟ configuration, however, has already been reported in literature for the 
interaction between both forms of CFX and lipid membranes.[120]  
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Figure 21 Detailed structure of four zCFX molecules adsorbed on inner surface. 
 
The same type of configuration is also observed for the adsorption of eight z and nCFX to 
the inner surface (figures 22c and 22d). Finally, the adsorption of eight zCFX molecules to 
the outer surface shows that some molecules are not parallel to the surface due to the 
intricate H-bonding network that they form (Figure 22a). On the contrary, the eight nCFX 
molecules are all parallel to the surface.  
 
 
Figure 22 Minimum geometry configuration of a) eight zCFXs and b) eight nCFXs adsorbed on the outer 
surface of SW-CNT in vaccum, and c) eight zCFXs, d) eight nCFXs adsorbed on the inner surface of SW-CNT 
in vacuum. For clarity, the structure of SW-CNT has not been reported. 
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In order to better understand the interaction between SW-CNT and CFX the minimum 
distances (rm) calculated between any pair of atoms closest to the two molecules as a 
function of time (rm vs. time) have been carry out. The average of rm (�௠̅̅̅) calculated from 
the graph of rm vs. time for each CFX molecule are between 2.64 ± 0.01 Å and 3.22 ± 0.01 
Å, indicating that these are the minimum distances between CFX and SW-CNT. The 
analysis of rm curves vs. time indicates that CFX stayed in contact with the surface for the 
entire trajectory in all cases.  
The �௠̅̅̅ values for the absorption of one CFX molecule on the outer SW-CNT surface are 
similar, however zCFX seems to be closer to the surface than nCFX (2.84 ± 0.01 Å and 2.90 
± 0.01 Å respectively); the same behaviour is observed for the adsorption to the inner 
surface (2.78 ± 0.01 Å for zCFX 2.86 ± 0.01 Å for nCFX). The graph rm vs. time relative to 
the adsorption of one CFX molecule shows an approximately constant value, however, for 
adsorption of zCFX on the inner surface, a decrease in the rm value from 3.00 ± 0.01 Å to 
2.70 ± 0.01 Å (Figure 23a) is registered around 1.8 ns, together with a decrease in the 
fluctuation of the rm value where a step-trend is observed. This is related to the cyclic 
conformation assumed by zCFX (Figure 18c), observed until the end of the simulation. The �௠̅̅̅ values for the absorption of two CFXs molecules are between 2.64 ± 0.01 Å and 2.95 ± 
0.01 Å and the graphs rm vs. time show an approximately constant value. The �௠̅̅̅ values 
for adsorption on the outer surface of four zCFX molecules are between 2.86 ± 0.01 Å and 
3.13 ± 0.01 Å, while for nCFX the �௠̅̅̅ values are similar, between 2.86 ± 0.01 Å and 2.97 ± 
0.01 Å. For adsorption to the internal surface, nCFX presents �௠̅̅̅ values ranging from 2.89 
± 0.01 Å to 2.96 ± 0.01 Å. In these cases, the graph rm vs. time shows an approximately 
constant value. For four zCFX molecules adsorbed to the inner surface, the �௠̅̅̅ values are 
between 2.92 ± 0.01 Å to 3.22 ± 0.01 Å, although the graphs rm vs. time show an increase 
in rm values for CFX 1 and CFX 3 after 1ns (Figure 23b and 23c)  from the beginning of the 
simulation. Trajectory analysis shows that, at the beginning of the simulation, the four 
zCFX molecules were in a linear structure (Figure 24) but, after about 1ns, where a step-
trend in the value of rm is observed, the structure changed completely; in fact, molecules 
presents a ͞sandǁich͟ configuration ;see Figure ϮϭͿ. This structure ǁas conserǀed until 
the end of the simulation (Figure 20c). It is interesting to note that after about 1 ns zCFX3 
has a high fluctuation in the values of rm (from 2.25 Å to 4.00 Å), due to the fluctuation of 
the sandwich structure; moreover, zCFX3 presents the highest value of �௠̅̅̅  (3.22 Å). 
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Figure 23 rm vs. time for: a) zCFX adsorbed on the inner surface, b) zCFX1 and c) zCFX3 for the adsorption of 
4CFX molecules on the inner surface, d) zCFX7 and e) zCFX8 for the adsorption of 8CFX molecules on the 
inner surface, f) nCFX1 g) nCFX2 for the adsorption of 8CFX molecules on the inner surface. 
 
Figure 24 Snapshot of the initial configuration of four zCFX molecules (t = 0 ns). For clarity, the structure of 
SW-CNT has not been reported. 
 pag. 151 
 
Chapter 4 
The �௠̅̅̅ values for the adsorption of eight molecules of zCFX and nCFX on outer surface are 
similar, ranging between 2.807 ± 0.01 Å and 3.063 ± 0.01 Å for zCFX and between 2.930 ± 
0.01 Å and 3.068 ± 0.02 Å for nCFX; the graph rm vs. time shows an approximately constant 
value. For zCFX molecules absorbed to the inner surface, �௠̅̅̅ values are between 2.93 ± 
0.01 Å and 3.16 ± 0.01 Å, while for nCFX molecules they are between 2.81 ± 0.01 Å and 
3.17 ± 0.01 Å. Moreover, the graph rm vs. time does not show a constant value. For zCFX, 
the molecules exhibiting nonlinear trends are CFX7 and CFX8 (Figure 23d and 23e). In 
addition, the trajectory analysis shows that, at the beginning of the simulation, the eight 
zCFX molecules were in a linear structure and CFX7 and CFX8 present cyclic conformations 
(Figure 25a, CFX7 and CFX8 highlighted in red), but after about 1.2 ns the structure 
changed completely, so CFX ŵolecules present a ͞sandǁich͟ configuration (see Figure 
22c). In the case of nCFX, the molecules that do not have a constant value are CFX1 and 
CFX2 (see Figure 23f and 23g) due to the change occurred in their conformation 
(highlighted in red in Figure 25b and 25c). Also in this case zCFX7 and nCFX8 present a high 
fluctuation in the values of rm (from 2.11 Å to 3.56 Å for zCFX7 and from 2.08 Å to 4.61 Å 
for nCFX2), due to the fluctuation of the complex structure that the eight molecules form. 
 
 
Figure 25 Snapshot from the eight zCFX molecules at the beginning of the simulation (a); snapshot taken 
from the eight nCFX molecules after 3ns of beginning of  the simulation (b), and at the end of simulation (c). 
For clarity, the structure of the SW-CNT has not been reported. 
 
Finally, radial distribution function curves (RDF), calculated between any pair of atoms of 
SW-CNT and CFX using Gromacs g_rdf tool, are reported in Figure 26.  
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Figure 26 RDFs Calculated between the SW-CNT surface and the centre of mass (COM) of CFX  in vacuum 
for a) 1, b) 2, c) 4, d) 8 CFX molecules. Black: zCFX adsorbed on the outer surface of SW-CNT, blue: zCFX 
adsorbed on the inner surface of SW-CNT, red: nCFX adsorbed on the outer of SW-CNT, purple: nCFX 
adsorbed on the inner surface of SW-CNT. 
 
The curves show a notable peak, which indicates the most probable distance between CFX 
and the SW-CNT surface. The peak positions for such curves occur in the range from 4.3 Å  
to 9.4 Å, implying the position of the first adsorption layer for CFX. Furthermore, the 
presence of a second peak has been observed, and the peak positions occur in the range 
from 22.1 Å to 22.3 Å for the adsorption on the outer surface and from 14.9 Å to 15.3 Å 
for the adsorption on the inner surface, due to the CNT carbon atoms on the opposite side 
of the surface. The RDF curves for the adsorption of one CFX molecule on the outer surface 
show a similar behaviour for both nCFX and zCFX, although the RDF curves for zCFX, 
adsorbed to the inner surface, are wider that nCFX, indicating that the adsorption of zCFX 
is less close around SW-CNT due to the cyclic conformation assumed by it (Figure 18c). 
The RDF curve for the adsorption of two zCFX molecules to the outer surface shows a 
decrease in intensity in the first peak in respect to nCFX, indicating that the adsorption is 
less compact around the outer surface of SW-CNT and could be related to the 
conformation assumed by the two molecules of zCFX (see Figure 19a). For four CFX 
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molecules, the RDF curve shows that the adsorption of zCFX is less compact around the 
inner surface of SW-CNT, which can be explained by observing that the CFX molecules 
present a ͞sandǁich͟ configuration ;figure ϮϬc and Ϯϭ). Finally, the RDF curves for the 
adsorption of eight CFX molecules show that the most compact adsorption is observed 
when CFXs are adsorbed to the outer surface. A widening of the RDF curve has been 
observed for the adsorption on the inner surface, due to the formation of sandwich 
configurations (see Figures 22c and 22d). In conclusion, CFX molecules remain adsorbed 
to the SW-CNT surface thanks to - interactions between CFX and SW-CNT aromatic 
rings. 
 
4.3.7.2 Interaction energy in vacuum 
The calculated interaction energy (Eint) and relaxed interaction energy (Eint-relax) for CFX 
with SW-CNT is reported in Table 11. 
 
Table 11 Eint and Eint-relax (kcal mol-1) in vacuum between SW-CNT and 1, 2, 4 and 8 molecules of n and zCFX. 
xCFX out (x = n or z): CFXs adsorbed on the outer SW-CNT surface, xCFX ins (x = n or z): CFXs adsorbed on 
the inner surface. 
 
1 CFX 2 CFX         4 CFX 8 CFX 
Conf. Eint Eint-realx Eint Eint-realx Eint Eint-realx Eint Eint-realx 
zCFX out -26.8 -25.7 -17.9 -17.4 -22.3 -20.3 -21.7 -20.2 
nCFX out -24.9 -23.8 -26.2 -25.1 -26.0 -25.2 -25.1 -23.9 
zCFX ins -34.9 -33.3 -39.5 -38.3 -29.4 -27.8 -31.9 -30.7 
nCFX ins -43.2 -41.3 -42.3 -39.3 -40.1 -38.1 -34.3 -33.0 
 
All the calculated Eint and Eint-relax are negative and presents the same trend, with the 
exception of an increase in energy values (from 0.5 to 3.0 kcal mol-1) observed passing 
from Eint to Eint-realx, indicating that the energy cost to bring CFX and SW-CNT from their 
minimum geometry configuration to those that take on the CFX-SW-CNT complex is 
minimal . In general, as shown by the data reported in Table 11, CFX molecules interact 
more strongly with the inner surface than with the outer surface. nCFX molecules interact 
more strongly with the SW-CNT surface compared to zCFX molecules, except when only 
one zCFX molecule is adsorbed to the outer surface. The increase in the number of CFXs 
molecules leads to a decrease in the Eint, a behavior that can be explained by observing in 
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Figure 2, 3, 4 and 5; when more CFXs molecules are adsorbed, they interact with each 
other (H-bond) leading to a decrease in the interaction between the quinolone rings of 
CFX and the aromatic rings of SW-CNT. However, this trend presents some anomalies. 
Indeed, a decrease in Ein value is observed for zCFX, going from two to four molecules 
adsorbed to the outer surface. Such behavior could be related to the conformation 
assumed by the two molecules of zCFX (Figure 19a). The same behavior is observed for 
the adsorption of 4 and 8 zCFX molecules to the internal surface of SW-CNT, when a 
decrease in interaction energy occurs. Another anomaly is reported for the absorption of 
zCFX on the inner surface, given that it passes from one to two molecules. An decrease in 
Eint values can be observed, and it could be explained by the fact that one zCFX molecule 
assumes a cyclic configuration (Figure 18c), while when two zCFX molecules are present 
they remain planar (Figure 19c). As reported in other works, the interaction between 
molecules and CNT surface depends on Lennard-Jones (LJ) potential, without considering 
the electrostatic potential and solvent effects[101,121]. The LJ potential was calculated on 
the minimum geometry configuration using Gromacs g_energy tool, and the values were 
very similar to those calculated for the Eint (see Table A6 in appendix B). 
 
4.3.7.3 MD simulation in water  
The calculations began by placing the CFXs molecules close to the surface of SW-CNT. The 
trajectory analysis showed that the CFX molecules remain adsorbed to the SW-CNT 
surface in direct contact with the SW-CNT walls, without any H2O molecule mediating the 
adsorption process. zCFX and nCFX are parallel to the outer surface of SW-CNT. Contrary 
to vacuum simulations, zCFX, adsorbed to the inner surface, has now a linear 
conformation and is parallel to the SW-CNT surface. The change in its behaviour is due to 
the formation of H-bonds between zCFX and water, which prevents the formation of the 
inter and intramolecular H-bond. The minimum geometry configuration for one zCFX 
adsorbed to the inner surface along with other important configurations are reported in 
Figure 27.  
In addition, an analysis of H-bonds was performed to understand how the solvent 
influences the interactions between CFX-CFX. The average number of H-bonds between 
CFX and CFX and between CFX and water is shown in the Table 12. 
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Figure 27 The most important minimum geometry configuration. a) zCFX, adsorbed on the inner surface;  b) 
nCFX adsorbed on the outer surface c) four nCFX molecules adsorbed on the outer surface, d) five of eight 
nCFX molecules adsorbed on the inner surface in water. 
 
Table 12 Average number of H-bonds between CFX molecules and between CFX and water for the 
adsorption of 1, 2, 4 and 8 CFX molecules. Where n° of ads CFX represents the absorption of 1, 2, 4, 8 CFX 
molecules, CFX-CFX is the average of H-bond between CFX molecules and w-CFX is the average of H-bond 
between water and CFX molecules.  
 zCFX out nCFX out zCFX ins nCFX ins 
n° ads CFX CFX-CFX w-CFX CFX-CFX w-CFX CFX-CFX w-CFX CFX-CFX w-CFX 
1 - 9.3 - 5.2 - 8.5 - 4.8 
2 0.2 18.1 0.0 10.4 0.2 16.4 0.1 8.8 
4 0.0 37.1 3.0 20.4 0.1 33.4 0.2 17.9 
8 0.5 72.5 0.3 40.0 4.2 54.2 0.1 30.4 
 
The data in Table 12 show that the number of H-bonds between CFX and CFX is close to 
zero.  For the adsorption of two CFXs, where all molecules are parallel to the SW-CNT 
surface, the molecules seems to interact less with each other compared to the behaviour 
observed in the vacuum, being the number of H-bonds between CFX-CFX close to zero. It 
is also interesting to note that 2 nCFX molecules interacted at the beginning of the 
simulation, but after 0.79 ns they tended to separate and not interact until the end of the 
simulation, when they were adsorbed to the outer surface (Figure 27b). 
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However, for the adsorption of four nCFX molecules on the outer surface, the number of 
H-bonds is 3.0 between CFX molecules, due to the linear conformation of the molecules 
(see Figure 27c). Even for 8 zCFX molecules absorbed to the inner surface the number of 
H-bonds is greater than zero (4.2), due to the ͞sandǁich͟ structure oďserǀed for the 8 
molecules (Figure 27d). The H-bond values calculated between CFX and water are 
completely different. In all cases, the number of H-bonds increases with the increase of 
the number of molecules, and the number of H-bonds in zCFX seems to be about double 
the number calculated for nCFX. The average number of H-bonds for adsorption of CFXs 
to the outer surface is slightly higher than the number calculated for adsorption to the 
inner surface. The data confirm that the molecules seem to interact less with each other 
and more with the solvent. 
The rm vs. time curves calculated between the surfaces of CFX and SW-CNT were used to 
clarify how the solvent affects CFX absorption. Also in this case, the analysis of rm vs. time 
curves indicates that CFX stayed in contact with the surface along the entire trajectory in 
all cases. The �௠̅̅̅, calculated from the graph of rm vs time are between 2.76 ± 0.02 Å and 
3.07 ± 0.02 Å, indicating that these are the minimum distances between CFX and SW-CNT. 
The values are very similar to those calculated for the absorption of CFX in vacuum (from 
2.64 ± 0.01 Å to 3.22 ± 0.01 Å), indicating that the absorption distance is not affected by 
the presence of the solvent. The values of �௠̅̅̅ for one zCFX and one nCFX are similar for 
the adsorption to both the outer (3.03 ± 0.02 Å and 3.05 ± 0.02 Å respectively) and the 
inner surface (2.80 ± 0.02 Å and 2.82 ± 0.02 Å respectively). As in the vacuum simulation, 
the molecules seem to be closer when adsorbed to the inner surface. The rm vs. time 
curves present constant values. The same behaviours are observed in �௠̅̅̅ trends and in 
graph rm vs. time for the absorption of 2, 4 and 8 CFX molecules; however, in the case of 
adsorption to the inner surface of eight z and nCFX molecules, they do not present a 
constant value. For zCFX, a slight decrease in the curves are observed around 2 ns (see 
Figure 28a-c). 
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Figure 28 Curve of rm vs time for: a) zCFX 2 b) zCFX 4 c) zCFX 7 for the adsorption of eight zCFX molecules on 
the inner surface in water; d) nCFX 2 e) nCFX 3 f) nCFX 4 g) nCFX5 for the adsorption of eight nCFX molecules 
on the inner surface in water. 
 pag. 158 
 
Chapter 4 
Trajectory analysis shows that four out of eight adsorbed zCFX molecules (highlighted in 
red in Figure 29a) presented a ͞sandǁich͟ configuration at the beginning of the 
simulation. After about 2ns, where a step-trend in the value of rm is observed, the 
structure taken by the molecules changed: the molecules were divided in two groups 
(highlighted in red and blue in the Figure 29b) and did not interact with each other.  
 
 
Figure 29 Snapshot from the eight zCFX molecules at the beginning of the simulation (a); and after 2ns of 
beginning of the simulation (b). 8 nCFX molecules at the beginning of the simulation (c); and at the end of 
the simulation (d). For clarity, the structure of the SW-CNT has not been reported.  
 
A similar behaviour is observed for the adsorption of 8 nCFX molecules to the inner 
surface; the non-constant value observed in rm vs. time graphs is due to the change in the 
structure taken by the eight molecules during the simulation (see Figure 29c and 29d). At 
the beginning of the simulation, all molecules seemed to interact with each other, but 
after 1 ns a progressive removal of three molecules took place (nCFX2 nCFX3 nCFX4), and 
at the end of the simulation the three molecules did not interact with the remaining 
molecules (see Figure 29d). Moreover, a change in the position of nCFX5 (highlighted in 
blue in figure 29c and 29d) from parallel to orthogonal with respect to the sandwich 
structure was observed. 
Finally, the RDF curves calculated between every pair of atoms of SW-CNT and CFX are 
reported in Figure 30. The curves show shapes similar to those obtained in vacuum. The 
notable peak positions occur in the range from 4.5 Å to 5.1 Å; however, the range of these 
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values is smaller than the calculated value, because the CFX molecules interact less with 
each other and more with the solvent, having a more compact adsorption around SW-
CNT. However, the RDF curves for eight nCFX molecules adsorbed to the inner surface are 
wider than those reported for the other cases, due to the fact that some CFX molecules 
present a ͞sandǁich͟ configuration ;Figure Ϯϴe), leading to a less compact adsorption 
around SW-CNT. In conclusion, the introduction of the solvent led to substantial changes 
in the morphology of the CFX-SW-CNT system, because the CFX molecules are dispersed 
on the surface of SW-CNT and interact less with each other. 
 
 
Figure 30 RDFs Calculated between SW-CNT surface and centre of mass (COM) of CFX  in water for a) 1, b) 
2, c) 4, d) 8 CFX molecules. Black: zCFX adsorbed on the outer surface of SW-CNT, blue: zCFX adsorbed on 
the inner surface of SW-CNT, red:  nCFX adsorbed on the outer surface of SW-CNT, purple: nCFX adsorbed 
on the inner surface of SW-CNT. 
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4.3.7.4 Interaction energy in water 
As observed for the simulations in vacuum, the interaction between CFX molecules and 
SW-CNT surface depended on LJ potential. In Table 13 the values calculated between CFX 
and SW-CNT on the minimum geometry configuration are reported. 
 
Table 13 LJint (kcal mol-1) in water between SW-CNT and 1, 2, 4 and 8 molecules of n and zCFX. xCFX out (x = 
n or z): CFXs adsorbed on the outer SW-CNT surface. xCFX ins (x = n or z): CFXs adsorbed on the inner surface. 
LJint  1 CFX 2 CFX 4 CFX 8 CFX 
zCFX out -22.7 -21.8 -23.5 -22.9 
nCFX out -25.4 -24.4 -24.5 -24.4 
zCFX ins -37.9 -35.9 -35.2 -36.2 
nCFX ins -37.8 -37.1 -36.9 -32.3 
 
nCFX present high LJint potential values in respect to zCFX in all cases except when one z 
and one nCFX molecule are adsorbed on the inner surface (in this case the LJint values are 
similar). For the adsorption of two molecules, a slight decrease in the LJint potential values 
can be observed; the strongest interaction is observed for nCFX adsorbed both to the 
outer and the inner surface. Such trend can be explained by observing that the 2 zCFX 
molecules interact with each other and could lead to a decrease in the interaction 
between the aromatic rings of zCFX and SW-CNT, while the 2 nCFX molecules are 
dispersed on the SW-CNT surface (Figure 27b). For what concerns the adsorption of four 
CFX molecules, there is a decrease of the LJint values for the adsorption on the outer 
surface and an increase for the adsorption to the inner surface. Finally, for the adsorption 
of eight CFX molecules, a little increase in LJint values has been observed in the case of 
adsorption to the outer surface, while for adsorption to the inner surface, there is an 
increase for nCFX while an decrease for zCFX. 
 
4.3.7.5 Free energy calculation 
Figure 31 describes the PMF profile along the reaction coordinate for the adsorption to 
the outer (Figure 31a) and inner (figure 31b) of SW-CNT surface (the PMF curves have 
been truncated at the minimum point). For the adsorption of zCFX to the outer surface 
the energy minimum is located at -9.5 kcal mol-1 at the distance of 13.02 Å from the SW-
CNT center of mass (COM), while for nCFX the minimum is located at -3.6 kcal mol-1 at the 
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distance 12.61 Å. The values are in good agreement with the  �௠̅̅̅ values calculated above. 
In both cases, an immediate increase in the free energy was observed due to the decrease 
in the interaction between CFX and SW-CNT. Furthermore, a change in the slope of the 
free energy trend was observed at 14.21 Å for zCFX and at 14.69 Å for nCFX. When zCFX 
and SW-CNT reach the distance of 16.2 Å from SW-CNT COM, a plateau in the free energy 
is observed; for nCFX the plateau is observed at a distance of 18.5 Å; indeed, nCFX begins 
to interact with the SW-CNT wall at a greater distance compared to zCFX.  
The PMF curves for the adsorption to the inner surface (figure 31b) show that the 
minimum energy is located at -12.5 kcal mol-1 for zCFX and at -20.9 kcal mol-1 for nCFX; 
moreover, both curves have sigmoid shapes. The first plateau, related to the interaction 
with the inner wall of CNT, starts at 25.92 Å for zCFX and 19.78 Å for nCFX, while the 
second plateau, due to the end of the interaction with the inner wall, starts at 37.88 Å for 
both zCFX and nCFX. The adsorption free energy (Gads) between CFX and SW-CNT 
calculated as difference between the highest (where the values of the PMF converge to a 
stable value at large COM distance) and lowest values of the PMF curves (Figure 31) are 
reported in table 14. 
 
 
Figure 31 Potential of mean force curve (truncated at minimum point) for: a) adsorption to the outer surface 
for zCFX (black curve) and nCFX (red curve); b) adsorption to the inner surface for zCFX (blue curve) and 
nCFX (purple curve). The reaction coordinate as a function on the centre of mass (COM) distance of CFX and 
SW-CNT. 
 
The results show that the Gads is negative in all cases, indicating that the adsorption 
process is thermodynamically favoured. For the adsorption to the outer surface, zCFX 
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shows a lowerGads value compared to nCFX, while an opposite behavior is observed for 
the adsorption to the inner surface. 
 
Table 14 Gads (kcal mol-1) for zCFX and nCFX for the adsorption to the outer and inner surface of SW-CNT. 
 
Gads  
zCFX out -9.5 
nCFX out -3.6 
zCFX ins -12.2 
nCFX ins -20.9 
 
Gads for adsorption of CFX on CNT can be found in literature; Li et al.[91] studied the 
adsorption of CFX on SW-CNT and calculated G = -8.7 Kcal mol-1, while Ncibi et al.[93] 
optimized the removal of CFX from aqueous solutions using CNT. The adsorption 
experiments were conducted at pH from 3 to 11 and reported a G of -9.2 Kcal mol-1. 
Moreover, in both the experiments no chemical systems (such as surfactants) were used 
to prevent the agglomeration of nanotubes,[122] because they could affect the CFX 
adsorption process. The data reported in the literature are in good agreement with those 
calculated by us for the adsorption of zCFX which, by the way, is the most abundant form 
in water. Indeed, the mole fractions of the zCFX and nCFX species reach the maximum 
values at the isoelectric point (pH 7), and zCFX is the most stable species,[26,27] as it seems 
to interact more strongly with water. In order to better understand this phenomena, a 
calculation of the hydration energy (Ehyd) for the single antibiotic (both forms of CFX in 
water without the CNT) was carried out. Ehyd is -104.9 kcal mol-1 for zCFX and -36.2 kcal 
mol-1 for nCFX, indicating that zCFX interacts more strongly with water compared to nCFX. 
The results could also explain the change in the behavior for the adsorption on the inner 
and outer surfaces. The spatial distribution function (SDF, Figure 32) calculated between 
water and CFX showed that water distributions around zCFX and nCFX are similar when 
the molecules are absorbed to the outer surface, although there seems to be a slightly 
greater density around zCFX (Figure 32a and 32c). Instead, in the case of the absorption 
to the inner surface a drastic change in water density around the CFX molecules is 
observed (Figure 32b and 32d); an increase in water density was observed for zCFX, while 
for nCFX density decreases. This behavior may be related to the fact that the nanotubes 
in which water molecules are placed constitute a hydrophobic environment, so the 
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molecules will tend to interact more with zCFX, which has a more negative Ehyd in respect 
to nCFX, leading to a possible decrease in the interaction between zCFX and the SW-CNT 
wall. Moreover, in a realistic situation; the molecules could experience difficulties in 
adsorption to the inert surface of CNT, due to the aggregation that such systems have 
when used in water.[90] 
 
 
Figure 32 Spatial distribution function (SDF), calculated between water and a) zCFX adsorbed to the outer 
surface, b) zCFX adsorbed to the inner surface, c) nCFX adsorbed to the outer surface and d) nCFX adsorbed 
to the inner surface. Isovalue 14. 
 
4.3.8 Conclusions 
MD simulations were carried out to investigate the adsorption of both neutral and 
zwitterionic form of CFX on SW-CNT in vacuum and water. The trajectory analysis and the 
calculation of rm vs. time curve show that CFX remains adsorbed to the surface of SW-CNT 
both in vacuum and in water thanks to - interactions. The calculated Eint and Eint-relax in 
vacuum are negative, and in general CFX molecules interact more strongly with the inner 
surface than with the outer surface; the calculation of the LJint potential gave values 
similar to those obtained for Eint. However, a change in SW-CNT-CFX morphology was 
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observed after the solvent was added; CFX molecules tend to form less H-bonds between 
themselves than with water, leading to a dispersion of the molecules on the SW-CNT 
surface. Finally, using COM pulling and umbrella sampling technique, we calculated Gads 
for zCFX and nCFX for the adsorption to the outer and inner surface of SW-CNT, finding 
out that adsorption is thermodynamically favoured and CFX molecules seem to interact 
more strongly with the inner surface than with the outer surface of SW-CNT. zCFX has a 
lower Gads than nCFX on the outer surface. An opposite behaviour was observed for 
adsorption to the inner surface. The calculated Gads for the adsorption of zCFX on the 
outer surface appears to be in good agreement with the data reported in the literature. 
Indeed, in a real situation the CFX molecules could experience difficulties in adsorption to 
the inert surface of CNT, due to the aggregation that such systems have when they are 
used in water solution. 
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In this thesis, computational methods (the quantum mechanics method and molecular 
dynamics simulations in particular) were used to study the reactivity of two classes of 
compounds and their interaction with carbon-based materials; the two classes are 
platinum-based antitumor drugs (chapter 3) and fluoroquinolones antimicrobials 
compounds (chapter 4).  
The first part of chapter 3 focuses on the hydrolysis reaction of cis-[Pt(PMe3)2(etga)], cis-
[Pt(PMe3)2(3-Hfl)]+ containing ethyl gallate (etga) and 3-Hydroxyflavone(3-HFl), designed 
to try to limit the side effects of cisplatin, studied by means of density functional theory 
(DFT) calculations. The calculations showed that: 
 The rate determining step is the first step of the hydrolysis reaction and that the 
formation of the hydroxo species is observed in both complexes. 
 
 The activation energies are significantly lower than those calculated for cisplatin. 
 
 High hydrolysis reaction rate that might make such complexes subject to fast 
degradation, causing potentially poor pharmacological activity. 
 
In the second part of chapter 3 the complete mechanism of action (hydrolysis reaction, 
reaction with DNA bases and reaction with cysteine) of phenanthriplatin, a 
monofunctional platinum complex, was studied by means of DFT calculations. Moreover, 
a comparison between phenanthriplatin and cisplatin was made with the aim of 
understanding why phenanthriplatin presents a higher cytotoxicity activity compared to 
cisplatin. The calculations showed that: 
 The hydrolysis reaction shoǁed that phenanthriplatin’s actiǀation energy ďarrier 
is close to the energy barriers obtained for the first hydrolysis of cisplatin. 
 
 Phenanthriplatin reacts with both guanine and adenine bases; with the latter, the 
formation of two products, N7 and N1, occurs, and the reaction rate follows the 
order N7-guanine > N7-adenine > N1-adenine. 
 pag. 172 
 
Final Remarks 
 
 
  The reaction with guanine is kinetically favoured in phenanthriplatin in respect to 
cisplatin.  
 
 The reaction between phenanthriplatin and cysteine showed that such reaction is 
disadvantageous, both kinetically and thermodynamically, in phenanthriplatin in 
respect to cisplatin.  
 
 This can explain why phenanthriplatin is more cytotoxic than cisplatin. 
 
In the last part of chapter 3 the non-covalent interaction between graphene prototypes, 
new candidates as drugs delivery systems, and cisplatin were investigated through MP2 
and DFT calculation: 
 Different orientations of cisplatin in respect to the circumcoronene (one parallel 
and three perpendicular) were taken into account. 
 
 Different DFT functional were tested and compared with the interaction energy 
obtained from MP2 calculations.  
 
 The best DFT functional is M62X-D3, which was used to obtain the energy profiles.  
 
 The parallel orientation presents the highest value of interaction energy in 
vacuum.  
 
 The density of states (DOS) analysis showed that when cisplatin is adsorbed with 
perpendicular orientations a destabilization of the circumcoronene electronic 
structure is observed.  
 
 Finally, the introduction of the solvent does not drastically change the interaction 
energy profiles between cisplatin and circumcoronene.  
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 Favourable adsorption of cisplatin on graphene can be predicted. 
 
As regards the fluoroquinolones (FQs) antimicrobials compounds, in the first part of 
chapter 4 the relative stability and photochemical behaviour of the different protonation 
states of CFX in gas phase and in water was studied by means of molecular dynamics 
simulations and DFT calculations. The calculations showed that: 
 The predominance of the zwitterionic form in water in respect to the neutral form, 
thanks to the introduction of a discrete-continuum approach. 
  
  The result was further confirmed through the calculated absorption UV-Vis 
spectra. 
 
  Finally, the protonation sequence was confirmed through the comparison with 
the crystalline structures found in the literature, through the calculation of the 
relative stability for such species and the calculated absorption UV-Vis spectra. 
 
In the last part of chapter 4 the adsorption of both neutral and zwitterionic forms of CFX 
to the inner and outer surface of carbon nano-tubes (CNTs) in vacuum and in water was 
studied through molecular dynamics simulations. The simulation results showed that: 
 CFX remains adsorbed to the surface of CNT both in vacuum and in water thanks 
to - interactions. 
 
 Change in CNT-CFX morphology was observed after the solvent was added; CFX 
molecules tend to form fewer hydrogen bonds between themselves and more 
with water, leading to a dispersion of the molecules on the CNT surface. 
 
 The adsorption Gibbs free energy (Gads) were carried out for the adsorbed zCFX 
and nCFX using the umbrella sampling technique, finding out that adsorption is 
thermodynamically favoured.  
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 CFX molecules seem to interact more strongly with the inner surface than with 
the outer surface of CNT. 
 
  Gads values are in good agreement with the data reported in the literature. 
 
In conclusion, the use of computational chemistry can help to rationalize the experimental 
data and to investigate various mechanicistic hypothesis. 
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3.2 Hydrolysis Reaction in Triphenylphosphane Pt(II) Complexes 
Containing Biologically Active Natural Polyphenols: DFT Study. 
 
Table A1 Relevant bond distances (Å) and angles (°) in first step of the hydrolysis in cis-[Pt(PMe3)2(etga)]. 
O(L) is the leaving oxygen of the ligand . P(c) is phosphorus in cis to leaving group. P(t) is phosphorus in trans 
to leaving group. O(ent.) is entering water oxygen. 
Bond Distances 
O1 path R1 RA1 TS1 PA1 O2 path R1 RA1 TS1 PA1 
Pt-O 2.033 2.034 2.029 2.064 Pt-O(L) 2.033 2.041 2.458 3.122 
Pt-O(L) 2.041 2.055 2.459 3.230 Pt-O 2.041 2.048 2.055 2.068 
Pt-P(t) 2.256 2.251 2.213 2.261 Pt-P(t) 2.256 2.253 2.214 2.264 
Pt-P(c) 2.256 2.268 2.272 2.259 Pt-P(c) 2.256 2.265 2.258 2.257 
Pt-O(ent.) - 3.714 2.332 2.056 Pt-O(ent.) - 3.859 2.335 2.053 
Angles 
O1 path R1 RA1 TS1 PA1 O2 path R1 RA1 TS1 PA1 
O(ent.)-Pt-P - 137 164 171 O(ent.)-Pt-P - 140 162 173 
O(L)-Pt-P(t) 167 170 129 119 O(L)-Pt-P(t) 173 172 130 113 
O(L)-Pt-P(c) 90 90 97 111 O(L)-Pt-P(c) 83 89 98 108 
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Table A2 Relevant bond distances (Å) and angles (°) in second step of the hydrolysis in cis-Pt(PMe3)2(etga). O(L) is the oxygen of the leaving ligand. P(c) is phosphorus in cis 
to leaving group. P(t) is phosphorus in trans to leaving group. Ow is the coordinated water oxygen and O(ent.) is entering water oxygen. 
Bond Distances 
O1 path R2 RA2 TS2 PA2 P2 O2 path R2 RA2 TS2 PA2 P2 
Pt-O(L) 2.064 2.076 2.452 3.492 - Pt-O(L) 2.068 2.079 2.468 3.635 - 
Pt-Ow 2.056 2.058 2.034 2.043 2.042 Pt-Ow 2.053 2.057 2.032 2.048 2.042 
Pt-P(t) 2.259 2.256 2.213 2.262 2.255 Pt-P(t) 2.257 2.256 2.213 2.264 2.257 
Pt-P(c) 2.261 2.270 2.278 2.264 2.257 Pt-P(c) 2.264 2.267 2.282 2.264 2.255 
Pt-O(ent.) - 3.973 2.406 2.072 2.042 Pt-O(ent.) - 3.829 2.412 2.071 2.042 
Angles 
O1 path R2 RA2 TS2 PA2 P2 O2 path R2 RA2 TS2 PA2 P2 
O(ent.)-Pt-P - 140 149 173 171 O(ent.)-Pt-P - 140 147 172 171 
O(L)-Pt-P(t) 166 164 138 124 - O(L)-Pt-P(t) 164 164 140 128 - 
O(L)-Pt-P(c) 86 84 96 112 - O(L)-Pt-P(c) 92 93 95 111 - 
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Table A3 Energy values (kcal mol-1) associated to the hydrolysis reaction pathway for cis-[Pt(PMe3)2(etga)], 
cis-[Pt(PMe3)2(3-Hfl)], cis-[Pt(Cl)2(PMe3)2] and cisplatin, in PCM water. 
First step Rϭ → RAϭ RA1 → TSϭ TSϭ → PAϭ PAϭ → Pϭ 
cis-Pt(PMe3)2(etga) O1 –1.9 22.8 10.7 – 
cis-Pt(PMe3)2(etga) O2 –3.0 18.7 7.1 – 
cis-[Pt(PMe3)2(3-Hfl)]+ O1 1.6 14.4 7.4 – 
cis-[Pt(PMe3)2(3-Hfl)]+ O2 –0.9 15.7 9.1 – 
cis-Pt(Cl)2(PMe3)2 0.2 11.3 1.8 7.2 
Cisplatin –1.8 21.4 2.4 12.1 
Second step RϮ → RAϮ RAϮ→ TSϮ TSϮ → PAϮ PAϮ → PϮ 
cis-Pt(PMe3)2(etga) O1 –2.5 15.1 0.7 14.1 
cis-Pt(PMe3)2(etga) O2 –3.1 14.7 0.4 14 
cis-[Pt(PMe3)2(3-Hfl)]+ O1 0.7 11.9 –1.1 2.3 
cis-[Pt(PMe3)2(3-Hfl)]+ O2 0.7 9.5 –2.9 0.6 
cis-Pt(Cl)2(PMe3)2 –4.5 12.9 3.0 16.2 
cisplatin –6.5 21.1 4.8 17.5 
 
 
 
Figure A1 DFT calculated structures of: a) first hydrolysis of cisplatin; b) second hydrolysis. Relevant bond 
distances and angles are reported in Table A4. 
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Table A4 Relevant bond distances (Å) and angles (°) in cisplatin. N(c) is nitrogen in cis to leaving group. N(t) is nitrogen in trans to leaving group. Ow is the coordinated water 
oxygen and O(ent.) is the entering water oxygen. 
Bond Distances 
First  
hydrolysis 
R1 RA1  TS1  PA1 P1 Second  
hydrolysis 
R2 RA2  TS2  PA2 P2 
Pt-Cl 2.308 2.314 2.316 2.314 2.284 Pt-Ow 2.101 2.075 2.083 2.055 2.102 
Pt-Cl(l) 2.308 2.322 2.747 3.901 - Pt-Cl(l) 2.284 2.299 2.722 3.770 - 
Pt-N(t) 2.089 2.078 2.063 2.047 2.030 Pt-N(t) 2.103 2.091 2.067 2.057 2.033 
Pt-N(c) 2.089 2.087 2.073 2.077 2.103 Pt-N(c) 2.030 2.041 2.029 2.056 2.033 
Pt-O(ent.) - 3.695 2.389 2.049 2.101 Pt-O(ent.) - 3.592 2.327 2.055 2.103 
Angles 
 
R1 RA1 TS1 PA1 P1 
 
R2 RA2 TS2 PA2 P2 
O(ent.)-Pt-N - 122 151 176 176 O(ent.)-Pt-N - 113 160 177 179 
Cl(l)-Pt-N(t) 178 178 140 137 - Cl(l)-Pt-N(t) 176 176 130 131 - 
Cl(l)-Pt-N(c) 84 85 76 51 - Cl(l)-Pt-N(c) 87 87 101 131 - 
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Figure A2 DFT calculated structures of: a) the first hydrolysis of cis-Pt(PMe3)2(Cl)2; b) second hydrolysis of 
cis-Pt(PMe3)2(Cl)2. Relevant bond distances and angles are reported in Table A5. 
 
Table A5 Relevant bond distances (Å) and angles (°) in cis-[Pt(Cl)2(PMe3)2]. P(c) is phosphorus in cis to leaving 
group. P(t) is phosphorus in trans to leaving group. Ow is the coordinated water and O(ent.) is the entering 
water oxygen. 
 
 
 
 
 
 
 
 
 
Bond Distances 
First  
hydrolysis 
R1 RA1  TS1  PA1 P1 Second  
hydrolysis 
R2 RA2  TS2  PA2 P2 
Pt-Cl 2.381 2.383 2.389 2.378 2.358 Pt-Ow 2.210 2.172 2.185 2.143 2.207 
Pt-Cl(L) 2.359 2.375 2.766 3.852 - Pt-Cl(L) 2.358 2.372 2.853 3.657 - 
Pt-P(t) 2.278 2.272 2.226 2.250 2.251 Pt-P(t) 2.288 2.287 2.247 2.267 2.275 
Pt-P(c) 2.268 2.277 2.266 2.282 2.288 Pt-P(c) 2.251 2.261 2.247 2.267 2.272 
Pt-O(ent.) - 3.817 2.383 2.114 2.210 Pt-O(ent.) - 3.863 2.265 2.151 2.229 
Angles 
 
R1 RA1  TS1  PA1 P1   R2 RA2  TS2  PA2 P2 
O(ent.)-Pt-P - 124 155 170 168 O(ent.)-Pt-P - 113 168 177 174 
Cl(L)-Pt-P(t) 170 170 132 132 - Cl(L)-Pt-P(t) 176 176 122 134 - 
Cl(L)-Pt-P(c) 88 89 82 70 - Cl(L)-Pt-P(c) 84 84 105 127 - 
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Table A6 Relevant bond distances (Å) and angles (°) in first step of the hydrolysis in cis-[Pt(PMe3)2(3-Hfl)]. 
O(L) is the oxygen of the leaving ligand. P(c) is phosphorus in cis to leaving group. P(t) is phosphorus in trans 
to leaving group. O(ent.) is the entering water oxygen. 
 
 
 
 
 
 
 
 
 
 
 
 
Bond Distances 
O1 path R1 RA1 TS1 PA1 O2 path R1 RA1 TS1 PA1 
Pt-O 2.059 2.069 2.064 2.070 Pt-O(L) 2.059 2.077 2.499 3.149 
Pt-O(L) 2.079 2.090 2.468 3.166 Pt-O 2.079 2.087 2.090 2.112 
Pt-P(t) 2.258 2.255 2.221 2.250 Pt-P(t) 2.265 2.261 2.227 2.278 
Pt-P(c) 2.265 2.271 2.268 2.277 Pt-P(c) 2.258 2.266 2.260 2.252 
Pt-O(ent.) - 3.570 2.422 2.151 Pt-O(ent.) - 3.743 2.342 2.059 
Angles 
O1 path R1 RA1 TS1 PA1 O2 path R1 RA1 TS1 PA1 
O(ent.)-Pt-P - 121 1556 175 O(ent.)-Pt-P - 136 161 176 
O(L)-Pt-P(t) 171 168 136 125 O(L)-Pt-P(t) 171 170 135 122 
O(L)-Pt-P(c) 91 92 100 113 O(L)-Pt-P(c) 90 93 102 113 
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Table A7 Relevant bond distances (Å) and angles (°) in second step of the hydrolysis in cis-[Pt(PMe3)2(3-Hfl)]. O(L) is the oxygen of the leaving ligand. P(c) is phosphorus in 
cis to leaving group. P(t) is phosphorus in trans to leaving group. Ow is the coordinated water oxygen and O(ent.) is the entering water oxygen. 
Bond Distances 
O1 path R2 RA2 TS2 PA2 P2 O2 path R2 RA2 TS2 PA2 P2 
Pt-O(L) 2.070 2.094 2.540 3.812 - Pt-O(L) 2.112 2.135 2.254 3.863 - 
Pt-Ow 2.151 2.159 2.115 2.134 2.182 Pt-Ow 2.059 2.066 2.052 2.050 2.029 
Pt-P(t) 2.277 2.271 2.232 2.283 2.287 Pt-P(t) 2.252 2.249 2.223 2.251 2.240 
Pt-P(c) 2.250 2.253 2.253 2.250 2.240 Pt-P(c) 2.278 2.283 2.278 2.281 2.287 
Pt-O(ent.) - 3.354 2.349 2.049 2.029 Pt-O(ent.) - 3.565 2.522 2.149 2.182 
Angles  
O1 path R2 RA2 TS2 PA2 P2 O2 path R2 RA2 TS2 PA2 P2 
O(ent.)-Pt-P - 123 152 172 168 O(ent.)-Pt-P - 126 147 167 165 
O(L)-Pt-P(t) 165 165 139 132 - O(L)-Pt-P(t) 168 168 147 130 - 
O(L)-Pt-P(c) 93 94 87 126 - O(L)-Pt-P(c) 90 90 95 128 - 
 pag. 182 
 
Appendix A 
3.3 Phenanthriplatin, an Unconventional Platinum Drug: 
Disentangling the Hydrolysis and DNA-binding Mechanisms by 
Theoretical Calculations. 
 
 
Figure A3 Optimized structures for first step of the hydrolysis reaction of cisplatin. 
 
Table A8 Relevant bond distances (Å) and angles (°) for optimized isomer P of phenanthriplatin, O(ent.) is 
entering water oxygen. 
Bond Distances  
Isomer P R RA TS PA P 
Pt-Cl 2.308 2.321 2.781 3.164 - 
Pt-N1 2.105 2.095 2.093 2.102 2.122 
Pt-N2 2.062 2.067 2.061 2.063 2.053 
Pt-N3 2.145 2.134 2.114 2.081 2.062 
Pt-O(ent.) - 3.562 2.302 2.100 2.132 
Angles 
Isomer P R RA TS PA P 
Cl-Pt-N1 85.44 86.45 78.50 72.06 - 
Cl-Pt-N2 89.82 89.94 95.18 98.25 - 
Cl-Pt-N3 178.72 179.05 128.54 116.78 - 
O(ent.)-Pt-N1 - 52.14 83.12 82.21 86.26 
O(ent.)-Pt-N2 - 126.24 92.89 92.52 90.83 
O(ent.)-Pt-N3 - 118.46 162.23 177.02 178.38 
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Table A9 Relevant bond distances (Å) and angles (°) for optimized isomer M of phenanthriplatin, O(ent.) is 
entering water oxygen. 
Bond Distances 
Isomer M R RA TS PA P 
Pt-Cl 2.308 2.323 2.796 3.438 - 
Pt-N1 2.105 2.097 2.090 2.094 2.122 
Pt-N2 2.062 2.068 2.060 2.069 2.054 
Pt-N3 2.145 2.133 2.113 2.082 2.063 
Pt-O(ent.) - 3.604 2.318 2.081 2.134 
Angles 
Isomer M R RA TS PA P 
Cl-Pt-N1 85.28 86.65 76.46 62.42 - 
Cl-Pt-N2 90.05 89.55 101.11 113.73 - 
Cl-Pt-N3 179.12 178.95 128.50 122.55 - 
O(ent.)-Pt-N1 - 50.99 82.39 83.44 85.97 
O(ent.)-Pt-N2 - 125.09 93.76 92.36 91.73 
O(ent.)-Pt-N3 - 119.16 162.81 177.00 179.20 
 
Table A10 Relevant bond distances (Å) and angles (°) for the first step of the hydrolysis of cisplatin, O(ent.) 
is entering water oxygen, Cl1(l) is the leaving Cl atom (see Figure A4). 
Bond Distances  
first step R RA TS PA P 
Pt-Cl1(L) 2.326 2.340 2.791 3.885 - 
Pt-N1 2.123 2.119 2.104 2.106 2.136 
Pt-N2 2.123 2.111 2.099 2.071 2.054 
Pt-Cl2 2.326 2.330 2.329 2.330 2.299 
Pt-O(ent.) - 3.604 2.395 2.075 - 
Angles 
first step R RA TS PA P 
Cl1(L)-Pt-N1 83.36 85.11 75.21 51.69 - 
Cl1(L)-Pt-N2 177.90 177.66 137.37 136.66 - 
Cl1(L)-Pt-Cl2 94.54 94.06 102.30 126.22 - 
O(ent.)-Pt-N1 - 51.83 86.88 87.67 87.43 
O(ent.)-Pt-N2 - 120.79 154.36 176.80 176.03 
O(ent.)-Pt-Cl2 - 127.50 89.23 90.40 89.11 
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Figure A4 atom labels for the first step hydrolysis reaction of cisplatin. 
 
Table A11 Relative Gibbs free energy values (kcal mol-1), associated to the hydrolysis reaction pathway for 
isomer P and isomer M of phenanthriplatin and first (cisplatin-I) hydrolysis reaction of cisplatin, in PCM 
water. 
G R → RA RA → TS TS → PA PA → P 
Complex P 5.3 22.4 -5.8 1.0 
Complex M 5.1 23.9 -9.8 3.0 
Cisplatin 4.2 23.4 -14.4 4.9 
 
 
Figure A5 Optimized structures for first step for the reaction between N7-9-methylguanine and cisplatin. 
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Table A12 Relevant bond distances (Å) and angles (°) for optimized isomer P of phenanthriplatin, N7 is 
entering nitrogen atom in N7 position of N7-Me-Gua, O(w) is the oxygen atom of water coordinated to Pt. 
Bond Distances 
Isomer P + N7-Me-Gua R RA TS PA P 
Pt-O(w) 2.133 2.076 2.363 3.98 - 
Pt-N1 2.122 2.113 2.083 2.093 2.100 
Pt-N2 2.053 2.061 2.069 2.074 2.070 
Pt-N3 2.062 2.084 2.086 2.107 2.105 
Pt-N7 - 4.241 2.610 2.051 2.061 
Angles 
Isomer P + N7-Me-Gua R RA TS PA P 
O(w)-Pt-N1 86.26 89.52 82.11 45.54 - 
O(w)-Pt-N2 90.83 88.05 95.99 133.41 - 
O(w)-Pt-N3 178.38 175.92 156.88 126.49 - 
N7-Pt-N1 - 78.00 90.96 88.26 89.33 
N7-Pt-N2 - 99.34 88.95 90.06 89.60 
N7-Pt-N3 - 152.83 135.64 178.21 178.11 
 
Table A13 Relevant bond distances (Å) and angles (°) for optimized isomer M of phenanthriplatin, N7 is 
entering nitrogen atom in N7 position N7-Me-Gua, O(w) is the oxygen atom of water coordinated to Pt. 
Bond Distances 
Isomer M + N7-Me-Gua R RA TS PA P 
Pt-O(w) 2.134 2.073 2.373 3.945 - 
Pt-N1 2.122 2.115 2.085 2.091 2.100 
Pt-N2 2.054 2.059 2.068 2.076 2.071 
Pt-N3 2.063 2.087 2.088 2.109 2.107 
Pt-N7 - 4.217 2.597 2.049 2.058 
Angles 
Isomer M + N7-Me-Gua R RA TS PA P 
O(w)-Pt-N1 85.97 89.84 82.54 46.41 - 
O(w)-Pt-N2 91.73 87.61 96.57 133.94 - 
O(w)-Pt-N3 179.20 176.02 154.05 125.53 - 
N7-Pt-N1 - 82.75 89.92 88.73 89.75 
N7-Pt-N2 - 95.97 88.57 89.62 89.66 
N7-Pt-N3 - 152.2 136.94 178.66 178.31 
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Table A14 Relevant bond distances (Å) and angles (°) for optimized isomer P of phenanthriplatin, N7 is 
entering nitrogen atom in N7 position of N7-Me-Ade, O(w) is the oxygen atom of water coordinated to Pt. 
Bond Distances 
Isomer P + N7-Me-Ade R RA TS PA P 
Pt-O(w) 2.133 2.042 2.356 4.003 - 
Pt-N1 2.122 2.111 2.095 2.103 2.113 
Pt-N2 2.053 2.064 2.067 2.078 2.071 
Pt-N3 2.062 2.111 2.090 2.111 2.110 
Pt-N7 - 4.384 2.652 2.049 2.054 
Angles 
Isomer P + N7-Me-Ade R RA TS PA P 
O(w)-Pt-N1 86.26 86.20 81.38 44.44 - 
O(w)-Pt-N2 90.83 91.08 95.90 131.94 - 
O(w)-Pt-N3 178.38 179.41 155.77 125.48 - 
N7-Pt-N1 - 64.49 89.53 87.73 88.26 
N7-Pt-N2 - 112.54 91.47 90.36 90.45 
N7-Pt-N3 - 155.10 134.93 179.39 178.92 
 
Table A15 Relevant bond distances (Å) and angles (°) for isomer M of phenanthriplatin, N7 is entering 
nitrogen atom in N7 position of N7-Me-Ade, O(w) is the oxygen atom of water coordinated to Pt. 
Bond Distances 
Isomer M + N7-Me-Ade R RA TS PA P 
Pt-O(w) 2.134 2.042 2.360 4.110 - 
Pt-N1 2.122 2.111 2.097 2.102 2.114 
Pt-N2 2.054 2.064 2.064 2.072 2.066 
Pt-N3 2.063 2.111 2.094 2.113 2.113 
Pt-N7 - 4.367 2.632 2.044 2.050 
Angles 
Isomer M + N7-Me-Ade R RA TS PA P 
O(w)-Pt-N1 85.97 86.04 82.20 42.25 - 
O(w)-Pt-N2 91.73 91.21 95.87 136.83 - 
O(w)-Pt-N3 179.2 179.56 153.28 126.60 - 
N7-Pt-N1 - 64.41 89.74 87.715 88.68 
N7-Pt-N2 - 113.43 89.35 90.32 89.84 
N7-Pt-N3 - 154.17 136.12 178.70 178.31 
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Table A16 Relevant bond distances (Å) and angles (°) for isomer P of phenanthriplatin, N1 is entering 
nitrogen atom in N1 position of N1-Me-Ade, O(w) is the oxygen atom of water coordinated to Pt. 
Bond Distances 
Isomer P + N1-Me-Ade R RA TS PA P 
Pt-O(w) 2.133 2.036 2.361 3.634 - 
Pt-N1 2.122 2.116 2.102 2.107 2.121 
Pt-N2 2.053 2.061 2.058 2.068 2.063 
Pt-N3 2.062 2.115 2.097 2.117 2.117 
Pt-N1' - 4.416 2.097 2.064 2.067 
Angles 
Isomer P + N1-Me-Ade R RA TS PA P 
O(w)-Pt-N1 86.26 85.73 82.77 51.93 - 
O(w)-Pt-N2 90.83 91.02 94.46 125.19 - 
O(w)-Pt-N3 178.38 179.22 152.04 104.65 - 
N1'-Pt-N1 - 62.27 86.91 87.73 87.90 
N1'-Pt-N2 - 114.89 91.34 89.95 89.95 
N1'-Pt-N3 - 154.07 136.25 178.16 178.05 
      
Table A17 Relevant bond distances (Å) and angles (°) for isomer M of phenanthriplatin, N1 is entering 
nitrogen atom in N1 position of N1-Me-Ade, O(w) is the oxygen atom of water coordinated to Pt. 
Bond Distances 
Isomer M + N1-Me-Ade R RA TS PA P 
Pt-O(w) 2.134 2.035 2.351 4.001 - 
Pt-N1 2.122 2.117 2.100 2.107 2.121 
Pt-N2 2.054 2.061 2.063 2.072 2.064 
Pt-N3 2.063 2.115 2.093 2.120 2.123 
Pt-N1 - 4.394 2.662 2.065 2.064 
Angles 
Isomer M + N1-Me-Ade R RA TS PA P 
O(w)-Pt-N1 85.97 86.1 81.56 44.18 - 
O(w)-Pt-N2 91.73 90.90 95.38 135.54 - 
O(w)-Pt-N3 179.2 179.61 155.88 110.03 - 
N1-Pt-N1 - 61.99 86.52 87.71 87.98 
N1-Pt-N2 - 114.73 93.55 90.28 90.25 
N1-Pt-N3 - 153.46 133.75 176.94 176.68 
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Table A18 Relevant bond distances (Å) and angles (°) for the first step of the reaction between N7-Me-Gua 
and cisplatin, N7 is entering nitrogen atom in N7 position of N7-Me-Gua, O(w) is the oxygen atom of water 
coordinated to Pt. 
Bond Distances 
Cisplatin + N7-Me-Gua R RA TS PA P 
Pt-O(w) 2.131 2.086 2.363 4.227 - 
Pt-N1 2.136 2.132 2.121 2.107 2.115 
Pt-N2 2.054 2.071 2.08 2.096 2.092 
Pt-Cl2 2.299 2.313 2.317 2.337 2.326 
Pt-N7 - 3.878 2.547 2.056 2.061 
Angles 
Cisplatin + N7-Me-Gua P RA TS PA P 
O(w)-Pt-N1 87.43 85.94 88.2 129.56 - 
O(w)-Pt-N2 176.03 175.93 154.25 129.33 - 
O(w)-Pt-Cl2 89.11 90.80 90.45 50.90 - 
N7-Pt-N1 - 104.48 87.74 89.91 91.03 
N7-Pt-N2 - 138.3 135.4 176.12 175.30 
N7-Pt-Cl2 - 71.79 90.86 90.73 89.96 
 
 
Table A19 Relative Gibbs free energy values (kcal mol-1), associated to the reaction between 9-
methylguanine 9-methyladenine and isomer P and isomer M of phenanthriplatin and cisplatin, in PCM 
water. 
G R → RA RA → TS TS → PA PA →P 
Complex-P + N7-Me-Gua -4.3 13.9 -26.8 -5.0 
Complex-M+ N7-Me-Gua -3.0 13.6 -27.2 -5.2 
Complex-P + N7-Me-Ade 3.6 15.2 -30.4 -2.8 
Complex-M + N7-Me-Ade 4.3 14.4 -30.8 -3.6 
Complex-P + N1-Me-Ade 1.6 16.9 -30.3 -6.2 
Complex-M + N1-Me-Ade 1.8 16.9 -31.2 -5.1 
Cisplatin + N7-Me-Gua -3.2 14.8 -26.7 -6.8 
CisplatinN7-Me-Gua + N7’-Me-Gua -4.3 16.6 -30.6 -3.3 
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Table A20 Relevant bond distances (Å) and angles (°) for RA in - interaction for isomer M, where Nb is the 
nitrogen atom of the bases, O(w) is the oxygen atom of water coordinated. At M06 level of theory. 
Bond Distances 
Isomer M N7-Me-Gua N7-Me-Ade N1-Me-Ade 
Pt-O(w) 2.068 2.039 2.038 
Pt-N1 2.108 2.109 2.109 
Pt-N2 2.064 2.064 2.065 
Pt-N3 2.089 2.115 2.118 
Pt-Nb 4.037 4.037 4.072 
Angles 
Isomer M N7-Me-Gua N7-Me-Ade N1-Me-Ade 
O(w)-Pt-N1 83.83 88.14 87.85 
O(w)-Pt-N2 90.75 87.54 88.20 
O(w)-Pt-N3 179.57 176.90 176.89 
Nb-Pt-N1 121.09 123.39 122.38 
Nb-Pt-N2 53.43 52.71 54.31 
Nb-Pt-N3 143.10 139.43 138.61 
 
Table A21 Relevant bond distances (Å) and angles (°) for TS in - interaction for isomer M, where Nb is the 
nitrogen atom of the bases, O(w) is the oxygen atom of water coordinated. At M06 level of theory 
Bond Distances 
Complex M N7-Me-Gua N7-Me-Ade N1-Me-Ade 
Pt-O(w) 2.373 2.360 2.348 
Pt-N1 2.085 2.097 2.101 
Pt-N2 2.068 2.064 2.061 
Pt-N3 2.088 2.094 2.091 
Pt-Nb 2.597 2.634 2.672 
Angles 
Complex M N7-Me-Gua N7-Me-Ade N1-Me-Ade 
O(w)-Pt-N1 82.55 82.45 81.01 
O(w)-Pt-N2 96.56 95.88 96.05 
O(w)-Pt-N3 154.05 153.14 156.07 
Nb-Pt-N1 89.90 88.90 88.07 
Nb-Pt-N2 88.59 90.34 91.72 
Nb-Pt-N3 136.93 136.18 133.97 
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Table A22 Relevant bond distances (Å) and angles (°) of TS obtained by the rotation of the phenanthridine 
ligand in [Pt(NH3)2(Ade)(phenanthridine)]2+, where Nb is the nitrogen atom of the bases. 
Bond Distances N7-Me-Ade N1-Me-Ade 
Pt-N1 2.115 2.115 
Pt-N2 2.138 2.127 
Pt-N3 2.133 2.121 
Pt-Nb 2.045 2.069 
Angles N7-Me-Ade N1-Me-Ade 
Nb-Pt-N1 83.95 84.72 
Nb-Pt-N2 96.50 90.67 
Nb-Pt-N3 170.46 170.75 
 
 
Figure A6 Optimized structures for the reaction between cisplatin and cysteine. 
 
Table A23 Relevant bond distances (Å) and angles (°) for optimized isomer P of phenanthriplatin, O(w) is the 
oxygen atom of water coordinated to Pt. 
Bond Distances 
Isomer P R RA TS PA P 
Pt-O(w) 2.133 2.090 2.525 4.042 - 
Pt-N1 2.122 2.115 2.100 2.106 2.136 
Pt-N2 2.053 2.056 2.063 2.073 2.056 
Pt-N3 2.062 2.079 2.105 2.123 2.128 
Pt-S - 4.833 2.775 2.371 2.380 
Angles 
Isomer P R RA TS PA P 
O(w)-Pt-N1 86.26 85.18 91.16 46.06 - 
O(w)-Pt-N2 90.83 90.25 89.88 136.91 - 
O(w)-Pt-N3 178.38 179.24 154.42 126.93 - 
S-Pt-N1 - 112.26 87.36 92.51 87.89 
S-Pt-N2 - 63.34 93.30 88.33 94.45 
S-Pt-N3 - 147.01 132.89 176.09 179.09 
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Table A24 Relevant bond distances (Å) and angles (°) for optimized isomer M of phenanthriplatin, O(w) is 
the oxygen atom of water coordinated to Pt. 
Bond Distances 
Isomer M R RA TS PA P 
Pt-O(w) 2.134 2.081 2.480 4.063 - 
Pt-N1 2.122 2.112 2.099 2.105 2.135 
Pt-N2 2.054 2.059 2.063 2.073 2.056 
Pt-N3 2.063 2.082 2.098 2.125 2.128 
Pt-S - 4.768 2.858 2.368 2.380 
Angles 
Isomer M R RA TS PA P 
O(w)-Pt-N1 85.97 85.06 86.74 45.52 - 
O(w)-Pt-N2 91.73 90.71 93.61 135.83 - 
O(w)-Pt-N3 179.20 179.48 154.11 127.83 - 
S-Pt-N1 - 102.51 87.82 92.53 87.84 
S-Pt-N2 - 74.77 92.03 88.18 94.25 
S-Pt-N3 - 150.38 132.29 176.32 177.92 
 
 
Table A25 Relevant bond distances (Å) and angles (°) for optimized cisplatin, O(w) is the oxygen atom of 
water coordinated to Pt. 
Bond Distances 
Cisplatin R RA TS PA P 
Pt-O(w) 2.131 2.110 2.402 3.444 - 
Pt-N1 2.136 2.116 2.121 2.123 2.149 
Pt-N2 2.054 2.059 2.097 2.094 2.119 
Pt-Cl2 2.299 2.314 2.318 2.324 2.308 
Pt-S - 4.178 2.776 2.359 2.359 
Angles 
Cisplatin P RA TS PA P 
O(w)-Pt-N1 87.435 86.08 82.11 56.16 - 
O(w)-Pt-N2 176.03 176.71 144.44 57.09 - 
O(w)-Pt-Cl2 89.11 89.52 93.58 121.52 - 
S-Pt-N1 - 98.22 90.57 91.13 89.92 
S-Pt-N2 - 131.22 132.10 175.03 176.41 
S-Pt-Cl2 - 78.32 88.66 90.73 91.67 
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Table A26 Relative Gibbs free energy values (kcal mol-1), associated to the reaction between cysteine and 
Isomer P and isomer M of phenanthriplatin and cisplatin, in PCM water. 
G  R → RA RA → TS TS → PA PA → P 
Complex P 2.3 15.1 -24 -2.9 
Complex M 0.6 20.4 -27.2 -5.3 
cisplatin 2.4 13.5 -24.5 -5.6 
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4.2 Chemical Properties: Inside the Acidity of Fluoroquinolone 
Antibacterials 
 
Table A1 Relevant bond distances (Å) and angles (°) for CFX-, nCFX and zCFX in optimized structures. 
Distance CFX- nCFX zCFX-N4' 
C11-O12 1.261 1.216 1.261 
C11-O11 1.251 1.336 1.250 
C11-C3 1.546 1.488 1.547 
C2-N1 1.362 1.345 1.362 
C9-N1 1.395 1.404 1.393 
N1-C12 1.452 1.458 1.452 
C4-O4 1.239 1.257 1.238 
Nϭ’-CϮ’ 1.465 1.467 1.460 
CϮ’-Cϯ’ 1.534 1.535 1.523 
Cϯ’-N4’ 1.466 1.465 1.509 
N4’-Cϱ’ 1.467 1.466 1.510 
Cϱ’-C6’ 1.530 1.531 1.520 
C6’-Nϭ’ 1.477 1.479 1.470 
Angles CFX- nCFX zCFX-N4' 
O12-C11-C3 115.3 123.5 115.2 
O11-C11-C3 118.0 115.2 118.0 
O4-C4-C3 126.3 122.7 126.5 
O4-C4-C10 119.3 121.9 119.2 
C2-N1-C9 119.2 119.8 119.1 
C2-N1-C12 119.9 119.7 119.9 
C9-N1-C12 120.6 120.3 120.7 
C7-N1'-C2' 117.9 118.5 117.9 
C7-N1'-C6' 117.4 118.7 117.1 
C2'-N1'-C6' 111.8 112.1 111.6 
C3'-N4'-C5' 110.7 110.7 112.1 
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Table A2 Relevant bond distances (Å) and angles (°) for the zCFX-N4’, zCFX-N1 and zCFX-Nϭ’ optimized 
structures. 
Distance  zCFX-N4' zCFX-N1 zCFX-N1' 
C11-O12 1.261 1.244 1.259 
C11-O11 1.250 1.246 1.249 
C11-C3 1.547 1.548 1.547 
C2-N1 1.362 1.486 1.364 
C9-N1 1.393 1.486 1.388 
N1-C12 1.452 1.516 1.454 
C4-O4 1.238 1.222 1.234 
Nϭ’-CϮ’ 1.460 1.469 1.525 
CϮ’-Cϯ’ 1.523 1.536 1.531 
Cϯ’-N4’ 1.509 1.464 1.460 
N4’-Cϱ’ 1.510 1.466 1.460 
Cϱ’-C6’ 1.520 1.531 1.532 
C6’-Nϭ’ 1.470 1.479 1.570 
Angles zCFX-N4' zCFX-N1 zCFX-N1' 
O12-C11-C3 115.2 115.9 115.2 
O11-C11-C3 118.0 113.3 117.5 
O4-C4-C3 126.5 122.0 126.9 
O4-C4-C10 119.2 121.9 118.9 
C2-N1-C9 119.1 115.2 119.0 
C2-N1-C12 119.9 108.7 120.0 
C9-N1-C12 120.7 111.5 120.7 
C7-N1'-C2' 117.9 119.1 113.8 
C7-N1'-C6' 117.1 120.1 112.9 
C2'-N1'-C6' 111.6 112.4 112.0 
C3'-N4'-C5' 112.1 110.7 111.9 
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Table A3 Relevant bond distances (Å) and angles (°)  for the calculated structures of zCFX-N4’, H2CFX-O11 
and H2CFX-Nϭ’, H2CFX-Nϭ’. 
Distance zCFX-N4' H2CFX+-O11 H2CFX+-N1 H2CFX+-N1' 
C11-O12 1.261 1.216 1.244 1.259 
C11-O11 1.25 1.336 1.245 1.248 
C11-C3 1.547 1.489 1.549 1.549 
C2-N1 1.362 1.346 1.486 1.364 
C9-N1 1.393 1.402 1.484 1.387 
N1-C12 1.452 1.459 1.517 1.454 
C4-O4 1.238 1.255 1.220 1.233 
Nϭ’-CϮ’ 1.460 1.461 1.463 1.519 
CϮ’-Cϯ’ 1.523 1.523 1.522 1.518 
Cϯ’-N4’ 1.509 1.509 1.508 1.507 
N4’-Cϱ’ 1.510 1.509 1.509 1.507 
Cϱ’-C6’ 1.520 1.520 1.520 1.518 
C6’-Nϭ’ 1.470 1.471 1.473 1.521 
Angles zCFX-N4' H2CFX+-O11 H2CFX+-N1 H2CFX+-N1' 
O12-C11-C3 115.2 123.4 116.0 115.1 
O11-C11-C3 118.0 115.2 113.1 117.5 
O4-C4-C3 126.5 122.9 122.4 127.1 
O4-C4-C10 119.2 121.8 121.6 118.8 
C2-N1-C9 119.1 119.7 115.2 119.0 
C2-N1-C12 119.9 119.7 108.8 120.0 
C9-N1-C12 120.7 120.4 111.6 120.7 
C7-N1'-C2' 117.9 118.4 118.6 113.3 
C7-N1'-C6' 117.1 118.1 119.0 112.4 
C2'-N1'-C6' 111.6 111.9 112.1 111.0 
C3'-N4'-C5' 112.1 112.0 111.8 111.9 
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Table A4 Relevant bond distances (Å) and angles (°)  for the calculated structures of H2CFX+-O11, H3CFX2+-
N1, H3CFX2+-N1', H3CFX2+-O4. 
Distance H2CFX+-O11 H3CFX2+-N1 H3CFX2+-N1' H3CFX2+-O4 
C11-O12 1.216 1.206 1.214 1.208 
C11-O11 1.336 1.326 1.335 1.336 
C11-C3 1.489 1.521 1.492 1.505 
C2-N1 1.346 1.462 1.346 1.333 
C9-N1 1.402 1.486 1.397 1.395 
N1-C12 1.459 1.543 1.461 1.468 
C4-O4 1.255 1.230 1.247 1.334 
Nϭ’-CϮ’ 1.461 1.464 1.521 1.464 
CϮ’-Cϯ’ 1.523 1.525 1.519 1.524 
Cϯ’-N4’ 1.509 1.509 1.507 1.508 
N4’-Cϱ’ 1.509 1.509 1.506 1.509 
Cϱ’-C6’ 1.520 1.520 1.518 1.520 
C6’-Nϭ’ 1.471 1.472 1.523 1.474 
Angles H2CFX+-O11 H3CFX2+-N1 H3CFX2+-N1' H3CFX2+-O4 
O12-C11-C3 123.4 121.4 123.1 121.1 
O11-C11-C3 115.2 115.9 115.4 118.4 
O4-C4-C3 122.9 121.0 123.7 117.3 
O4-C4-C10 121.8 123.0 121.1 122.8 
C2-N1-C9 119.7 115.4 119.7 120.5 
C2-N1-C12 119.7 112.3 119.9 119.3 
C9-N1-C12 120.4 109.6 120.4 120.1 
C7-N1'-C2' 118.4 120.4 113.7 119.5 
C7-N1'-C6' 118.1 121.3 112.1 120.4 
C2'-N1'-C6' 111.9 112.4 111.0 112.4 
C3'-N4'-C5' 112.0 112.1 112.0 112.0 
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4.3 Antibacterial Fluoroquinolones as Pollutants: Adsorption on 
Carbon Nano-tube, a Molecular Dynamics Simulation Study 
Table A5 MK charges and atomic mass used in nCFX and zCFX, the atoms numbering is reported in Scheme 
11. 
 
zCFX nCFX 
Atom Charge Mass Charge Mass 
N1 0.031 14.0067 -0.059 14.0067 
C12 0.151 12.0110 0.157 12.0110 
H12 0.079 1.0080 0.090 1.0080 
C13 0.000 14.0270 0.012 14.0270 
C14 0.000 14.0270 0.012 14.0270 
C2 -0.110 12.0110 0.109 12.0110 
H2 0.138 1.0080 0.105 1.0080 
C3 -0.261 12.0110 -0.471 12.0110 
C11 0.706 12.0110 -0.471 12.0110 
O1 -0.759 15.9994 -0.584 15.9994 
O2 -0.759 15.9994 -0.652 15.9994 
C4 0.539 12.0110 0.576 12.0110 
O3 -0.607 15.9994 -0.620 15.9994 
C10 -0.179 12.0110 -0.143 12.0110 
C5 -0.145 12.0110 -0.201 12.0110 
H5 0.147 1.0080 0.173 1.0080 
C6 0.105 12.0110 0.178 12.0110 
F1 -0.149 18.9984 -0.150 18.9984 
C7 0.180 12.0110 0.104 12.0110 
C8 -0.203 12.0110 -0.174 12.0110 
H8 0.071 1.0080 0.079 1.0080 
C9 0.068 12.0110 0.134 12.0110 
N1' -0.287 14.0067 -0.205 14.0067 
C2' 0.202 14.0270 0.110 14.0270 
C3' 0.172 14.0270 0.223 14.0270 
N4' -0.186 14.0067 -0.758 14.0067 
H4' 0.341 1.0080 0.386 1.0080 
H-z-n 0.341 1.0080 0.458 1.0080 
C5' 0.172 14.0270 0.223 14.0270 
C6' 0.202 14.0270 0.110 14.0270 
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Table A6 LJint in vacuum between SW-CNT and 1, 2, 4 and 8 molecules of n and zCFX. xCFX out (x = n or z): 
CFXs adsorbed on the outer SW-CNT surface, xCFX ins (x = n or z): CFXs adsorbed on the inner surface. 
 
LJint kcal mol-1  1 CFX 2 CFX 4 CFX 8 CFX 
zCFX out -26.8 -17.9 -22.3 21.8 
nCFX out -24.9 -26.2 -26.5 -25.1 
zCFX ins -34.9 -39.5 -29.4 -31.9 
nCFX ins -43.2 -43.2 -40.1 -34.3 
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Platinum complexes bearing phosphane ligands in cis configuration with deprotonated flavonoids (3-
hydroxyflavone, quercetin) and deprotonated ethyl gallate were synthesized starting from cis-[PtCl2(PPh3)2].
In all cases, O,O chelate structures were obtained. While quercetin and ethyl gallate complexes are quite stable
in solution, the 3-hydroxyflavonate complex undergoes a slow aerobic photodegradation in solutionwith forma-
tion of salicylic and benzoic acids. The X-ray diffraction structures of quercetin and ethyl gallate complexes are
reported. Cell cycle studies (in the dark) of the complexes in two human cell lines revealed that the cytotoxic ac-
tivity of the complex bearing 3-hydroxyflavonate is higher than those exhibited by 3-hydroxyflavone or by cis-
[PtCl2(PPh3)2] alone. Density functional theory studies on the hydrolysis pathway for the 3-hydroxyflavone
and ethyl gallate complexes explained the different cytotoxic activity observed for the two compounds on the
basis of the different intermediates formedduring hydrolysis (relatively inert hydroxy Pt complexes for ethyl gal-
late and monoaqua complexes for 3-hydroxyflavone).
© 2016 Elsevier Inc. All rights reserved.
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1. Introduction
The discovery of antiproliferative activity of cisplatin by Rosenberg
et al. [1] in 1965 contributed to the development of cancer chemother-
apy. Today cisplatin is a widely used drug in chemotherapy, but its ap-
plicability has many disadvantages, as it causes many severe side
effects including: nephrotoxicity, neurotoxicity, myelotoxicity, hemato-
logical toxicity and gastrointestinal reactions [2–4]. In addition, some
tumors have acquired resistance to cisplatin,while others develop resis-
tance after the initial treatment. In view of these limitations, research
has been extended to other platinum complexes. A large number of
platinum analogs have been tested during the last 30 years [5]. Unfortu-
nately, the vast majority of these compounds were rejected in preclini-
cal or early clinical stages of testing (only carboplatin and oxaliplatin,
Scheme 1, are in world-wide clinical use) and the discovery of a new
platinum drug more selective and less toxic than cisplatin is still highly
desirable.
Recently, the antitumor activity of dietary flavonoids (flavus =
yellow), which are primarily benzo-γ-pyrone (phenylchromone)
derivatives (Scheme 2), comprising a massive group of polyphenolic
compounds [6–7] universally distributed in the plant kingdom, has
been reviewed [8]. The pharmacological effects of flavonoids include in-
duction of apoptosis, suppression of protein tyrosine kinase activity,
antiproliferation, antimetastatic and antiinvasive effects, and anti-
angiogenesis [8].
Because of structural differences, flavonoids are divided into eight
different groups, flavonols being one of them. 3-Hydroxyflavone
(Scheme 3a) is the backbone of all flavonols [9], while quercetin
(Scheme 3b) is another very important flavonol with well-known anti-
cancer activity [10]. Due to their polyphenolic structure, flavonols are
effective metal ion chelators, playing a key role in the initiation of free
radical and antioxidant processes [11]. Moreover flavonols can interca-
late into deoxyribonucleic acid (DNA) as well as covalently bind to DNA
and proteins [12–13]. As a result of these characteristics, flavonols have
complex biological interactions and in some therapies they are com-
bined with cisplatin increasing efficacy over individual treatments [14]
and reducing side effects associated with cisplatin [15]. However, com-
binations of flavonols with platinum are poorly understood, although
multiple theories currently exist trying to explain the interactions be-
tween cisplatin and flavonols [16].
Like flavonols, also plant phenols, such as ethyl gallate (Scheme 3c),
have antitumor activity [17–20] and can effectively bind metal ions.
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All these considerations prompted us to check whether platinum
complexes of natural polyphenols would exhibit synergic cytotoxic ac-
tivity. Although since the early 1980s scientists have investigated
more than 40 metal–flavonoid complexes [21–22], to the best of our
knowledge Pt(II) complexes with 3-hydroxyflavone and ethyl gallate
as ligands have never been synthesized. On the contrary, the synthesis
of a platinum(II) complex with quercetin has already been reported
[23]. Its formula is cis-[Pt(NH3)2(que)] (que = dianion of quercetin)
and a complexation of platinum(II) to the ligand through oxygen
atoms at C3’ and C4’ was hypothesized, although neither XRD (X-ray
diffraction) nor citotoxicity studies were carried out.
Phosphane ligands with hydrophobic character have been shown to
increase in some cases the cytotoxicity of their platinum complexes,
possibly by enhancing the cellular membrane transfer process [24].
In previous works [25–26], interesting results were obtained by
synthetizing platinum compounds bearing two mutually cis
triphenylphosphanes with bioactive ligands. In these studies, it has
been reported that Pt(II) complexes containing PPh3 and theN7-coordi-
nated anionic ligand 8-MTT (8-(methylthio)theophyllinate) have a
remarkable cytotoxic activity on some cancer cell lines. This antiprolif-
erative activity on both cisplatin-sensitive T2 and cisplatin-resistant
SKOV3 cell lines decreased when PPh3was substituted by themore hy-
drophilic 1,3,5-triaza-7-phosphaadamantane (PTA) ligand. Although
the total replacement of the usually employed amine carrier ligands
(Scheme 1) for air and water stable triarylphosphanes may exhibit
some disadvantages (themajor of them being that a tertiary phosphane
cannot establish any hydrogen bondwith the DNA backbone), however
it has been found that triarylphosphane ligands may stabilize DNA-Pt
adducts through π-π interactions occurring between the phosphane
phenyl groups and the nucleobases [27]. For this reason, recently a
series of platinum compounds where the two ammonia ligands of
cisplatin and cisplatin analogs were replaced by phosphanes have
been prepared and biologically characterized [28–29]. In some cases
promising interactions between DNA (or cell proteins) and platinum
complexes bearing two phosphane groups in mutually cis position
have been found and studied [30–34], in spite of the poor antiprolifera-
tive activity of cis-[PtCl2(PPh3)2] [35]. Moreover, PR3 ligand has a kinetic
trans effect stronger than NH3, which can facilitate the leaving group
displacement by H2O in the human cell. The ligand release by hydrolysis
is a key-step for the DNA-adduct formation and attracted numerous
Scheme 1. Platinum based anticancer drugs used in clinical therapies.
Scheme 2. Flavone backbone.
Scheme 3. (a) 3-Hydroxyflavone; (b) quercetin; (c) ethyl gallate.
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experimental studies [36]. Furthermore, in the last decade a variety of
theoretical approaches have been applied to obtain an accurate picture
of the hydrolysis mechanism of Pt(II)-based anticancer drugs and ulti-
mately of the structure-activity relationship [37–41]. In this framework,
we started a project aiming at preparing new platinum complexes con-
taining triphenylphosphane as carrier ligand andflavonolates or natural
polyphenolates as leaving groups. Herein, we report on the synthesis,
characterization, cytotoxicity and DFT studies of cis-[Pt(PPh3)2(que)]
(1, que = dianion of quercetin), cis-[Pt(PPh3)2(3-Hfl)]Cl (2, 3-Hfl =
monoanion of 3-hydroxyflavone), and cis-[Pt(PPh3)2(etga)] (3, etga =
dianion of ethyl gallate).
2. Experimental section
2.1. Material and methods
Tap water was de-ionized by ionic exchange resins (Millipore) be-
fore use. All chemicals and solvents were purchased from commercial
suppliers and used without further purification. cis-Pt(PPh3)2Cl2 was
synthetized according to literature procedures [42].
Melting points were determined with a Büchi Melting Point B-540
apparatus and are uncorrected. Elemental analyses were carried out
with a Perkin Elmer 2400 CHN Elemental Analyzer at the Microanalyti-
cal Laboratory of the University of Bari, Department of Pharmacy. IR
spectra were recorded on a Bruker-Vector 22 spectrometer. NMR spec-
tra were recorded on a BRUKER Avance 400 spectrometer; frequencies
are referenced to Me4Si (
1H and 13C), 85% H3PO4 (
31P) and H2PtCl6
(195Pt). The signal attributions and coupling constant assessment were
made on the basis of amultinuclear NMR analysis of each compound in-
cluding, besides 1D spectra, 1H\\31P HMQC, 1H\\195Pt HMQC, 1H\\13C
HSQC, 1H\\13C HMBC and 1H COSY. High resolution mass spectrometry
(HR-MS) analyses were performed using a time-of-flight mass spec-
trometer equipped with an electrospray ion source (Bruker micrOTOF).
The sample solutions were introduced by continuous infusion with the
aid of a syringe pump at a flow rate of 180 μL/min. The instrument was
operated at end plate offset−500 V and capillary−4500 V. Nebulizer
pressure was 1.5 bar (N2), and the drying gas (N2) flow was 10 L/min.
Capillary exit and skimmer 1 were 120 and 40 V, respectively. The dry-
ing gas temperature was set at 220 °C. The calculated (exact mass) and
the experimental (accurate)m/z values were compared considering the
principal ion (which gives themost intense peak) of the isotope pattern.
The software used for the calculated HRMS-spectra is Bruker Daltonics
Data Analysis (version 3.3).
2.2. Synthesis of cis-[Pt(PPh3)2(que)] (que = dianion of quercetin) (1)
A solution of KOH (2.90mmol, 162.7mg) in ethanol (7.0mL) kept at
40 °C was added dropwise to a clear yellow solution of cis-
[PtCl2(PPh3)2] (1.45 mmol, 1.149 g) and quercetin (1.45 mmol,
0.439 g) in CH2C12 (80 mL) at room temperature under stirring. After
overnight stirring at room temperature, the resulting dark orange reac-
tion mixture was filtered (in order to remove KCl) and dried under re-
duced pressure. The red orange residue was dissolved in CH2Cl2
(10 mL) and added of n-hexane (30 mL), which caused the formation
of a red-orange precipitate. This solid was filtered after overnight
cooling at 4 °C, washed with n-hexane (3 × 10 mL) and dried under
vacuum.
Yield: 1.073 g, 72%. Mp = 212.5 °C (dec).
Relevant 1H and 13C{1H} NMR features are reported in Tables 3 and
2, respectively, except those belonging to PPh3 groups. PPh3 region:
1H
NMR (400 MHz, dmso-d6, 25 °C) δ = 7.45 ppm (m, 12H, Hortho),
7.42 ppm (m, 6H, Hpara), 7.29 ppm (m, 12H, Hmeta);
13C{1H} NMR
(100 MHz dmso-d6, 25 °C) δ= 134.7 ppm (s, Cortho), 131.6 (s, Cpara),
128.8 (s, Cipso), 128.6 (s, Cmeta).
31P{1H} NMR (121.5 MHz, dmso-d6, 25 °C): δ= 9.6 ppm (d,
2JPP =
23 Hz, 1JPtP = 3565 Hz); 8.3 ppm (d,
2JPP = 23 Hz,
1JPtP = 3600 Hz).
195Pt{1H} NMR (85.99 MHz, dmso-d6, 25 °C): δ = −4062 ppm
(dd, 1JPtP = 3565 Hz,
1JPtP = 3600 Hz).
IR (KBr, cm−1): 3372–3633 (b, m, O\\H), 3058 (m, C\\H), 1650
(s, C_O), 1617 (s, C_C), 1515 (s, C_C), 1491 (s, C_C), 1426 (s,
C_C), 1354 (m, O\\H), 1270 (s, C-O-C), 1162 (m, O\\H), 1099 (m,
C\\H), 997 (m, C-O-C), 741 (m, C\\H), 530 (m, Pt\\O).
HRMS (ESI, acetonitrile, positive ion mode) m/z: calcd. for
C51H38O7P2Pt [M]
+ 1019.1740; found 1019.1681. HRMS (ESI, acetoni-
trile, negative ion mode) m/z: calcd. for C51H37O7P2Pt [M-H]
−
1018.1672; found 1018.1678.
2.3. Synthesis of cis-[Pt(PPh3)2(3-Hfl)]Cl (3-Hfl = monoanion of 3-
hydroxyflavone) (2)
A solution of KOH (0.64 mmol, 35.9 mg) in ethanol (4.5 mL) kept at
40 °C was added dropwise to a clear yellow solution of cis-
[PtCl2(PPh3)2] (0.64 mmol, 506.0 mg) and 3-hydroxyflavone
(0.64 mmol, 152.5 mg) in CH2Cl2 (40 mL) at room temperature under
stirring. After overnight stirring at room temperature, the reaction mix-
ture was filtered to remove KCl and the resulting orange solution was
concentrated to 2 mL under reduced pressure and added of ethanol
(10 mL). Addition of pentane (30mL) caused the precipitation of an or-
ange solid from the solution. The solid was washed with n-pentane
(3 × 10 mL) and dried under vacuum.
Yield: 0.403 g, 63.5%. Anal. Calcd. for 2, C51H39O3P2PtCl: C, 61.68; H,
3.93. Found: C, 61.09; H, 4.18. Mp = 219.1 °C (dec).
1H and 13C{1H} NMR features are reported in Tables 3 and 2, respec-
tively, except those belonging to PPh3 groups. PPh3 region:
1H NMR
(400 MHz, dmso-d6, 25 °C) δ = 7.78–7.16 ppm;
13C{1H} NMR
(100 MHz, dmso-d6, 25 °C) δ= 135–128 ppm.
31P{1H} NMR (121.5 MHz, dmso-d6, 25 °C): δ= 8.60 ppm (d,
2JPP=
24 Hz, 1JPtP = 3667 Hz); 4.26 ppm (d,
2JPP = 24 Hz,
1JPtP = 3991 Hz).
195Pt{1H} NMR (85.99 MHz, dmso-d6, 25 °C): δ = −4077 ppm
(dd, 1JPtP = 3667 Hz,
1JPtP = 3991 Hz).
IR (nujolmull, cm1): 3059 (m, C\\H), 1613 (s, C_O), 1568 (s, C_C),
1257 (m, C-O-C), 1093 (m, C\\H), 996 (m, C-O-C), 755 (s, C\\H), 515
(m, Pt\\O).
HRMS (ESI, acetonitrile, positive ion mode) m/z: calcd. for
C51H39O3P2Pt [M-Cl]
+ 956.2021; found 956.2021.
2.4. Synthesis of cis-[Pt(PPh3)2(etga)] (etga= dianion of ethyl gallate) (3)
A solution of KOH (1.29 mmol, 72.4 mg) in ethanol (4.5 mL) kept at
40 °C was added dropwise to a clear yellow solution of cis-
[PtCl2(PPh3)2] (0.64 mmol, 0.505 g) and ethyl gallate (0.64 mmol,
126.8 mg) in CH2Cl2 (40 mL) at room temperature under stirring.
After overnight stirring at room temperature, the reaction mixture
was filtered to remove KCl and the resulting solution was evaporated
under reduced pressure and added of CH2Cl2 (10 mL). Addition of n-
pentane (30 mL) caused the precipitation of a yellow solid from the
dark yellow solution. The solid was washed with n-pentane
(3 × 10 mL) and dried under vacuum.
Yield: 0.376 g, 69.1%. Anal. Calcd. for 3, C39H44O5P2Pt: C 58.97, H
4.15; found C 58.41, H 4.22.
IR (nujol mull, cm−1): 3496 (s, O\\H), 3049 (m, C\\H), 2000–1813
(w, aromatic overtone), 1688 (s, C_O), 1591 (s, C_C), 596 (s, Pt\\O).
1H NMR (400 MHz dmso-d6, 25 °C) δ= 7.44 ppm (m, 12H, Hortho,
PPh3), 7.43 ppm (m, 6H, Hpara, PPh3), 7.28 ppm (m, 12H, Hmeta, PPh3),
6.56 ppm (s, 1H, 6-H), 6.41 ppm (s, 1H, 2-H), 5.60 ppm (s, 1H, 5-H),
4.10 ppm (q, 2H, CH2,
3JHH = 7.1 Hz), 1.20 ppm (t, 3H, CH3,
3JHH =
7.1 Hz). 13C{1H} NMR (100 MHz dmso-d6, 25 °C) δ = 167.2 ppm (s,
CO), 163.1 ppm (s, C3), 154.6 ppm (s, C4), 144.6 (s, C5), 134.8 ppm (s,
Cortho, PPh3), 131.8 ppm (s, Cpara, PPh3), 128.8 ppm (s, Cmeta, PPh3),
128.5 ppm (s, Cipso, PPh3), 116.8 ppm (s, C
1), 109.6 ppm (s, C2),
104.3 ppm (s, C6), 59.9 8 s, CH2), 14.8 (s, CH3).
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31P{1H} NMR (121.5 MHz, dmso-d6, 25 °C): δ=11.2 ppm (d,
1JPtP=
3552 Hz, 2JPP = 24 Hz); 6.4 ppm (d,
1JPtP = 3660 Hz,
2JPP = 24 Hz).
195PtNMR (85.99MHz, dmso-d6, 25 °C): δ=−4062 ppm(pseudo t).
HRMS (ESI, acetonitrile, positive ion mode) m/z: calcd. for
C45H38O5P2Pt [M]
+ 916.1841; found 916.1845; calcd. for
C45H38O5P2PtNa [M + Na]
+ 938.1739; found 938.1755; calcd. for
C45H38O5P2PtK [M + K]
+ 954.1478; found 954.1496.
2.5. Photodegradation of 2
Four NMR tubes were filled with a dmso-d6 solution (0.6 mL) of 2
(10−6 mol), two of them under aerobic conditions and the others
under nitrogen atmosphere, using de-aerated solvent. Each tube was
then capped and a 1H NMR spectrumwas immediately recorded. After-
wards, one of the NMR tubes under air and one under nitrogen were
placed in the dark, leaving the others in the daylight. The solutions
were checked by 1H NMR after five days.
2.6. Crystallographic analysis
Compounds 1 and 3 underwent batch crystallization, by slow diffu-
sion of n-pentane in a solution of tetrahydrofuran (thf) containing the
respective complex. Crystals suitable for diffraction analysis were ob-
tained after 2 weeks.
The single-crystal X-ray diffraction data for crystals 1 and 3were col-
lected on a Kappa CCD Nonius area detector diffractometer, in φ and ω
scans mode. Reflection data were measured at 293 K, using graphite
monochromatedMoKα radiation (λ=0.71073Å). Datawere corrected
for Lorentz and polarization effects [43] and for absorption [44].
The structures were solved by the Patterson deconvolution proce-
dure of SIR2014 [45] and refined by the full-matrix least-squares tech-
nique based on F2 with SHELXL2014/7 [46], using collected reflections
with I ≥ 2σ(I); up to 0.85 Å (crystal 1) and 0.83 Å (crystal 3) resolution;
measured reflections with |(Iobs –Ical)/SigW(I)| N 10 were excluded dur-
ing the refinement process. The non-hydrogen atomswere refinedwith
anisotropic thermal parameters. The aromatic,methyl and hydroxyl hy-
drogen atomswere placed in calculated positions, refinedwith isotropic
thermal parameters [U(H) = 1.2Ueq(C), U(H) = 1.5Ueq(Me,O)], and
allowed to ride on their carrier atoms. The SQUEEZE routine in PLATON
[47],designed to treat electron density of disordered and diffused sol-
vents, was applied to improve the structure refinement for 1. Crystallo-
graphic data collection and refinement parameters are given in Table 1.
Molecular graphicswere generated by usingMERCURYCSD 2.0 [48] and
JAV [49]. Two atoms separated by less than the sum of their Van der
Waals radii have been considered in contact: for intermolecular con-
tacts the two atomsmust belong to different symmetry-equivalentmol-
ecules, for intramolecular contacts the additional requirement is that
the two atoms must be separated by more than 4 bonds. The cif files
CCDC-1430059 for 1 and -1430058 for 3 contain the supplementary
crystallographic data for this paper. These data can be obtained free of
charge from the Cambridge Crystallographic Data Centre.
2.7. Computational details
In this work we studied the hydrolysis reaction for cis-
[Pt(PMe3)2(etga)], cis-[Pt(PMe3)2(3-Hfl)]
+, and cis-[PtCl2(PMe3)2] by
means of Density Functional Theory (DFT) calculations using
mPW1PW91 functional, which has been previously demonstrated to
provide reliable structures and energies for cisplatin and its derivatives
[37]. Phenyls in PPh3 groups have been replaced bymethyl (Me) groups
for computational convenience. Geometry optimizations were carried
out in vacuum and with a 6-31+G(d) basis set for all atoms except
the platinum atom, which was described by the quasi-relativistic Stutt-
gart–Dresden pseudopotential (SDD) [50]. In order to confirm that sta-
tionary points were actually minima or transition state geometries, the
analytical calculation of secondderivatives of the energy and vibrational
frequency analysis were carried out. Due to the key role of solvation in
influencing thermodynamic and kinetic parameters in metal complex
reactivity [51–55], environmental effects have been introduced by
representing water surrounding the reagents, transition states and the
products, as a polarizable continuum (PCM) [56]. Potential energy pro-
files were estimated from total electronic energies and adding zero
point energy (ZPE) and thermal corrections at 298.15 K. Total electronic
energies plus thermal corrections (instead of free energies) are reported
in order to uniform our data to those obtained in previous works [37,
57]. DFT calculations were performed with the Gaussian 09 program
[58].
2.8. Cytotoxicity assays and combination index (CI) calculations
Cell Lines: U87 cells from human glioblastoma andMCF-7 cells from
breast carcinoma were grown in Dulbecco's modified Eagle's medium
(DMEM, Euroclone). The complete culture medium was supplemented
with 10% heat-inactivated fetal bovine serum (Euroclone), streptomy-
cin (0.2mgmL−1), and penicillin (200 IUmL−1). For U87 cells the com-
plete medium was added with 1% of non-essential amino acids. Cells
were incubated at 37 °C and 5% CO2 in a humidified incubator. The cyto-
toxicity assays were performed as previously described [59]. Briefly,
U87 cells from human glioblastoma and MCF-7 cells from breast carci-
nomawere exposed to tested compounds for a period of 72 h. All tested
compounds were dissolved in dmso prior to their dilution with com-
plete cell culture medium to the predetermined experimental concen-
trations (seven concentrations ranging from 0.10 to 200 μM). In all
experiments the percentage of dmso never exceeded 1%. Cytotoxicity
(IC50) values for the tested compoundswere determined using themet-
abolic reduction of the soluble 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) by a mitochondrial enzyme of cultured
cells into an insoluble colored formazan product. In particular, cells
were seeded at a density of about 5000 cells/well in a 96 well plate
and incubated at 37 °C for 72 h in the presence and absence of the tested
compounds. Untreated cellswere used as positive control. Then, 10 μL of
5mgmL−1MTT solutionwas added to eachwell and the plateswere in-
cubated for additional 3 h at 37 °C. Next, cells were lysed by the addition
of 150 μL of 50% (v/v) dmso and 50% (v/v) ethanol solution, and the ab-
sorbance of each individualwell wasmeasured using amicroplate read-
er at 570 nm (Wallac Victor3, 1420 Multilabel Counter, Perkin-Elmer).
The reported values are the average of triplicate measurements per-
formed in three separate experiments.
Table 1
Crystal data, experimental details and refinement parameters for 1 and 3.
1 3
Chemical formula C51H38O7P2Pt C45H38O5P2Pt
Mr 1019.84 915.78
Crystal system Orthorhombic Triclinic
Space group Pbnb P1
a, b, c (Å) 15.372, 22.066, 32.445 11.038, 12.269, 15.242
α, β, γ (°) 90.00, 90.00, 90.00 72.53, 85.17, 89.25
V (Å3) 11,005.3 1961.9
Z 8 2
F(000) 4064 912
Dx (Mg m
−3) 1.231 1.550
μ (mm−1) 2.65 3.70
Crystal shape Prismatic Rod-shaped
Color Red Pale yellow
Crystal size (mm) 0.25 × 0.25 × 0.10 0.25 × 0.13 × 0.03
No. of measured reflections 87,739 20,140
No. of independent reflections 9323 7162
Rint 0.175 0.127
θ values (°) θmax = 24.7, θmin = 2.0 θmax = 25.4, θmin = 2.6
R[F2 N 2σ(F2)], wR(F2), S 0.064, 0.178, 0.98 0.060, 0.167, 0.89
No. of observed reflections
[I N 2σ(I)]
5316 4984
No. of parameters 553 479
Δρmax, Δρmin (e Å
−3) 2.01,−0.73 0.90,−1.54
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The cytotoxic effects measured for tested compounds were further
analyzed according to the Chou and Talalaymethod on CompuSyn soft-
ware (ComboSyn, Inc., Paramus, NJ, USA) [60]. The combination index
(CI) was calculated according to the equation of Chou-Talalay for two
drugs: CI = (D)1/(Dx)1 + (D)2/(Dx)2, where (Dx)1 and (Dx)2 are
the doses (concentrations) of Drug1 alone and Drug2 alone, respective-
ly, that inhibit x% of cell viability. (D)1 and (D)2 are the doses of Drug1
and Drug2, respectively, used in combination (D)1 + (D)2, able to in-
hibit x% of cell viability. Complexes 2 and 3 were considered at a
fixed-dose-ratio combination (1:1) of their building blocks [(D)1 =
(D)2]. CI = 1 indicates an additive effect in the absence of synergism
or antagonism; CI b 1 indicates synergism; CI N 1 indicates antagonism.
3. Results and discussion
3.1. Synthesis and characterization of platinum polyphenolate complexes
The synthesis of the platinum polyphenolate complexes was
achieved by reaction of cis-[PtCl2(PPh3)2] with deprotonated forms of
the selected biologically active natural polyphenols in dichlorometh-
ane/ethanol [61].
The reaction between cis-[PtCl2(PPh3)2] and quercetin leading to cis-
[Pt(PPh3)2(que)] (1, que= dianion of quercetin) is depicted in Scheme
4. The target complex was obtained in high yield and ca. 95% purity by
slowly adding ethanolic KOH to a dichloromethane solution of cis-
PtCl2(PPh3)2. The presence of ca. 5% impurities, which we were not
able to separate from the major product, prevented the use of complex
1 in cytotoxic essays. The formation of side-products in the synthesis of
1 is probably due to the presence of several coordination sites in querce-
tin [62,63]. Indeed, beside metal complexes whereby quercetin is
bonded via C3’-O and C4’-O [64] as in 1, metal(II) complexes of quercetin
bonded through the keto group (C4 = O) and the C3\\O oxygen atom
are known [21,65,66] and, in principle, also C7\\O bonded metal com-
plexes may form.
When we tried to obtain 1 by adding an ethanolic solution of the
pre-formed salt of quercetin to a solution of cis-[PtCl2(PPh3)2], the reac-
tionwas even less selective and several platinum compounds formed, as
shown by 31P NMR analysis.
Scheme 4. Synthesis of cis-[Pt(PPh3)2(que)] (que = dianion of quercetin) (1).
Fig. 1. Experimental (top) and calculated (bottom) HRMS-spectra of 1 showing the
ion [1 – H]−. The error between the calculated and observed isotopic patterns is 3.4 ppm.
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The formula proposed for 1 was confirmed by HR ESI-MS analysis.
The ESI-MS spectrogram in negativemode of a diluted acetonitrile solu-
tion of 1 showed an intense peak atm/z 1018.1678, whose isotope pat-
tern is perfectly superimposable to that calculated for the anion
[C51H37O7P2Pt]
− (corresponding to [1-H]−), obtained by deprotonation
of an hydroxyl group under analysis conditions (Fig. 1).
The 31P{1H} NMR spectrum of 1 in dmso-d6 showed two mutually
coupled doublets (2JP,P = 23 Hz) flanked by
195Pt satellites at δ 9.6
(1JPt,P = 3565 Hz) and δ 8.3 (
1JPt,P = 3600 Hz). The
31P\\31P coupling
constant indicates a structure in which the PPh3 groups are mutually
cis, while the direct 31P\\195Pt coupling constant values are compatible
with phosphane groups in trans position to an oxygen atom [64]. The
13C{1H} NMR spectrum of complex 1 showed a ca. 20 ppm downfield
shift with respect to the free ligand of the carbon signals which are
close to the coordination sites. The resonance of C3’ and C4’ signals
were found (by means of 1H\\13C HMBC and 1H\\13C HSQC experi-
ments, Figs. S1 and S2) at δ 166.6 and δ 163.4, respectively, with those
of free quercetin falling at δ 143.6 and δ 145.0, respectively (Table 2).
All 1H NMR signals were unambiguously assigned by means of 1D and
2D NMR experiments (see Figs. S1–3) and are reported in Table 3. The
signal of C5OH (Δν1/2 = 2 Hz) is much sharper than those of C
3OH
(Δν1/2=12Hz) and C
7OH (Δν1/2=94Hz), probably due to the forma-
tion of intramolecular C5OH···OC4 hydrogen bond in solution. This is
confirmed by the high value of the chemical shift found for the C5OH
proton (δ 12.64). The large broadness of the C7OH proton signal is as-
cribable to the fast exchange with water. The 195Pt{1H} NMR spectrum
of 1 consists of a doublet of doublets at δ −4062, in the region of
Pt(II) phosphane complexes [64].
The IR spectrum of 1 showed broad bands at 3372–3633 cm−1 that
can be assigned to the hydroxyl groups C7O-H, C5O-H and C3O-H, along
with the typical bands ascribed to the skeletal C_C (1650 and
1426 cm−1) and C-O-C (1270 cm−1) stretchings. All IR bands of coordi-
nated deprotonated quercetin are only slightly shifted in comparison to
those assigned to free quercetin [67]. In particular, the 1650 cm−1 band
assigned to the C4_O stretching (1661 cm−1 in free quercetin) con-
firms that the coordination of quercetin does not involve the oxygen
atom of the carbonyl group (the 11 cm−1 red-shift can be due to ring
deformation caused by platinum bonding to quercetin). Complex 1
was crystallized from thf/n-pentane to give crystals suitable for X-ray
diffraction. An ORTEP [68] drawing of the molecule is shown in Fig. 2.
Table 4 reports selected bond lengths and angles for 1. The Pt atom
has a distorted square-planar coordination geometry imposed by the
O,O chelation of quercetin. In the molecular unit of 1 the Pt atom is
displaced from the mean plane passing through the basal atoms P1,
P2, O5 and O2 by 3.0 Å. The Pt\\P (2.25 Å) and Pt\\O (2.06 Å) distances
are similar to those reported for other triarylphosphane platinum(II)
complexes containing chelating phenoxides [69]. Complex 1 has ortho-
rhombic symmetry, and a large crystal cell (cell volume11,005.3 Å3, vol-
ume per atom 22.6 Å3). The packing in the crystal cell is dominated by
the interactions among the PPh3 rings, which arrange them in planes
perpendicular to the longer c axis (Fig. S4). The dianion of quercetin
are instead arranged parallel to the c axis, spacing out the stacked
PPh3 ligands. The O8–H8 hydroxyl group and O7 give rise, also in the
solid state, to an intramolecular hydrogen bond.
Table 2
13C NMR spectral data of 1, 2 , quercetin and 3-hydroxyflavone (dmso-d6, 298 K). Bold
typeface refers to largest changes in chemical shifts observed comparing free with metal
coordinated ligand.
Complex 1 Quercetin Complex 2 3-Hydroxyflavone
C2 128.9 135.6 173.6 139.1
C3 149.4 146.8 182.6 145.2
C4 175.5 175.7 207.0 173.1
C5 161 160.6 125.5 124.8
C6 98.5 98.1 128.9 124.5
C7 163.8 163.8 134.3 133.7
C8 93.6 93.3 118.3 118.4
C9 156.3 156.1 155.2 154.6
C10 103.2 103 121.8 121.2
C1’ 118.4 121.9 131.8 131.3
C2’ 114.1 115.1 128.2 127.6
C3’ 166.6 147.6 128.4 128.6
C4’ 163.4 145.0 129.1 129.6
C5’ 115.1 115.5 128.4 128.6
C6’ 118.1 119.9 128.2 127.6
Table 3
1H NMR spectral data of 1, 2, quercetin and 3-hydroxyflavone (dmso-d6, 298 K).
Complex 1 Quercetin Complex 2 3-Hydroxyflavone
H3 8.81 9.6 – 9.68
H5 12.64 12.42 8.10
(d, 3JH5,H6 = 8.4 Hz)
8.16
(d, 3JH5,H6 = 8.1 Hz)
H6 6.12
(d, 4JH6,H8 = 2.1 Hz)
6.18
(d, 4JH6,H8 = 2.0 Hz)
7.51 (m) 7.50 (m)
H7 10.63 10.76 7.87 (m) 7.82 (m)
H8 6.32
(d, 4JH6,H8 = 2.1 Hz)
6.40
(d, 4JH6,H8 = 2.0 Hz)
7.98
(d, 3JH7,H8 = 7.7 Hz)
7.78
(d, 3JH7,H8 = 8.0 Hz)
H2’ 7.00
(d, 4JH2’,H6’ = 2.0 Hz)
7.67
(d, 4JH2’,H6’ = 2.2 Hz)
8.24
(d, 3JH2’,H3’ = 7.7 Hz)
8.26
(d, 3JH2’,H3’ = 7.9 Hz)
H3’ – 9.31 7.74 (m) 7.63 (m)
H4’ – 9.39 7.55 (m) 7.54 (m)
H5’ 6.19
(d, 3JH5’,H6’ = 8.4 Hz)
6.89
(d, 3JH5’,H6’ = 8.3 Hz)
7.74 (m) 7.63 (m)
H6’ 7.25 (m) 7.53
(dd, 8.3 Hz, 2.2 Hz)
8.24
(d, 3JH5’,H6’ = 7.7 Hz)
8.26
(d, 3JH5’,H6’ = 7.9 Hz)
Fig. 2. ORTEP [68] drawing of 1, by using ellipsoids at 50% probability level.
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DFT calculations on the relative stability of all the possible Pt-querce-
tin coordination isomers confirmed that the structure reported in Fig. 2
is the most stable one (see Scheme S1 and Table S1).
When 3-hydroxyflavone reacted with cis-[PtCl2(PPh3)2] under alka-
line conditions, complex salt cis-[Pt(PPh3)2(3-Hfl)]Cl (2, 3-Hfl =
monoanion of 3-hydroxyflavone) formed (Scheme 5), in which
deprotonated 3-hydroxyflavone coordinates Pt through its O3 and O4
atoms. The formula proposed for 2 was indicated by HR ESI(+)-MS
analysis which showed an intense peak atm/z 956.2021, whose isotope
pattern is perfectly superimposable to that calculated for
[C51H39O3P2Pt] corresponding to the cation cis-[Pt(PPh3)2(3-Hfl)]
+ (ex-
perimental and calculated HRMS-spectra are reported in Fig. S5).
The ionic structure for 2 was confirmed by comparing the dmso-d6
solution 31P{1H} NMR signals of 2 before and after addition of solid
AgBF4. The addition of AgBF4 to the yellow solution of 2 caused the im-
mediate precipitation of AgCl, and the chemical shifts of the 31P NMR
signals of 2 did not change after replacement of the chloride with a
poorly coordinating anion (BF4
−), ruling out, for instance, the possibility
of a neutral penta-coordinated structure [30] for 2.
1H, 31P and 195Pt NMR features of 2 (Table 3 and Experimental Sec-
tion) are consistent with the structure proposed in Scheme 5. As for
complex 1, the 13C{1H} NMR spectrum of 2 showed a significant down-
field shift of the carbon signals close to the coordination site (Table 2).
On the contrary, the 13C NMR chemical shift values belonging to nuclei
of A- and B-rings were very similar to the ones reported for free 3-
hydroxyflavone [70]. The IR spectrum of 2 exhibited a strong sharp
peak at 1613 cm−1 which can be assigned to the coordinated carbonyl
group, while no absorptions were observed in the O\\H stretching
region. The ca. 50 cm−1 red shift of the carbonyl band observedwith re-
spect to free 3-hydroxyflavone [62] indicates that the metal coordina-
tion involves the oxygen atom of the carbonyl group. Theoretical
vibrational analysis qualitatively confirms the frequency (Table S2) of
the coordinated carbonyl stretching mode (1593 cm−1), red-shifted
with respect to that calculated for the free ligand (1700 cm−1).
Single crystals of 2 obtained by slow diffusion of n-pentane into the
thf reaction solution were submitted to XRD analysis, but were not of
sufficient quality to warrant a complete X-ray structure determination.
Nonetheless, the collected data confirmed unambiguously for 2 the
atom connectivity shown in Scheme 5, with the chlorine atom, whose
refined occupancywas 0.45, placed in the same plane of themonoanion
Table 4
Selected bond lengths [Å] and angles [°] for complex 1.
Bond lengths
Pt1-P2 2.253(2) Pt1-O2 2.059(6)
Pt1-P1 2.249(3) C17-O5 1.338(10)
Pt1-O5 2.055(6) C7-O2 1.386(10)
Angles
P1-Pt1-P2 98.67(9) P2-Pt1-O2 167.27(19)
P2-Pt1-O5 84.78(18) P1-Pt1-O2 93.48(18)
P1-Pt1-O5
Pt2-O3’-C17
176.51(18)
110.6(6)
Pt1-O2-C7
O5-Pt1-O2
108.0(57)
83.0(2)
Scheme 5. Synthesis of cis-[Pt(PPh3)2(3-Hfl)]Cl (3-Hfl=monoanion of 3-hydroxyflavone) (2).
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of 3-hydroxyflavone unit and far away from the coordination sphere of
the platinum center. Three additional molecules were found in the ele-
mentary cell (vide infra), due to photodegradation processes.
Complex 3 was synthesized by reacting ethyl gallate with cis-
[PtCl2(PPh3)2] under alkaline conditions (Scheme 6). The formula
proposed for 3 was confirmed by HR ESI-MS analysis. The ESI-MS
spectrogram in positive mode of 3 showed an intense peak at m/z
916.1845, whose isotope pattern is perfectly superimposable to
that calculated for the radical cation [C45H38O5P2Pt]
+ (correspond-
ing to [3]+, (experimental and calculated HRMS-spectra are reported
in Fig. S6).
The 31P{1H} NMR spectrum of 3 in dmso-d6 showed the expected
doublets at δ 11.2 (1JPt,P = 3552 Hz) and δ 6.4 (
1JPt,P 3660 Hz), while
the 195Pt{1H} NMR spectrum showed a pseudo-triplet at δ−4400. The
C5\\OH proton of 3 (δ 5.60) was significantly shielded respect to the
free ligand (δ 9.30), presumably due to the weakening of the hydrogen
bond system caused by Pt coordination. The 13C{1H} NMR spectrum
confirmed the coordination of the C3\\O and C4\\O phenoxides onto
Pt: C3 and C4 signals of the coordinated ethyl gallate were found at δ
163.1 and δ 154.6, ca. 18 ppm down-field shifted respect to the free li-
gand (δ 145.6 for C3 and δ 138.3 for C4).
Slow diffusion of n-pentane into a thf solution of 3 afforded crys-
tals suitable for XRD analysis. An ORTEP [68] drawing of 3 is shown
in Fig. 3, while relevant bond lengths and angles are collected in
Table 5. The Pt atom adopts an almost square-planar coordination
geometry imposed by the O,O chelation of the dianion of ethyl gal-
late, as well as by the crystal packing on the PPh3 ligands (Fig. S7).
In the elementary cell, ethyl gallate moieties are all aligned in the
(113) plane. Deviation from planarity of the PtP2O2 plane was ob-
served, as measured by the improper dihedral angle value (3.2°),
being the plane of the two P atoms rotated with respect to the
plane of the ethyl gallate molecule.
3.2. Photo degradation of 2 under aerobic conditions
The photo degradation of 3-hydroxyflavone to 3-hydroxy-3-phe-
nyl-1,2-indandione (4, Scheme 7) [71] is a well-known phenome-
non, which has attracted the interest of the academic community
[71–74], because it affects both biological and antioxidant activities
[75] of 3-hydroxyflavone as well as its peculiar photochemical prop-
erties [76–81].
Conrard and coworkers reported that Zn(II) and Pb(II) 3-
hydroxyflavonate complexes decompose when exposed to daylight
affording 4 under both aerobic and anaerobic conditions, thus indicating
that the coordination to themetal center does not influence the decom-
position pathway [82].
On the contrary, Berreau and coworkers reported that Pb(II), Zn(II),
Ru(II) and other divalent metal flavonolate complexes undergo oxida-
tive photochemical degradation with loss of CO [83] and formation of
O-benzoyl salicylate complexes under aerobic conditions, and can act
as catalysts for the photoinduced oxidative ring opening of 3-
hydroxyflavone to give O-benzoyl salicylic acid (5) [84–85]. A similar
behavior was observed by Speier and coworkers for Cu(II) flavonolate
complexes under aerobic and thermal conditions [86].
In our case, we observed an oxidative photo degradation of 2 under
aerobic conditions. In fact, when a dmso-d6 solution of 2was left stand-
ingunder air in thedaylight for five days, a new compound formed in ca.
10% yield, which was characterized by NMR (Fig. S8) and GC–MS as O-
benzoyl salicylic acid (5). This compoundwasnot observedwhen a sim-
ilar solution of 2was left standing for ten days either in the dark and/or
in the absence of dioxygen.
In addition, as previously mentioned, XRD analyses of crystals ob-
tained by a slow diffusion of n-pentane/thf solution of 2 kept one
month under air in daylight showed in the elementary cell additional
atoms beside those belonging to complex 2. They have been placed to
interpret clear peaks emerging in the difference Fourier electron densi-
ty, and allowed to improve significantly the refinement of the whole
structure. Such atoms are grouped to form three additional molecules:
a salicylic acid, a thf (crystallization solvent) molecule and a fragment,
which was tentatively identified as benzoic acid, but whose low resolu-
tion prevented a conclusive assignment.
On the basis of these observations, the photo degradation pathway
followed by 2 should resemble the one already reported by Berreau
Scheme 6. Synthesis of cis-[Pt(PPh3)2(etga)] (etga = dianion of ethyl gallate) (3).
Fig. 3. ORTEP [68] drawing of 3 by using ellipsoids at 50% probability level.
Table 5
Selected bond lengths [Å] and angles [°] for complex 3.
Bond lengths
Pt1-P1 2.261(3) Pt1-O1 2.028(7)
Pt1-P2 2.260(3) C7-O2 1.346(13)
Pt1-O2 2.053(7) C1-O1 1.357(13)
Angles
P1-Pt1-P2 99.17(10) P1-Pt1-O1 169.9(2)
P1-Pt1-O2 87.6(2) P2-Pt1-O1 90.4(2)
P2-Pt1-O2 172.3(2) Pt1-O2-C7 109.6(6)
Pt1-O1-C1 110.3(6) O1-Pt1-O2 83.1(3)
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and coworkers for Ru(II) flavonolate complexes [83] (Scheme 8). Aero-
bic oxidation of 2 would result in a carbonyl Pt complex bonded to the
anion of O-benzoyl salicylic acid. This intermediate can decompose, in
the presence of adventitious water, to give 5 plus unidentified Pt spe-
cies. The formation of salicylic acid and benzoic acid during slow crystal-
lization of 2 in n-pentane/thf might then derive from hydrolysis of 5.
3.3. DFT calculations
On the basis of a large number of experimental data, it is widely
accepted that the hydrolysis of platinum(II) anticancer complexes is a
bimolecular nucleophilic substitution (SN2)which is the rate-determin-
ing step of the process leading to the formation of the adduct with DNA
nucleobases [36]. In particular, for cisplatin the mono-aquo species is
believed to be the key player, since it coordinates to the N7 atom of a
guanine base in DNA producing a monofunctional adduct [36,87].
Once coordinated, the second chloride is released and platinum binds
a second base producing the crosslink, which distorts DNA [36]. Due
to their importance, the hydrolysis reactions of platinum complexes
have been studied by means of a variety of theoretical methods in the
last decade [37–41]. In our case, the activation energies for the hydroly-
sis reactions of complexes 2 and 3 have been calculated because they
could be correlated to their potential synergic cytotoxicity, since poly-
phenols are released in solution.
The first hydrolysis leads to the ring-opening process, with the 3-Hfl
and etga derivatives remainingmono-coordinated to themetal ion cen-
ter. The secondhydrolysis (second step) leads to the complete release of
3-Hfl and etga (Scheme 9). For comparison purposes, we considered
also the hydrolysis of cis-[Pt(PMe3)2(Cl2)] (see Supplementary Informa-
tion), and that of cisplatin [37].
3.3.1. Hydrolysis reaction for cis-[Pt(PMe3)2(etga)]
The theoretical geometry of the model complex cis-
[Pt(PMe3)2(etga)] (Table S3) is in excellent agreement with the exper-
imental ones found for complex 3 (Table 5), thus confirming the reli-
ability of the computational protocol used. In Fig. 4 the structures of
reactants (R), products (P) and transition states (TS) are shown for
both reaction paths of cis-[Pt(PMe3)2(etga)] (Scheme 9a). Relevant
bond distances of all optimized complexes are reported in Table S3
and S4.
The reaction energy (E) profiles are shown in Fig. 5 (Table S5). The
energy values are referred to the separated reactants (R) rather than re-
actant adducts (RA) (Fig. 4), since it is widely accepted that at the begin-
ning of the reaction, thewatermolecule in the second coordination shell
of the metal is possible only in vacuum, but it seems an artifact in solu-
tion [88,89]. The detachment of the etga ligand in the first hydrolysis
can occur in two different ways (Scheme 9a): by breaking of the bond
that involves the oxygen in α position to the OH group (O1 path) or
the other Pt\\O bond (O2 path). Both O1 and O2 paths (Fig. 4a) showed
Scheme 7. Photo degradation of 3-hydroxyflavone in the absence of metal ions.
Scheme 8. Plausible pathway for the aerobic photo degradation of 2. [Pt] represents undefined Pt species.
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a proton transfer from the incoming water molecule to the closer
oxygen of the ligand (OL). This result has been previously reported
also for the hydrolysis of other platinum drugs under neutral conditions
[39,40]. Mono- and di-hydroxo complexes should form under physio-
logical conditions, although it has been reported that the local pH in
the vicinity ofmacromolecules could be different from the physiological
one [90,91].
The energy profiles for the first step of the hydrolysis indicate that
the formation of the reactant adducts (RA1-O1 and RA1-O2) is energet-
ically favored (Fig. 5a and Table S5).
Both transition states TS1-O1 and TS1-O2 have a penta-coordinated
structure, with imaginary frequencies of 99.7 cm−1 for TS1-O1 and
157.8 cm−1 for TS1-O2 corresponding to the rupture of the platinum-li-
gand bond (Pt-OL) and the simultaneous formation of a new bond be-
tween the metal and a water molecule. The activation energies (Ea =
Etransition state – Ereactants) for the two paths are rather different: for the
O1 path Ea = 22.8 kcal mol
−1, while the O2 path shows a Ea =
18.7 kcal mol−1 (Table S5). According to these results, the release of
ethyl gallate by the opening of the Pt\\O2 bond is kinetically preferred.
Furthermore, O2 pathway leads to the most stable product [ΔE =
E(PA1-O1) – E(PA1-O2) = 3.6 kcal mol−1]. This difference could be
due to the formation of two hydrogen bonds in the case of PA1-O2
with respect to PA1-O1 where only one hydrogen bond is possible
(Fig. 4a).
The transition states in the second hydrolysis have a penta-coordi-
nated structure with imaginary frequencies of 103.9 cm−1 for TS2-O1
and 101.7 cm−1 for TS2-O2 (Fig. 4b) corresponding to the simultaneous
rupture of the bond between platinum and the ligand (Pt-OL) and the
formation of the metal-water bond. The calculated profiles (Fig. 5b)
show that the two reaction paths have comparable activation energy
[ΔEa = Ea(TS2-O1) – Ea(TS2-O2) = 0.4 kcal mol
−1, Table S5]. Also the
final products (P2) have almost the same energy of TS2-O1 and TS2-
O2 (Table S5).
As shown in Fig. 5 and Table S5, the first hydrolysis step has a higher
activation energy with respect to the second step, irrespective of the
ring opening order, thus the first hydrolysis process is the rate deter-
mining step (RDS) of the whole reaction leading to the release of ethyl
gallate in solution.
Regarding the first hydrolysis (Fig. 5a), by comparing the energy
profiles of cis-[Pt(PMe3)2(etga)] with those of the highly cytotoxic cis-
platin, it appears that the Ea in O2 path is lower than the cisplatin one
(ΔEa=Ea(TS1-O2) – Ea(cisplatin)=−2.7 kcalmol
−1); on the contrary
the Ea in O1 path is higher than the one calculated for cisplatin (ΔEa =
+1.4 kcal mol−1) (Fig. 5a and Table S5). For the second hydrolysis
step, Ea values for both O1 and O2 paths are much lower than cisplatin
one (ΔEa = −6 kcal mol
−1 for O1 path and ΔEa = −6.4 kcal mol
−1
for O2 path) (Fig. 5b and Table S5). The obtained results suggest that
cis-[Pt(PMe3)2(etga)] leads to a mono-hydroxo complex with etga
mono-coordinated to the metal, which promptly reacts with another
water molecule giving the di-hydroxo species. The mono-hydroxo and
di-hydroxo species are consideredpoorly reactive for DNAcoordination,
thus their formation can limit the efficacy of a platinum metallodrug
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Scheme 9. Hydrolysis reactions for: a) cis-[Pt(PMe3)2(etga)] and b) cis-Pt[(PMe3)2(3-Hfl)]
+.
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[92]. Furthermore, the low activation energy barriers of the second step
and the consequent high hydrolysis reaction rate mightmake this com-
plex subject to fast degradation, causing potentially poor pharmacolog-
ical activity [93]. The obtained Ea value (11.3 kcal mol
−1) calculated for
the first hydrolysis of cis-[PtCl2(PMe3)2] (taken as a model for the bio-
logically inactive (vide infra) cis-[PtCl2(PPh3)2]) is much lower than
the Ea calculated for cis-[Pt(PMe3)2(etga)] and cisplatin (Fig. 5 and
Table S5). Then, the Ea calculated for the second hydrolysis of
[Pt(PMe3)2(etga)] is close to that of cis-[PtCl2(PMe3)2] (Fig. 5) and
much lower than cisplatin. On this basis of DFT calculations, complex
3 should not be expected highly cytotoxic.
3.3.2. Hydrolysis reaction for cis-[Pt(PMe3)2(3-Hfl)]
+
In Fig. 6 the optimized structures of the complexes involved in the
hydrolysis of cis-[Pt(PMe3)2(3-Hfl)]
+ are displayed, with relevant
bond distances reported in Tables S6 and S7.
The energy profiles for the reactions in Scheme 9b are shown in
Fig. 7 (values in Table S5).
Fig. 4. Optimized structures for the hydrolysis reaction of cis-[Pt(PMe3)2(etga)]. a) First step; b) second step.
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The formation of the intermediate RA1-O2 is slightly energetically
favored, while RA1-O1 formation energy is slightly positive. Also in
this case, the transition states of both O1 and O2 paths have a penta-co-
ordinated structure with imaginary frequencies of 87 cm−1 for TS-O1
and 78 cm−1 for TS-O2. The calculated Ea values are 14.4 kcal mol
−1
and 15.7 kcal mol−1 for O1 and O2 path, respectively. The O1 opening
produces the mono-aqua derivative, while in the O2 path a proton
transfer leading to the mono-hydroxo complex occurs. Also the PA1-
O1 is more stable than PA1-O2 [ΔE = E(PA1-O1) – E(PA1-
O2) =−1.7 kcal mol−1, Table S5]. In conclusion, in the first hydrolysis
step the O1 path, leading to amonoaqua Pt complex, should bemore fa-
vored than the O2 one (which leads to a monohydroxo Pt complex).
In the second hydrolysis (Fig. 7b), transition states with a penta-co-
ordinated Pt geometry are obtained characterized by a single imaginary
frequency (89 cm−1 for TS2-O1 and 83 cm−1 for TS2-O2). The calculat-
ed Ea values are 11.9 kcalmol
−1 and 9.5 kcal mol−1 for O1 and O2 path,
respectively (Table S5). Therefore, also for cis-[Pt(PMe3)2(3-Hfl)]
+ the
first hydrolysis is the rate determining step of thewhole process leading
to the complete release of the 3-Hfl. Furthermore, by analyzing the ob-
tained Ea values (Fig. 7b, Table S5), it emerges that the secondhydrolysis
step proceeds faster for cis-[Pt(PMe3)2(3-Hfl)]
+ (bothO1 andO2paths)
than for cisplatin and cis-Pt(PMe3)2(egta). On the contrary, the first
hydrolysis is slower for cis-[Pt(PMe3)2(3-Hfl)]
+ with respect to cis-
[PtCl2(PMe3)2] (Fig. 7a, Table S5).
In the O1 path the final product shows a proton transfer from the
water molecule bonded to platinum to the closer oxygen of the ligand,
while in the O2 path this does not occur. The final product of cis-
[Pt(PMe3)2(3-Hfl)]
+ hydrolysis is the monoaqua-monohydroxo com-
plex (cis-[Pt(PMe3)2(H2O)(OH)]
+, Fig. 6b).
On the basis of DFT calculations, some synergic cytotoxic effect be-
tween platinum center and 3-hydroxyflavon leaving group effect
might be expected for cis-Pt[(PMe3)2(3-Hfl)]
+, because the mono-
aqua platinum species formed in both first and second hydrolysis
steps, could coordinate DNA [36]. On the other hand, the theoretical hy-
drolysis activation energy (mainly affected by the trans influence of the
carrier ligand), is significantly lower with respect to cisplatin (Fig. 7)
and could lead to fast deactivation of platinum compound and thus
poorer biological activity [93].
3.4. Cytotoxicity
The antiproliferative potential of the new complexes 2 and 3 was
assessed in human glioblastoma (U87) and human breast cancer
(MFC-7) cells, being the first cellular line sensitive to cisplatin and the
latter cisplatin resistant. Since complex 2 was found to be photosensi-
tive (see paragraph 3.2), cytotoxicity studies were carried out in the
dark for all examined compounds, in order to avoid photodegradation
processes. Complex 1was not taken into consideration, due to the diffi-
culty in separating it from the side-products formed in minor amounts
during its synthesis.
For comparison purposes, the cytotoxicity of 3-hydroxyflavone,
ethyl gallate and cis-[PtCl2(PPh3)2] was evaluated under the same ex-
perimental conditions employed for the othermetal complexes. Cellular
viability was determined by colorimetric MTT assay [MTT = 3-(4,5-di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. The viability of
cells in the presence of the tested compoundswas compared to that ob-
served for control cultures and the inhibition of growth (%) was calcu-
lated. The half maximal inhibitory concentration (IC50) values
obtained following exposure to increasing concentrations (from 0.10
to 200 μM) of the different compounds for 72 h are shown in Table 6,
which reports also the relevant IC50 values for cisplatin taken from the
literature [94,95].
At the tested concentrations, the Pt complexes 2 and 3 showed a dif-
ferent biological effect on bothU87 andMCF-7 cell lines (Table 6), being
2more cytotoxic than 3, following the same trend observed for the rel-
evant ligands. In fact, 3-hydroxyflavone was found more cytotoxic than
ethyl gallate on the examined cell lines. This behavior confirms what
predicted by DFT calculations (see previous paragraph), that is com-
plexes 2 and 3 easily lose their natural ligands with the consequence
that their cytotoxicity is mainly affected by the biological activity of
their leaving groups. Theoretical studies also predicted that the plati-
num species (intermediates and final product) obtained from the hy-
drolysis of complex 3 should poorly interact with DNA: thus the
cytotoxicity of complex 3 is expected to be determined by ethyl gallate
only (no synergic effect). Interestingly, considering the cytotoxicity on
MFC-7 cells, complex 2 is more active than the basic compounds, i.e.
3-hydroxyflavone and cis-[PtCl2(PPh3)2], the latter having a very negli-
gible in vitro cytotoxicity (IC50 N 200 μM) for both studied cell lines. The
synergism shown by 2 could be related to the formation of mono-aqua
platinum species which are known to interact with DNA [36].
It is widely recognized that the anticancer mechanism of cisplatin
and, by extension, of the related platinum drugs is formed by four
steps: (i) cellular uptake, (ii) aquation/activation, (iii) DNA binding
and (iv) cellular processing of DNA lesions leading to apoptosis [96].
Two pathways have been proposed for the first step: passive diffusion
through the plasmamembrane and active transport mediated bymem-
brane proteins [97]. The majority of the academic world thinks that
rapid diffusion is the predominant cisplatin uptake mechanism [98].
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Fig. 5. Activation energy profiles of: a) the first and b) the second step of the hydrolysis reaction of cis-[Pt(PMe3)2(etga)] (both O1 and O2 paths), cis-[PtCl2(PMe3)2] and cisplatin in PCM
water. The energy values for cisplatin are taken from ref. [37].
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For example, drug accumulation experiments [99] carried out on two
different cancer lines (colon carcinoma and colon mesothelioma) have
shown that the intracellular (nucleus + cytoplasm) Pt concentration
was 3–6 μM after one hour of 5 μM cisplatin incubation. In other
words, the measured intracellular Pt concentration was quite similar
to the Pt concentration in the medium after only one hour of exposure.
In another study [100], cellular platinum accumulation measure-
ments were carried out on MDA-MB-435 breast cancer cells and PC-3
cells after 2 h, 4 h and 6 h of treatment at 20 μM of cisplatin and of
some new neutral and cationic Pt complexes. These experiments have
shown that inmost cases (including cisplatin) the cellular Pt concentra-
tion found after 2 hwas approximately equal to thatmeasured after 6 h.
Notably, a higher platinum cellular uptakewas found for cationicmono-
nuclear platinum compounds with respect to cisplatin. Also Quirante
and coworkers [101] noticed the same behavior for their cationicmono-
nuclear Pt compounds.
To gain insights into the stability of complex 2 under physiological
conditions, a 200 μM solution of 2 in cell culture media kept in the
dark at 37 °C was time monitored by means of 31P{1H} and 1H NMR.
We found out that compound 2 completely lost its polyphenol ligand
after 3 h under physiological conditions. On the basis of the all over re-
ported findings, we could assume that 3 hmight be a reasonable period
of time for complex 2 to pass the cell's lipid bilayer (compound 2 bears
lipophilic thiphenylphosphane ligands).
Fig. 6. Optimized structures for the hydrolysis reaction of cis-[Pt(PMe3)2(3-Hfl)]
+. a) First step; b) second step.
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On the other hand, some studies have reported that cell uptake per
se may not necessarily give an indication of the level of the antitumor
activity [102],
We also evaluated the combination index (CI), which allows to
compare the single-drug dose-response to that of their combination.
In complexes 2 and 3 the ratio between cis-[PtCl2(PPh3)2] and 3-
hydroxyflavone or ethyl gallate was set to 1:1, respectively. The
isobologramstudy evidenced that CI valueswere always N1 for complex
3, indicating no synergic effect between the polyphenol ligand and the
Pt moiety. For complex 2, the observed CI value was b1 when the frac-
tional effect (Fa) ranged from 0 to 0.7, and higher than 1 when Fa value
was above 0.7 (Fig. 8).
4. Conclusions
This article describes the synthesis and in vitro anticancer fea-
tures of new cis-diphenylphosphane platinum(II) complexes bearing
biologically active polyphenolate leaving group ligands. The coordi-
nation modes of deprotonated quercetin, 3-hydroxyflavone and
ethylgallate to platinum(II) were determined in solution by NMR
spectroscopy and in the solid state by X-ray diffraction. Biological as-
says carried out on complexes 2 and 3 indicate that these compounds
did not show higher cytotoxicity compared to cisplatin for the con-
sidered cell lines (U87 and MCF-7). Theoretical calculations confirm
that the studied complexes easily release their biologically active li-
gand in solution, thus suggesting a possible origin of the fact that
their cytotoxicity is at least similar to that of their natural leaving
groups.
Although complexes 2 and 3 have similar O,O chelate structure,
there is a small difference in their natural ligand coordination mode,
being the leaving group a deprotonated α-hydroxy ketone in the first
complex and a double deprotonated 1,2-diol in the second one.
This small difference may affect the biological activity of the new
compounds.
In fact, a biological synergic effect between the ligand and the
starting platinum compound was interestingly observed for complex 2
bearing 3-hydroxyflavonate, for which mono-aqua platinum species
(able to coordinate DNA) smoothly form in both first and second hydro-
lysis steps, according to theoretical studies. However, the cytotoxicity of
cisplatin is still higher than that of complex 2 one because of a too fast
hydrolysis rate of the latter, due to the higher trans effect of the carrier
ligand.
When compound 3 is considered, theoretical calculations suggest
that the lack of synergic cytotoxicity effect may be due either to pro-
duction of relatively inert mono- and di-hydroxo complexes under
physiological conditions (determined by ethyl gallate leaving
group) and to a too fast hydrolysis rate (determined by carrier ligand
features).
In conclusion, this study suggests that fine tuning of chemical pa-
rameters of both leaving groups and carrier ligands is a key step in
designing biologically active Pt complexes. Therefore, further studies
are warranted to synthesize new platinum(II) 3-hydroxoflavonate
complexes bearing carrier ligands different than triarylphosphanes.
Table 6
Cytotoxicity of hydroxyflavone, ethyl gallate, Pt complex 2, Pt complex 3, cis-
[PtCl2(PPh3)2] and cisplatin toward U87 and MCF-7 cancer cell lines.
IC50 (μM)
Compound U87[a] MCF-7[a]
Complex 2 26.3 ± 2.1 55.2 ± 1.7
3-Hydroxyflavone 27.5 ± 2.3 108.1 ± 3.5
Complex 3 123.7 ± 3.8 N200
Ethyl gallate 97.7 ± 2.6 N200
cis-[PtCl2(PPh3)2] N200 N200
Cisplatin 1.76 ± 0.22[b] 14 ± 3[c]
[a] Cells were seeded at a density of ∼5000 cells per well into 96-well microliter plates.
Following overnight incubation, cells were treated with a range of drug concentrations
(from 0.10 to 200 μM) and incubated at 37 °C under a humidified atmosphere with 5%
CO2 for a period of 72 h. Data are themean values± SD of three independent experiments
performed in triplicate.
[b] Data taken from ref. [94].
[c] Data taken from ref. [95].
Fig. 8. CI/fractional effects (Fa) curve of complex 2 for MCF-7 cells. According to the
equation of Chou-Talalay for two drugs [60], CI = (D)1/(Dx)1 + (D)2/(Dx)2, where
(Dx)1 and (Dx)2 are the doses (concentrations) of 3-hydroxyflavone alone and cis-
[PtCl2(PPh3)2] alone, respectively, that inhibit x% of cell viability. (D)1 and (D)2 are the
doses of 3-hydroxyflavone and cis-[PtCl2(PPh3)2], respectively, used in combination
[(D)1 + (D)2] {[(D)1 + (D)2] = dose of complex 2, (D)1 = (D)2}, able to inhibit x% of
cell viability. CI = 1 indicates an additive effect in the absence of synergism or
antagonism; CI b 1 indicates synergism; CI N 1 indicates antagonism.
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Fig. 7.Activation energy profiles of: a) thefirst and b) the second step of the hydrolysis reaction of cis-[Pt(PMe3)2(3-Hfl)]
+ (bothO1 andO2paths), cis-[PtCl2(PMe3)2] and cisplatin in PCM
water. The energy values for cisplatin are taken from ref. [37].
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The knowledge of the speciation of fluoroquinolones is of great actuality for the implications on the activity,
bioavailability and pharmacokinetics. Literature reports a number of contrasting evaluations on the existence
of tautomeric forms of mono-protonated species, described by a set of protonation micro-constants. Here the
protonation sequence and the related protonation constants of four representative molecules are evaluated by
a combined potentiometric-spectrophotometric method. The experimental observations necessary to differenti-
ate between a protonation scheme represented by macro-constants alone, and the one that requires the intro-
duction of a micro-protonation scheme, are clearly delineated based on a careful analysis of experimental data
and of simulatedmodels. The role of the mediumwas investigated and UV–vis spectra in water- methanol solu-
tion were analyzed. The existence of the zwitterionic species alone at physiological pH in water, and an increase
of the relative amount of the neutral species with the lipophilicity of the mediumwere remarked. This surely af-
fects the bioavailability of FQs, with the increase of the neutral species when the molecules approach the local
lipophilic environment close to the cellular membranes. NMR studies allowed the attribution of the protonation
sites of the different forms. Quantum chemical evaluation of all the possible existent formswith different proton-
ation degrees and indifferent sites strongly substantiates the experimental results. The study of the relevant fron-
tier molecular orbitals completed the detailed theoretical characterization of the species.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
Quinolones are a family of synthetic antibacterial agents, structural-
ly related to nalidixic acid, introduced in clinical practice in the sixties
for the treatment of urinary infections (Emmerson and Jones, 2003).
Quinolones are based on the skeleton of 4-oxo-1,4-dihydro-3-
quinolinecarboxylic acid (Scheme 1a), whose pharmacological and
pharmacokinetic properties were improved by the insertion of a fluo-
rine atom in position 6 and successively of a piperazine unit in position
7 (Scheme 1b).
Themechanism bywhich fluoroquinolones (FQ) exert their antibac-
terial activity consists in the inhibition of the activity of bacterial topo-
isomerase by interaction with the single stranded DNA gyrase (Fan et
al., 1995). The significance of the pH both in the activity and in the phar-
macokinetics of a drug is well known and principally related to its acid-
base properties. The knowledge of the speciation pattern of a drug is
therefore of paramount importance from the pharmacological point of
view (Park et al., 2002). The protonation equilibria of FQs have received
wide attention and several techniques have been used to evaluate both
the equilibrium constants and the proton coordination sites (Ross and
Riley, 1990; Takács-Novák et al., 1990; Rusu et al., 2012; Ross and
Riley, 1992; Wallis et al., 1994; Hernàndez-Borrell and Montero, 1997;
Park et al., 2000). FQs are ampholyte compounds, which present multi-
ple sites that can be protonated depending on the pH. However, the re-
ported acid–base properties of FQs are controversial with regard to the
values of protonation constants and the number of basic sites (Rusu et
al., 2012). The FQs might exist in five different pH-dependent proton-
ation species, namely di-cation H3FQ2+, cation H2FQ+, zwitterion
zHFQ, neutral species nHFQ and anion FQ−. A scheme of the possible
equilibria involving these species is reported in the Supporting Informa-
tion (ESI), together with the relationships between the micro- and
macro-constants of protonation. At the isoelectric point of FQs in
water (about pH 7), the mole fractions of the zHFQ and nHFQ species
reach their maximum values. It seems that zHFQ is themost stable spe-
cies (Ross and Riley, 1990; Barbosa et al., 1998), even if some theoretical
works predict that the most stable species should be nHFQ (Musa and
Eriksson, 2009; Vitorino et al., 2006). In these theoretical works the
polarizable continuum model (PCM) was employed to simulate the
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solvent, but when a discrete-continuum approach was employed (i.e.
some solvent molecules placed near the ionizable groups of solute)
the reverse order of stability was obtained (Lambert et al., 2007).
The H3FQ2+ species (existing only in extremely acidic conditions) can
be protonated either at the piperazine ring (Rusu et al., 2012; Lin et al.,
2004) or at carbonyl oxygen (Gerasimenko et al., 2008; Polishchuk et
al., 2008).
The existence of micro-protonation equilibria implies tautomeric
forms with the same degree of protonation, with the protons located
on different basic sites of the molecule. In particular, in the zwitterion
zHFQ the carboxylic group is in the negatively charged form (carboxyl-
ate) and the 4′ nitrogen atom in piperazine ring is protonated and pos-
itively charged. In the neutral form nHFQ, the carboxylic group is
protonated, and the nitrogen atom not. The micro-protonation con-
stants determine the relative amount of these two forms. The two
tautomers have chemical properties markedly different, which depend
on the different interactions with the medium and with the compo-
nents of physiological barriers, thus determining both the solubility
and the bioavailability of the molecule. The pharmacodynamics and
the pharmacological properties strictly rely on the prevalence of the
zwitterion or of the neutral species. The disagreement on the numerical
values for themicro-constants reported in literature depends on the dif-
ferent used approaches, and on different assumptions, but mainly on
the little attention paid to the information contained in the experimen-
tal results, which allows to discriminate whether micro-protonation
equilibria exist or not, disregarding limiting assumptions that can inval-
idate the final conclusions. Moreover, once the existence of tautomers
has been ascertained, this information allows quantifying their relative
amounts through a correct and reliable evaluation of the micro-
constants.
Scheme 1. a) Structure of 4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and b) numbering scheme of fluoroquinolones.
Table 1
Trade name, IUPAC formula, structure and acronym of studied compounds.
Name IUPAC formula Molecular structure and acronym
Ciprofloxacin 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
Lomefloxacin 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid
Norfloxacin 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-
dihydroquinoline-3-carboxylic acid
Ofloxacin 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-
2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-
carboxylic acid
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In this paper, we present a thorough study on the protonation
equilibria of four representative FQs (Table 1) by using a robust com-
bined potentiometric-spectrophotometric procedure of high precision
and accuracy (Crisponi et al., 2004; Nurchi et al., 2013).
The experimental evidence necessary to introduce a micro-proton-
ation scheme is discussed, following a careful analysis of UV–vis spectra
and NMR data as a function of pH. The experimental indications are
corroborated with the aid of simulated speciation models. The role of
the medium on the molecular structure and relative stability of the
differently protonated forms was investigated in water and in water-
methanol solutions on the representative compound CFX.
Density Functional Theory (DFT) calculations were run to provide
geometries, relative stability, absorption spectra of the different proton-
ation states of CFX in gas phase and PCM solvent. A discrete-continuum
approach was also introduced, to include explicit hydrogen bonds.
2. Experimental
2.1. Reagents
Lomefloxacin hydrochloride and Ofloxacin were Sigma products.
Norfloxacin, and Ciprofloxacin were Fluka products. KOH and KCl, HCl
and methanol were purchased from Aldrich. The compounds were
used without further purification. Potassium hydroxide carbonate free
solutions were prepared as reported in a previous paper (Nurchi et al.,
2011).
2.2. Potentiometric-spectrophotometric measurements
2.2.1. Water solutions
Protonation equilibria were studied in a thermostatted glass cell
equipped with a magnetic stirrer, a Metrohm LL UNITRODE glass elec-
trode connected to a Metrohm 691 pH-meter, a microburet delivery
tube connected to a Dosimat 665 Metrohm titrator, an inlet–outlet
tube for Argon and a 0.2 cmpath length fibre optic dip probe, connected
to a Varian Cary 50 UV–vis spectrophotometer. This device allows
potentiometric and spectrophotometric measurements on the same
system at the same time. Ligand solutions (2.5 × 10−4 M; 0.1 M KCl
ionic strength) were titrated at 25.0 °C with carbonate-free KOH 0.1 M
(Albert and Serjeant, 1984). The electrode was calibrated daily by titrat-
ing HCl with KOH in the same experimental conditions as above and the
resulting data were processed according to the Gran procedure (Gran,
1952). The ionization constants were calculated using Hyperquad2013
and HypSpec2014 programs (http://www.hyperquad.co.uk/HQ2013.
htm, 2016). The first two protonation equilibria were followed with a
base titration of the FQ solutions containing hydrochloric acid at a con-
centration twice than that of the ligand. The study of the third proton-
ation step required the use of highly concentrated acid solutions and
was studied only by UV–vis spectroscopy. Hydrochloric acid was used
as the most suitable acid thanks to the non-oxidizing nature. Proper
amounts of ligands were dissolved in HCl solutions ranging from 0.1 M
to 6.0 M. The spectra of these solutions were collected in the range
200–450 nm using a 1 cm quartz cell. Instead of pH, Ho functions were
used in the calculations (Hammett and Deyrup, 1932; Paul and Long,
1957; Aragoni et al., 1995).
2.2.2. Water-methanol solutions
The titrations of CFX 2.5·10−4 Mwere performed in a 50/50 water/
methanol solution with KOH 0.1 M, at 25 °C and 0.1 M KCl ionic
strength. The potentiometric and UV–vis data were collected in the
same experimental conditions as in water alone.
2.3. NMR spectroscopy
Nuclear Magnetic Resonance (NMR) measurements were per-
formed on a Bruker Ascend™ 400 MHz spectrometer equipped with a
5 mm automated tuning and matching broadband probe (BBFO) with
z-gradients, as previously described (Zoroddu et al., 2007; Zoroddu et
al., 2010; Peana et al., 2013; Zoroddu et al., 2008; Zoroddu et al., 2014;
Zoroddu et al., 2009).
NMR experiments were carried out using 5–8 mM concentration of
CFX or OFL in 90/10 (v/v) H2O/D2O or D2O at 298 K in 5 mm NMR
tubes. The pD values measured for the D2O solutions were converted
into the pH values using the deuterium isotopic correction pH =
pD − 0.4 (Alner et al., 1967). 2D 1H-13C heteronuclear correlation
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Fig. 2. UV–vis spectra acquired in the acidity range H°−1.7–pH 1.0, in the spectral range
200–420 nm for CFX, as a “typical” case.
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Fig. 1. UV–vis spectra acquired during the basic titration of CFX, as a “typical” case, in the
spectral range 200–400 nm.
Table 2
Protonation constants (log βi and log Ki) of the FQs.
Ligand Log β1 Log K1 Log β2 Log K2
Log K2
spec data Log β3 Log K3
NOR 8.78(2) 8.78 14.92(2) 6.14 6.12(2) 14.36 −0.56(2)
CFX 8.56(1) 8.56 14.61(2) 6.05 6.06(2) 13.89 −0.72(2)
LFX 9.01(1) 9.01 14.88(1) 5.87 5.85(3) 13.96 −0.92(3)
OFL 8.28(1) 8.28 14.28(1) 6.00 6.02(2) 13.48 −0.80(2)
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spectra (HSQC) were acquired using a phase-sensitive sequence
employing Echo-Antiecho-TPPI gradient selection with a heteronuclear
coupling constant JXH = 145 Hz, and shaped pulses for all 180° pulses
on f2 channel with decoupling during acquisition. Sensitivity improve-
ment and gradients in back-inept were also used. Relaxation delays of
2 s and 90° pulses of about 10 μs were employed in all the experiments.
Solvent suppressionwas carried out using excitation sculptingwith gra-
dients. The spin-lock mixing time of TOCSY experiments was obtained
with MLEV17. 1H-1H TOCSY spectra were performed using mixing
times of 60 ms. A combination of 1D, 2D TOCSY experiments were
used to assign all the proton signals of the molecules at different pH
values. All NMR data were processed with TopSpin (Bruker Instru-
ments) software and analyzed by Sparky 3.11 and MestRe Nova 6.0.2
(Mestrelab Research S.L.) programs.
2.4. Computational details
DFT calculations have been carried out for the CFX fluoroquinolone.
All geometries of CFX in different protonation states have been carried
out in vacuum using the B3LYP functional (Becke, 1993; Lee et al.,
1988) and a gaussian-type 6-311G(d,p) basis set for all atoms. This
level of theory has been previously demonstrated to provide accurate
geometries and thermochemical properties for many molecular
systems (Endrizzi et al., 2015; Mendonça et al., 2013; Del Piero et al.,
2006; Melchior et al., 2004; Melchior et al., 2013; Comuzzi et al., 2003;
Fries et al., 2010).
Solvent effects were taken into account by two alternative ways: a)
implicit solvent introduced by the PCM method (Tomasi et al., 2005);
b) a discrete-continuum approach obtained by combining the PCM sol-
vationwith the effect of a small numberwatermolecules placed close to
the protonated groups of the solute. In the latter case, water molecules
were selected by examining based the average number of waters that
form hydrogen bonds with the ionizable groups of CFX in a molecular
dynamics simulation (performed using Gromacs 5.0.4) (摇Hess, 2008)
using the GROMOS force field (Schmid et al., 2011). A cluster composed
by 10watermolecules and CFXwas constructed by taking a representa-
tive snapshot from the MD simulation and then optimized at DFT level.
In all cases, to confirm that stationary points were true minima,
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Fig. 4. Speciation plots of simple bi-protic acidswith log K 2=8 and variable log K 1. The trend of the sum of the relative concentration of the species HFQ and FQ− is remarked as red line.
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Fig. 3. Speciation plots of CFX, as a “typical” case.
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vibrational analysis has been carried out to confirm the absence of imag-
inary frequencies. Free energies were calculated by the total electronic
energies and adding zero point energy (ZPE) and thermal corrections
at 298.15 K.
Excitation spectra of the H3FQ2+, H2FQ+, zHFQ, nHFQ and FQ−were
calculated using the time-dependent formalism (TD-DFT) (Scalmani et
al., 2006). DFT calculations were performed with the Gaussian 09 pro-
gram (Frisch et al., 2009).
3. Results and discussion
Three protonation steps characterize the studied FQs, the first takes
place aroundpH8.5, the secondaroundpH6 and the last at highly acidic
conditions, according to the general scheme:
FQ− þ Hþ ⇄ HFQ ð1Þ
HFQ þ Hþ ⇄ H2FQ
þ ð2Þ
H2FQ
þ þ Hþ ⇄ H3FQ
2þ ð3Þ
The first two protonation equilibria were studied by potentiometric
titrations alone at 0.1 M KCl ionic strength. The resulting data were
processed by Hyperquad program (http://www.hyperquad.co.uk/
HQ2013.htm, 2016) and allowed the calculation of the protonation con-
stants, log K1 and log K2 (Table 2).
The three protonation constants K1, K2 and K3 are defined on the
base of the equilibria 1–3 as
K1 ¼
½HFQ 
½FQ− ½Hþ , K2 ¼
½H2FQ
þ 
½HFQ ½Hþ and K3 ¼
½H3FQ
2þ 
½H2FQ
þ ½Hþ , and the cumulative
protonation constants, according to IUPAC (http://www.iupac.org/
goldbook/P04909.pdf), as β1 = K1, β2 = K1K2 and β3 = K1K2K3.
The UV–vis spectra, collected during the basic titration of CFX, as a
“typical” case, relative to the first two protonation steps in the pH
range 4–9.1, are presented in Fig. 1. The analogous spectra for all the
four fluoroquinolones are reported in Supplementary Information
(Fig. S1s). No spectral change occurs during the first protonation step.
Evidence of that is given by the overlapping of the spectrum collected
at pH 9.1, where the deprotonated species FQ− exists at 50–90%, and
that at pH 7.5, where the concentration of the neutral formHFQ reaches
its maximum (both spectra are reported in red in Fig. 1).
At lower pH values, where the second protonation step occurs,
major variations are the decrease of the intensity of the principal band
at about 280 nm accompanied by its shift to lower wavelengths, and
the increase of the bands between 320 and 360 nm. Sharp isosbestic
points are observed. These remarkable spectral variations connected
with the second protonation equilibrium permitted a further evaluation
of log K2 (Table 2, log K2 spec data).
The study of the third protonation step, conducted by UV–vis spec-
troscopy, required the use of highly concentrated acid solutions. Proper
amounts of ligands were dissolved in HCl solutions ranging from 0.1 M
to 6.0 M. Instead of pH, Ho functions were used in the calculations
(Hammett and Deyrup, 1932; Paul and Long, 1957; Aragoni et al.,
1995). The resulting spectra for some representative solutions of CFX,
as a “typical” case, are reported in Fig. 2.
By increasing acid concentration a new band appears at 360–400 nm
for all four ligands (Fig. 2 and Fig. S2s), accompanied by a decrease of the
other bands. In the case of OFL, also a red shift of the intense band at
292 nm is observed. Sharp isosbestic points accompany spectral varia-
tions. It has to be underlined that the ionic strength at which that data
were collectedwas not constants due to the extremely acidworking solu-
tions. The log K3 values obtained from these data are reported in Table 2.
200 240 280 320 360 400
Wavelength (nm)
0.0
0.4
0.8
1.2
1.6
2.0
A
bs
or
ba
nc
e
pH 4.0
pH 7.0pH 10.0
Fig. 6.UV–vis spectra acquired during the basic titration of CFX in 50:50 water-methanol,
in the spectral range 200–420 nm.
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The speciation plots reported in Fig. 3 for CFX, as a “typical” case and
in Fig. S3s for all the fourfluoroquinolones, clearly show that at neutral -
physiological pH the species HFQ is the predominant one (N90%) to-
gether with some percent of both the positively charged H2FQ+, and
the anionic species FQ−. The species HFQ, according to the current liter-
ature, could exist either as zwitterion form zHFQ with the positive
charge on the protonated N4′ and the negative on carboxylate, or as
neutral species nHFQ.
According to Ross and Riley (Ross and Riley, 1992) “The zwitterion
species and the neutral species are likely to have different distribution
properties and therefore to fully understand and interpret differences
in bioavailability and the structure-activity relationships of these com-
pounds, it is necessary to consider their microscopic dissociations”.
Based on the above considerations several articles proposed amicro-
scopic dissociation scheme (Supplementary Information). These papers
can be classified according to the different approaches they used, based
on:
1) the assumption that the basic groups are so spatially apart that it is
reasonable to assume that the charge of one functional group will
not significantly affect the protonation constant of the other group
(Ross and Riley, 1990);
2) the knowledge of the protonation macro-constants of parent and
model compounds (ester derivatives) can be an adequate set of
data for calculating all the protonation micro-constants (Rusu et
al., 2012; Lin et al., 2004);
Fig. 8. Selected portion of 1H NMR spectra of CFX quinolone molecule at variable pH.S2NMR–S3NMR and Tables S2NMR–S3NMR). This behavior is in agreement with the first two proposed
protonation equilibria. Indeed, the shifts observed in the NMR spectra by increasing the pH, are towards higher fields for the protons neighboring the site of protonation. These shifts
are in agreement with the shielding following the process. In particular, the detected trend supports the observation that, whereas the first protonation involves N4′ in the piperazine
moiety, to form the charged HN4′+ species, the second protonation involves the carboxylate group to form COOH.
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at 338 nm (triangles).
385V.M. Nurchi et al. / European Journal of Pharmaceutical Sciences 93 (2016) 380–391
3) the spectral variations, with the assumption that they can be
completely associated to the protonation of a single group, the carbox-
ylate group in the case of FQs. The fraction of carboxylate group, inde-
pendent on N4′ ionization, can be calculated from the equation 4,
αCOO− ¼
ApH−ACOOH
ACOO−−ACOOH
ð4Þ
where αCOO- is the fraction of FQ as zwitterion, ApH is the absorbance at
a given pH value, ACOOH is the absorbance at an acid pH value in which
the carboxylic group is completely protonated, and ACOO- is the absor-
bance at a pH value in which the carboxylic group is completely
deprotonated (Takács-Novák et al., 1990; Hernàndez-Borrell and
Montero, 1997).
Some concerns should be raised regarding the points listed above: 1)
the total charge of the molecule always influence its protonation equi-
libria, in different amounts according the distance; 2) although this ap-
proach had historical merits in the determination of the complete
protonation scheme for simple amino acids (Edsall and Blanchard,
1933; Edsall et al., 1958), it has some limits, taking in mind that the
diprotic acids are not equivalent to the ester derivative models; 3)
even if potentiometric data alone allow obtaining correct macroscopic
protonation constants, they do not contain the necessary information
to infer a micro-protonation scheme.
The assumption that a micro-protonation scheme is necessary to
correctly describe the studied system should be based on experimental
observations appropriate to discriminate between the two opposite
situations outlined in the following:
– the macro-protonation constants (calculated from potentiometric
data, which depend only on the protonation degree of themolecule)
completely describe the system since the first proton is acquired
from only one site, leading to a single zHFQ or nHFQ species;
– the introduction of a micro-protonation scheme is necessary to de-
scribe the system. In this case, the first proton is acquired from the
two different sites leading to the contemporary presence of both
the species zHFQ and nHFQ, whose amounts depend on the ratios
of micro-constants.
Some simulated examples can be of great aid for defining the spec-
tral trend we should expect during a titration of a diprotic acid in the
two different situations, making use of the unique assumption that
only the protonation of the carboxylate group is accompanied by mea-
surable spectral variations. A further requirement is that the experi-
mental device allows the collection of a sufficient number of high
quality spectra in the pH range log K2±2. In the first casewe calculated
the speciation plots for different couples log K1− log K2 inwhich the log
K2 of carboxylic group was held constant (log K2 = 6) and the log K1
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Fig. 9. 1H NMR chemical shifts of some representative protons of CFX vs pH. The experimental chemical shifts are reported as points, and the trends, calculated from the speciation plots
and from the intrinsic chemical shifts obtained with the HypNMR software (www.hyperquad.co.uk/hypnmr.htm), as continuous lines. Two grid lines are drown at pH values
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assumed the decreasing values 9, 8.5, 8 and 7.5, i.e. the Δlog K was de-
creased from 3 to 1.5. The speciation plots in Fig. 4 point out that, as
Δlog K decreases, the amount of the mono-protonated species HFQ in
its maximum drops from ~96% to ~73%, with corresponding increasing
amounts both of the bi-protonated H2FQ+ and of the completely
deprotonated form FQ− at the pH value of the maximum of the mono-
protonated species HFQ.
If spectral variations depend only on the protonation state of the car-
boxylic group, the band connected to the protonated form COOH de-
creases with pH in a way proportional to the blue curve related to the
Fig. 10.Minimum energy structures of: a) FQ−, nHFQ and zHFQ\\N4′ for CFX; b) zHFQ; c) H2FQ
+ and d) H3FQ
2+.
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H2FQ+ species, while that of carboxylate increases with a trend propor-
tional to the sum of the HFQ and FQ− curves (red curve). The trend of
these curves,which is typical of amonoprotic acidwith a logK 6, is iden-
tical in all the four cases, not influenced at all by the protonation state of
the amino group.
As far as the second case is concerned, in Fig. 5a a typical behavior of
a diprotic acid is reported.
This acid is characterized by the macro-protonation constants log
K1 = 8 and log K2 = 6 (as in the third case in Fig. 4) and by the
micro-constants log KzHFQ = 7.8 (chosen by us) and log KnHFQ =
7.5671 (calculated with the restraints imposed by the macro-constant,
Scheme S1). The species zHFQ represents the zwitterion protonated
on the piperazine nitrogen atom N4′ and nHFQ the neutral species pro-
tonated on the carboxylate. The band connected to the protonated form
COOH decreases with pH in a way proportional to the curve in blue. In
this case the blue curve does not correspond to that of H2FQ+ species
(that can lose the first proton not only from the carboxylic group but
also from the nitrogen atom N4′) but to the sum of the H2FQ+ and
nHFQ species, i.e. to all the species protonated on the carboxylate
group. The band of carboxylate increases with a trend proportional to
the sum of the zHFQ and FQ− curves (red curve). The trend of these
blue and red curves differs from that of a simple monoprotic acid in an
amount that depends on the weight of the nHFQ and of zHFQ species.
Furthermore, there is no symmetry between the two curves. In Fig. 5b
the sum zHFQ + FQ− is reported for systems always characterized by
the same macro-protonation constants log K1 = 8 and log K2 = 6, and
by variable log KzHFQ, and log KnHFQ, in order to have an increasing
weight of the nHFQ form. A progressive deviation from the trend of a
simple monoprotic acid is apparent. Hence the trend of the absorbance
vs pH clearly remarks the presence or not of micro-protonation equilib-
ria in a non-questionable way.
Coming back to our experimental observations, the illustrative case
of ciprofloxacin (not different from that of the other examined FQs) is
analyzed, by comparing the UV–vis data collected in water (Fig. 2)
and in water-methanol solution (Fig. 6).
The spectra in Fig. 2 and in Fig. 6 were decomposed in the constitu-
ent Gaussian peaks,1 and the normalized heights of the bands at
282 nm, attributable to the carboxylic group, and those at 338 nm, at-
tributable to carboxylate, are reported in Fig. 7 togetherwith the species
distribution. The estimated heights of the spectral bands are more accu-
rate than the absorbance values measured at the wavelengths of band
maxima, since they derive from a large number of experimental points,
and are depurated from the contribute of any overlapping band. The
experimental points in water perfectly overlap the speciation curves
calculated from the macro-constants evaluated from potentiometric
data (Fig. 7, left), similarly to the red and blue curves depicted in
Fig. 5. This confirms that the acid base equilibria of CFX are completely
represented by the macro-constants and nomicro-protonation scheme
has to be introduced.
When the protonation equilibria of CFX is studied in water-metha-
nol solution a different trend is observed (Fig. 6), where the bands of
carboxylate decrease not only in the second protonation step (pH 4–
7) but also in first (pH 7–10). The heights of the bands at 282 and
338 nm reported in Fig. 7 right show the characteristic trend of the
micro-protonation equilibrium depicted in Fig. 5 and well overlap the
sum of the H2FQ+ and zHFQ species and the sum of the nHFQ and
FQ− curves.1 Methanol, less polar than water, stabilizes the neutral
form that appears at a concentration about one half that of the zwitter-
ion species. In this case, the trend of spectral data as a function of pH
permits to ascertain the existence of a micro-protonation equilibrium
in an unequivocal way.
The first two protonation equilibria for FQs have also been studied
by using 1H NMR spectroscopy in the pH range 2–12, to substantiate
1 The values log k1z=7.61(2), log k1n=7.25(2) and log β2=14.01(3) were estimated
from the spectrophotometric measurements using a non-linear least squares procedure
Fig. 11. Optimized nHFQ and zHFQ\\N4′ species with 10 solvating molecules in PCM water.
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the attribution of the protonation sites made based on the UV spectral
results. The 1H spectra and the resonance assignments are reported in
Figures S1NMR–S3NMR and Tables S1NMR–S3NMR. In Fig. 8 selected por-
tions of 1H NMR spectra for CFX molecule at variable pH are reported.
The δ variations in the aromatic region remark that the H2 proton,
close to the carboxylic group in position 3 (Scheme 1b), undergoes the
most pronounced changes (Δδ = −0.228 ppm from pH 5.98 to
pH 9.42, Table S1NMR, Fig. 9). Above pH 8, the protons H3′-5′ on the
piperazine ring and H2’-6′ in the aliphatic region undergo the highest
variation in their chemical shifts (Δδ H3’-5′ = −0.396 ppm and Δδ
H2′-6′ =−0.269 ppm from pH 7.06 to pH 11.3 respectively, Figure 9,
Table S1NMR). The same trend has been also observed for the other
FQs here studied (Figures
The remarkable NMR spectral variations with pH related to the first
protonation allows to attribute it to the zwitterionic species protonated
on N4′ site on piperazine ring, while the second protonation process in-
volves the carboxylate group. These attributions are in good agreement
with the other experimental data and the quantum chemical evaluation
reported in the following.
3.1. Computational results
3.1.1. First protonation and second protonation
Literature reports that formation of both nHFQ (protonation of O11
oxygen) and zHFQ (protonation of N4′ nitrogen, zHFQ\\N4′) species
(Scheme S2a, Scheme S2 shows all tautomeric forms studied in this
work) occur, following the first protonation in Equation (1), and that
zHFQ\\N4′ is the most stable tautomeric species for CFX in water
(Ross and Riley, 1990; Takács-Novák et al., 1990; Rusu et al., 2012;
Ross and Riley, 1992; Wallis et al., 1994; Hernàndez-Borrell and
Montero, 1997; Park et al., 2000). The minimum energy structures of
the possible protonated species in the first protonation step are shown
in Fig. 10a (Fig. 10 shows all structures optimized in this work in
water). Small structural changes occur on going from FQ− to nHFQ,
zHFQ\\N4′ species and selected bond lengths and angles values are re-
ported in Table S1. The calculated structure of CFX compounds in
zHFQ\\N4′ is in good agreement with the experimental ones (Turel et
al., 1997) (Table S2).
Calculations in gas phase show that the nHFQ is more stable than
zHFQ\\N4′, being ΔG = 90.9 kcal mol−1 (ΔG = GzHFQ\\N4′ − GnHFQ)
and the trend in stability does not change introducing the implicit
water (ΔG = 24.7 kcal mol−1). This result is in agreement with other
computational works (Musa and Eriksson, 2009; Vitorino et al., 2006)
but in contrast with the experimental data (Ross and Riley, 1990;
Takács-Novák et al., 1990; Rusu et al., 2012; Ross and Riley, 1992;
Wallis et al., 1994; Hernàndez-Borrell and Montero, 1997; Park et al.,
2000) reported in the literature. Therefore, the effect of the presence
of explicit water molecules solvating the ionisable groups was consid-
ered. Water molecules were introduced to obtain a cluster composed
by CFX and 10 water molecules. The number of water molecules
added to CFX was calculated based on the average number of waters
solvating theMD simulations (see Computational Details). The obtained
cluster was then optimized in PCM water to produce stable final struc-
tures (Fig. 11).
With this last approach, zHFQ\\N4′ species is found to be slightly
more stable than the nHFQ form (ΔG = −2.1 kcal mol−1) in good
agreement with experimental literature (Ross and Riley, 1990;
Takács-Novák et al., 1990; Rusu et al., 2012; Ross and Riley, 1992;
Wallis et al., 1994; Hernàndez-Borrell and Montero, 1997; Park et al.,
2000).
The stabilization of the zHFQ\\N4′ species could be related to the
energy contribution of hydrogen bonds. To clarify this point, the cluster
formation energies for the water cluster in absence of CFX, (ΔE =
Ecluster10w − E10w), and in presence of CFX (ΔX = Xcluser10w-HFQ −
Xcluster10w+HFQ) have been for nHFQ and zHFQ\\N4′ are reported in
Table 3.
The results show that the ΔE without CFX, is negative in both cases,
but theΔE of the nHFQ is about 4 kcalmol−1 lower than the zHFQ\\N4′.
When CFX is present ΔE is muchmore negative for zHFQ\\N4′ than for
nHFQ form (35 kcalmol−1). When the clusters shown in Fig. 11 have
been optimized using methanol as implicit solvent the computed free
energies show that zHFQ\\N4′ is slightly more stable than nHFQ
(ΔG = −1.6 kcal mol−1). Other possible zHFQ form (Scheme S2b)
could be present as the protonation can take place at N1 (zHFQ\\N1),
N1′ (zHFQ\\N1′) or at O4 (zHFQ\\O4). The optimized geometries of
these species in implicit water are shown in Fig. 10b. When zHFQ\\O4
(proton placed in O4 in the starting structure) geometry is optimized
a transfer of the proton occurs from O4 to O11 and the nHFQ species
is obtained. Small structural changes occur on going from zHFQ\\N4′
to zHFQ\\N1 and zHFQ\\N1′, selected bond lengths and angles values
are reported in Table S3.
The relative stability of the forms in Fig. 10b is summarized in Table
4a. TheΔG valueswere calculated as difference between the zHFQ\\N4′
(taken as reference) and other zHFQ forms (ΔG= GzHFQ-n− GzHFQ\\N4′
where zFHQ-n is zHFQ\\N1, N1′).
The results show that in gas phase both zHFQ\\N1 and zHFQ\\N1′
forms are more stable than the zHFQ\\N4′ form, with zHFQ\\N1′ the
most stable species. The introduction of implicit water again leads to
an inversion of this trend and themost stable species is now zHFQ\\N4′
isomer in agreement with experimental data (Ross and Riley, 1990;
Rusu et al., 2012; Ross and Riley, 1992; Wallis et al., 1994;
Hernàndez-Borrell and Montero, 1997; Park et al., 2000).
Fig. 12. Computed UV-vis spectra in implicit water of FQ− (black line), nHFQ (red line),
zHFQ\\N4′ (blue line) and H2FQ+\\O11 (green line) species. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this
article.)
Table 4
Relative stability (ΔG in kcal mol−1) of the different zHFQ forms in gas-phase and PCM
water.
Gas-phase Water
zHFQ isomers
zHFQ\\N4′→ zHFQ\\N1 −6.8 34.8
zHFQ\\N4′→ zHFQ\\N1′ −11.2 9.3
H2FQ+ isomers
H2FQ+\\O11→ H2FQ+\\N1 92.4 59.9
H2FQ
+
\\O11→ H2FQ
+
\\N1′ 119.8 45.4
Table 3
Cluster formation Energy (kcal mol−1).
ΔE
10H2O→ Cluster10w (nHFQ) −18.6
10H2O→ Cluster10w (zHFQ\\N4′) −14.4
nHFQ + cluster10w→ cluster10w-nHFQ −31.7
zHFQ\\N4′ + cluster10w→ cluster10w-zHFQ\\N4′ −66.7
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For the second protonation reaction, the experimental data (Ross
and Riley, 1990; Takács-Novák et al., 1990; Rusu et al., 2012; Ross and
Riley, 1992; Wallis et al., 1994; Hernàndez-Borrell and Montero, 1997;
Park et al., 2000) suggest that there is the formation of the H2FQ+ spe-
cies (protonation of O11, oxygen, H2FQ+\\O11) reported in Scheme
S2c, but also other protonated species could form (Scheme S2d). The
minimum energy structures in water are displayed in Fig. 10c, while se-
lected bond lengths and angles values are reported in Table S4 for opti-
mized structures. The calculated structures of the CFX isomers are again
in excellent agreement with the available X-ray (Turel et al., 1997) ex-
perimental data (Table S5).
The relative stability of these forms are summarized in Table 4b. The
ΔG values were calculated as difference between the H2FQ+\\O11
(taken as reference) and the other H2FQ+ forms (ΔG = GH2FQ+-n −
GH2FQ+\\O11 where H2FQ+-n is H2FQ+\\N1,N1′,O4).
The results in gas-phase andwater show that the H2FQ+\\O11 is al-
waysmuchmore stable than the other possible form, in agreementwith
the literature data (Ross and Riley, 1990; Takács-Novák et al., 1990;
Rusu et al., 2012; Wallis et al., 1994; Hernàndez-Borrell and Montero,
1997; Park et al., 2000).
In summary, for the first protonation it has been observed that the
zHFQ is slightlymore stable than the nHFQ protonated in N4′. The intro-
duction of methanol as a solvent, leads to a slight decrease in the ΔG
with respect to those calculated in water. Furthermore, the zHFQ\\N4′
is the most stable species compared to all other possible tautomeric
zHFQ forms. The most stable form relative to the second protonation
step results to be H2FQ+\\O11.
4. UV-vis spectra
The UV–vis spectra were simulated to have a comparison with the
experimental ones. Calculated absorption spectra are shown in Fig. 12.
Themain absorption peak of these species is located in theUV region
of the spectrum at 260–280 nm and all species display weaker absorp-
tion in the 300–400 nm range. These findings are in good agreement
with experimental spectra (Fig. 1) and with previous computational
works available for NOR (Musa and Eriksson, 2009).
The larger changes in experimental spectra with decreasing pH cor-
respond to the increase of the intensity of the main peak at around
280 nm accompanied by its shift to higher wavelengths, and the de-
crease of the intensity of the bands between 320 and 360 nm. To under-
stand the effect of the protonation site on the absorption spectra, the
relevant frontier molecular orbitals, which play a dominant role in elec-
tronic transitions of FQs, have been reported in Fig. S1 and the main
transitions are reported in Table S6. It is interesting to note that the
bands at higher wavelength, which corresponds to the HOMO →
LUMO excitation is useful to distinguish the zHFQ (λ = 310 nm) from
the nHFQ (λ = 342 nm). This can be explained by observing that the
HOMOof the nHFQorbital it is localized in the piperazine and quinolone
ring, while for zHFQ is located in the carboxyl group (Fig. S1).
With the first protonation step (FQ−→ nHFQ + zHFQ\\N4′) a shift
of the main maximum towards higher wavelengths is observed
(+15 nm in the case of nHFQ, +8 nm for zHFQ\\N4′ and
H2FQ+\\O11) in agreement with the experimental trend. According
to Fig. 12, an absorption peak relative to nHFQ should appear in the
high wavelength range by lowering the pH. On the contrary, in the ex-
perimental titration (Fig. 2) only a weak shoulder appears in the 360–
400nmrange: therefore, it can be proposed that nHFQ species is formed
only in small amounts. The formation of a small shoulder in the low
wavelength range (~210 nm, Fig. 2) is compatible with the formation
of the H2FQ+\\O11 species (green line in Fig. 12).
5. Third protonation
The experimental data show that H3FQ2+ species can be only
formed in extremely acidic conditions. In this case, however, the litera-
ture is ambiguous, indicating that this last protonation could take place
or in N1′ nitrogen of piperazine ring (H3FQ2+\\N1′) (Rusu et al., 2012;
Lin et al., 2004) or in carbonyl oxygen (H3FQ2+\\O4) (Gerasimenko et
al., 2008; Polishchuk et al., 2008). The DFT study was extended also to
these last species, taking into account also the additional H3FQ2+\\N1
form (Scheme S2e). The optimized structures of the different isomers
are displayed in Figs. 10d (some structural parameters reported in
Table S7). In Table S8, the more significant calculated atomic distances
of H3FQ2+\\O4 are inserted together with the available experimental
data (Gerasimenko et al., 2008). TheΔGvalueswere calculated as differ-
ence between the H3FQ2+\\O4 (taken as reference) and other H3FQ2+
forms (ΔG=GH3FQ2+-n−GH3FQ2+\\O4whereH2FQ2+-n is H3FQ2+\\N1
and N1′).
The results shows that the H3FQ2+\\O4 form is the most stable iso-
mer both in gas phase and inwater (Table 5). However, the introduction
of the implicit solvent leads to a drastic reduction of the energy differ-
ences between H3FQ2+\\O4 and H3FQ2+\\N1′.
The electronic spectra of the various H3FQ2+ forms have been calcu-
lated and are shown in Fig. 13. The main absorption maxima wave-
lengths, orbitals involved, relative percentage contribution and the
oscillator strength are reported in Table S9. The molecular orbitals in-
volved in the electronic transitions are shown in Fig. S2.
Themain experimental absorption peak of these species is located in
the 250–290 nm spectral range. The major variations in experimental
spectra, passing from the H2FQ+ to the H3FQ2+ species (decreasing
the pH) is the appearance of the band at 360–400 nm accompanied by
a decrease of intensity of the other bands (Fig. 2). The computed spec-
trum that best reproduces this trend seems to be the H3FQ2+\\O4
form (Fig. 13, Table S9). In conclusion, by the relative stability data, of
the various forms of H3FQ2+, and the computed UV-vis spectra, we
can propose that the most probable species formed at very low pH is
H3FQ2+\\O4.
6. Conclusion
Theprotonation sequence of four differentfluoroquinolones has been
fully evaluated with the aid of different complementary techniques. In
Fig. 13. Computed UV-vis spectra in PCMwater of H3FQ2+\\N1 (black line), H3FQ2+\\N1′
(red line), H3FQ2+\\O4 (blue line), H2FQ+\\O11 (dotted green line) forms. (For
interpretation of the references to color in this figure legend, the reader is referred to
the web version of this article.)
Table 5
Relative stability (ΔG in kcal mol−1) of the different H3FQ
2+ forms in gas-phase and in
PCM water.
Form Gas-phase Water
H3FQ
2+
\\O4→ H3FQ
2+
\\N1 39.5 33.2
H3FQ
2+
\\O4→ H3FQ
2+
\\N1′ 41.0 3.7
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particular, the experimental observations necessary to discriminate be-
tween a protonation scheme represented by macro-constants alone,
and one that requires the introduction of a micro-protonation scheme,
are clearly delineated based on careful analysis of experimental and sim-
ulated data. This should overcome the contrasting literature evaluations
of the existence of tautomeric forms of mono-protonated species
(neutral form or zwitterion), described by a set of protonation micro-
constants.
The comparison of the trend of spectral data as a function of pH of
CFX in water and in water-methanol solution allows ascertaining in an
unequivocal way the existence of a micro-protonation equilibrium in
themixture, whereas nomicro-protonation schememust be introduced
inwater. The trend of NMR spectra as a function of pH inwater substan-
tiates the formation of the zHFQ species alone in the first protonation
step.
DFT calculations carried out for CFX indicate the predominance of
the zNHFQ\\N4′ form in water solution, and this is confirmed also by
comparing the calculated and experimental absorption spectra. A slight
decrease of relative stability of the zHFQ\\N4′ species with respect to
the nHFQ was observed by passing from water to methanol as implicit
solvent, due to the lower polarity of the last solvent.
Theoretical stabilities and electronic spectra suggest that O11 andO4
should be protonated in the H2FQ+ and H3FQ2+ species respectively.
As a concluding comment, we have remarked the existence of the
zwitterionic species alone at physiological pH in water, and an increase
of the neutral species with the lipophilicity of the medium. This proper-
ty will surely affect the bioavailability of FQs, causing an increase of the
neutral species when the molecules approach the local lipophilic envi-
ronment close to the cellular membranes.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ejps.2016.08.053.
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